MicroRNA Signatures and Transcriptional Regulatory Networks in Glioblastoma by Henriksen, Michael
 
  
 
Aalborg Universitet
MicroRNA Signatures and Transcriptional Regulatory Networks in Glioblastoma
Henriksen, Michael
DOI (link to publication from Publisher):
10.5278/vbn.phd.med.00097
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Henriksen, M. (2017). MicroRNA Signatures and Transcriptional Regulatory Networks in Glioblastoma. Aalborg
Universitetsforlag. Ph.d.-serien for Det Sundhedsvidenskabelige Fakultet, Aalborg Universitet
https://doi.org/10.5278/vbn.phd.med.00097
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 30, 2020
M
IC
H
A
EL TØ
R
N
G
R
EN
 H
EN
R
IK
SEN
M
IC
R
O
R
N
A SIG
N
ATU
R
ES A
N
D
 TR
A
N
SC
R
IPTIO
N
A
L
R
EG
U
LATO
RY N
ETW
O
R
K
S IN
 G
LIO
B
LA
STO
M
A
MICRORNA SIGNATURES AND
TRANSCRIPTIONAL REGULATORY
NETWORKS IN GLIOBLASTOMA
BY
MICHAEL TØRNGREN HENRIKSEN
DISSERTATION SUBMITTED 2017
MicroRNA Signatures and
Transcriptional Regulatory
Networks in Glioblastoma
Ph.D. Dissertation
Michael Tørngren Henriksen
A dissertation submitted to the Department of Health Science and
Technology, The Doctoral School in Medicine, Biomedical Science and
Technology, in partial fulfilment of the degree of Doctor of Philosophy,
Aalborg, Denmark, August, 2016

Dissertation submitted: January, 2017
PhD supervisor:  Assoc. Prof. Meg Duroux
   Laboratory of Cancer Biology
   Department of Health Science and Technology
   Aalborg University, Denmark
PhD committee:  Professor Karen Dybkær Sørensen (chairman)
   Aalborg University, Denmark
   Clinical Professor, PhD, MD Bjarne Winther Kristensen
   Odense University Hospital, Denmark
   Associate Professor, PhD Ondrej Slaby
   University Campus Bohunice, Czech Republic
PhD Series: Faculty of Medicine, Aalborg University
ISSN (online): 2246-1302
ISBN (online): 978-87-7112-890-1
Published by:
Aalborg University Press
Skjernvej 4A, 2nd floor
DK – 9220 Aalborg Ø
Phone: +45 99407140
aauf@forlag.aau.dk
forlag.aau.dk
© Copyright: Michael Tørngren Henriksen
Printed in Denmark by Rosendahls, 2017
No part of this work may be reproduced, stored in a retrieval system, or transmitted in 
any form or by any means, electronic, mechanical, photocopying, microfilming, recor-
ding or otherwise, without prior written permission from the Publisher.

Dedicated to Linda

"If you haven’t found it yet, keep looking.
Don’t settle. As with all matters of the heart,
you’ll know when you find it.
And like any great relationship,
it just gets better and better as the years roll on"
Steven Paul Jobs

CURRICULUM VITAE
Michael Tørngren Henriksen
3. November 1982
Flakholmen 22, 2. th.
2720 Vanløse
Employment
Teacher at HTX, Københavns Tekniske Skole, København, 2014 – present
PhD. Fellow at Department of Health Science and Technology, Aalborg University,
Aalborg, Laboratory of Cancer Biology, 2010 – present
Publications
Møller H G, Rasmussen A P, Andersen H H, Johnsen K B, Henriksen M, Duroux M,
“A systematic review of microRNA in glioblastoma multiform: micro-modulators in
the mesenchymal mode of migration and invasion,” Molecular Neuropathology, vol. 47,
no. 1, pp. 131-144, 2013.
Pilgaard L, Mortensen J H, Henriksen M, Olesen P, Sørensen P, Laursen R, Vyberg M,
Agger R, Zachar V, Moos T, Duroux M, “Cripto-1 expression in glioblastoma multi-
form,” Brain Pathology, vol. 24, no. 4, pp. 360-370, 2014.
Henriksen M, Johnsen K B, Andersen H H, Pilgaard L, Duroux M, “MicroRNA ex-
pression signatures determine prognosis and survival in glioblastoma multiform – a
systematic review,” Molecular Neurobiology, vol. 50, no. 3, pp. 896-913, 2014.
Henriksen M, Johnsen K B, Olesen P, Pilgaard L, Duroux M, “MicroRNA expression
signatures and their correlation with clinicopathological features in glioblastoma mul-
ix
tiform,” Neuromolecular Medicine, vol. 16, no. 3, pp. 565-577, 2014.
Henriksen M, Duroux L, Zachar V, Duroux M, “Brain-specific fatty acid binding pro-
tein transcriptional regulatory network,” BBA – Gene Regulatory Mechanisms, (under
review), 2016.
Henriksen M, Duroux L, Pilgaard L, Agger R, Moos T, Zachar V, Duroux M, "The
elusive expression of FABP7 and its association to the molecular subtype of GBM," (in
preparation).
PREFACE
To further our understanding of glioblastoma (GBM) biology, a deeper insight
into the mechanisms of this severe disease is necessary, though also a daunt-
ing task. Much is already discovered with respect to the genetic instability
underpinning this aggressive cancer, with many key signalling pathways dys-
regulated providing distinguishable hallmarks. However, not everything can
be explained purely by the expression of the gene. Here microRNAs (miR-
NAs), which are post-transcriptional regulators of gene expression, have shed
light on new aspects of both gene regulation as well as post-transcriptional
regulation in GBM.
This thesis has been divided into two parts composed of four papers.
Part I looks at the microRNA regulatory landscape and takes the form of two
papers. The first paper “MicroRNA Expression Signatures Determine Prognosis
and Survival in Glioblastoma Multiforme – A Systematic Overview” aimed at pro-
viding an up-to-date account of the miRNA expression profiles in tumour
tissue associated with prognosis and survival in GBM. Based on literature, a
signature or pattern of miRNAs was derived which has a prognostic poten-
tial and the miRNAs reported to have a protective or risk-associated profile
have been highlighted in relation to GBM. Finally, the studies that have re-
ported miRNA signatures with respect to prognosis have been compared to
find a common miRNA profile across the different studies. However, the
coherence between these signatures was small, and correlations to clinico-
pathological features other than survival are seldom seen. Building on these
findings, paper two “MicroRNA Expression Signatures and their Correlation with
Clinicopathological Features in Glioblastoma” aimed to identify any significant
relationship between miRNA signatures and clinicopathological data com-
bining pathological features with miRNA and mRNA analysis. In fourteen
GBM tumours a total of 61 miRNAs were shown to cluster the GBM tumours
into long- and short-term-surviving patients. Many of these miRNAs were
associated with differential expression in GBM, including a number of miR-
NAs shown to confer risk or protection with respect to clinical outcome and
to modulate the mesenchymal mode of migration and invasion (MMMI). An
inverse relationship between miR-125b and Nestin expression was identified
xi
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and correlated with overall survival in GBM patients, eloquently illustrating
how clinicopathological findings and molecular profiling may be a relevant
combination to predict patient outcome. The intriguing finding that many
of the differentially expressed miRNAs contained exosome-packaging motifs
in their mature sequence suggested that we must expand our view to en-
compass complex intercellular communication in order to identify molecular
prognostic biomarkers and to increase our knowledge in the field of GBM
pathogenesis.
In part II, the scope of the thesis broadens still in the field of gene regula-
tion, looking at the expression of brain fatty acid binding protein (FABP7), a
protein tightly linked to the invasive nature of GBM. Paper three, a compre-
hensive review “Brain-Specific Fatty Acid Binding Protein Transcriptional Regu-
latory Network” was aimed at providing an up-to-date account of transcrip-
tional regulatory elements, factors and DNA-binding proteins of the FABP7
gene, which have been reported in the literature or extracted from public
electronic databases. It was assumed that the entire set of transcription fac-
tors binding to the FABP7 gene was finite and that the tight spatio-temporal
control of FABP7 expression in normal development, as well as in patholo-
gies such as astrocytoma and other types of cancer, was in part the result of
their combinations. An exhaustive list of FABP7 transcription factors, as well
as a physical map of their interaction sites was established. Establishing such
a map should be helpful to unravel and understand FABP7 transcriptional
regulation in normal development and pathological conditions, and eventu-
ally to understand evolutionary divergence from closely related paralogues
also expressed in nervous tissue (i.e. heart-type fatty acid binding protein
and epidermal fatty acid binding protein). With this regulatory map in place,
the expression of FABP7 was further investigated in tissue and primary cell
lines and is presented in paper four “The elusive expression of FABP7 and its
association to the molecular subtype of glioblastoma”. High FABP7 expression in
tumour tissue was not mirrored in patient matched primary culture, an ob-
servation previously reported by De Rosa et al. [72], which made us question
the validity of such model primary cultures with respect to loss of FABP7
expression and what factors underpine this change in expression. It was
hypothesed that the elusive FABP7 behaviour was due to factors known to
regulate FABP7 and to the presence or absence of molecular subtypes. Here
it was found that FABP7 belonged to the classical subtype of GBM, though
some tumours with high FABP7 expression showed characteristics of a mes-
enchymal subtype. Both subtypes had characteristics that were associated
with FABP7 function, which suggested that FABP7 belonged to one or the
other. This, the association with both subtypes, could be multifaceted where
the protein plays different functional roles linked to one or more of the GBM
hallmarks that facilitate tumour progression.
xii
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ABSTRACT
The overall objective of this thesis was to gain a better understanding of
the molecular mechanisms that underpin the invasive nature of GBM. The
dysregulation of key signalling pathways plays a role in tumourgenesis and
relapse [160] giving rise to GBM hallmarks [134]. One of the most promi-
nent hallmarks of GBM is the invasive or infiltrative nature which can in
part be due to a population of cells called cancer stem cells (CSCs), which
supports the tumour growth in a heterogeneous hypoxic niche [15]. Gene
regulation, pre- and post-transcriptional (microRNA), and how this can be
linked in some way to the expression of stem cell like proteins that are dys-
regulated has been the main focus point in this thesis and by looking at these
in combination with clinicopathological features, we have learnt more about
the underlying pathology of this disease and its progression.
This thesis is a compilation of several papers, which are subdivided into
two parts based on theme. Part one, “MicroRNA in Glioblastoma”, explores
the role of microRNA (miRNA) in GBM and their association with survival.
An overview of signatures or patterns of miRNAs, which are of prognostic
potential, was established to find a common miRNA profile and to identify
miRNAs associated with survival, clinical outcome and the modulation of the
mesenchymal mode of migration and invasion (MMMI). A number of these
were associated with differential expression in GBM patients, including miR-
125b which had an inverse correlation with Nestin expression and correlated
with overall survival in GBM patients, eloquently illustrating how clinico-
pathological findings and molecular profiling may be a relevant combination
to predict patient outcome.
The second part, “Brain Specific Fatty Acid Binding Protein in Glioblastoma”,
looks extensively into the regulation of the brain fatty acid binding protein
(FABP7), a highly upregulated protein in GBM and part of its underlying
invasive nature. FABP7 is a stem cell marker in GBM and was early on
recognised as a gene involved in GBM biology. However, the fundamental
aspects of regulation within cancer are, at the moment, still elusive. The regu-
latory landscape of FABP7 is comprised of many aspects, with some revealed
xv
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but most still elusive. A comprehensive map of the binding of transcription
factors, the primal regulator, was generated, describing the function of 27
transcription and signalling factors with reference to their effect on FABP7
expression, their role in neural development, and in GBM. A majority of
these are associated with regulatory modules in GBM, confirming FABP7 as
a target gene in GBM. Though FABP7 is highly upregulated in GBM, it is
notoriously lacking from many GBM cell lines (e.g. U87) or primary cell cul-
tures. It was found that FABP7 is lost upon cultivation of GBM tissue, how-
ever, for some cultures, the protein could be re-expressed upon neurosphere
formation or xenografting. This elusive behaviour was hypothesised to be in
part a function of the molecular subtype which led to the finding that FABP7
belongs to the classical subtype, along with Nestin, another known stem cell
marker.
xvi
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(Abstract in Danish)
Det overordnede formål med denne afhandling var at opnå en bedre forståelse
for de molekylære mekanismer, der understøtter den invasive natur af GBM.
Forstyrrelse i reguleringen af vigtige signalveje spiller en rolle i tumorgene-
sis og tilbagefald [160], hvilket giver anledning til kendetegnende for GBM
[134]. Et af de mest fremtrædende kendetegn for GBM er den invasive eller
infiltrative natur som til dels kan skyldes en population af celler kaldet can-
cer stamceller (CSCr), som understøtter tumorvækst i en heterogen hypoxisk
niche [15]. Genregulering, før og efter transcription (microRNA), og hvordan
dette kan være forbundet på en eller anden måde til ekspressionen af stam-
celle lignende proteiner der ikke er korrekt reguleret, har været det vigtigste
fokuspunkt i denne afhandling og ved at se på disse i kombination med
klinisk-patologiske træk, har vi lært mere om den underliggende patologi af
denne sygdom og dens progression.
Denne afhandling er en samling af flere artikler, der er opdelt i to dele
baseret på temaer. Første del, "MicroRNA i glioblastom", udforsker rollen af
microRNA (miRNA) i GBM og deres forbindelse til overlevelse. En oversigt
over signaturer eller mønstre af miRNA, som er af prognostisk potentiale,
blev etableret for at finde en fælles miRNA profil og identificere miRNA for-
bundet til overlevelse, kliniske udfald og modulation af mesenkymal form
for migration og invasion (MMMI). En del af disse var forbundet med vari-
erende udtryk af miRNA’er i GBM patienter, herunder miR-125b, som havde
en omvendt sammenhæng med udtrykningen af Nestin og passede med
overlevelse i GBM patienter samlet set, hvilket illustrerer hvordan klinisk-
patologiske fund og molekylære profiler kan være en relevant kombination
til at forudsige udfaldet for patienten.
Den anden del, "Hjerne specifik fedtsyrer-bindende protein i glioblastom", ser
omfattende på reguleringen af hjernens fedtsyre-bindende protein (FABP7),
et yderst opreguleret protein i GBM og en del af GBMs underliggende in-
vasive natur. FABP7 er en stamcelle markør i GBM og blev tidligt anerk-
endt som et gen involveret i GBM biologi. Men de grundlæggende aspekter
xvii
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af regulering inden for kræft er i øjeblikket stadig undvigende. Regulerin-
gen af FABP7 består af mange aspekter, med nogle afsløret, men de fleste
stadig uafklaret. Et omfattende kort over bindingen af transkriptionsfak-
torer, de primærer regulatorer, blev genereret. Her beskrives funktionen af
27 transskriptions og signaleringsfaktorer med henvisning til deres effekt på
udtrykningen af FABP7, deres rolle i udvikling af hjernen og i GBM. Et flertal
af disse er forbundet med regulatoriske moduler i GBM, der bekræfter FABP7
genet som mål i GBM. Selvom FABP7 er stærkt opreguleret i GBM, er det no-
torisk manglende fra mange GBM cellelinier (fx U87) eller primære cellekul-
turer. Det blev konstateret, at FABP7 er tabt ved dyrkning af GBM væv, men
for nogle kulturer kunne proteinet blive udtrykt på ny ved dannelsen af neu-
rosfære eller et xenotransplantat. Det blev formodet at denne undvigende
opførsel delvis kunne være en funktion af den molekylære undertype, som
førte til den konklusion, at FABP7 tilhører den klassiske undertype, sammen
med Nestin, en anden kendt stamcellemarkør.
xviii
THESIS DETAILS
Thesis Title: MicroRNA Signatures and Transcriptional Regulatory Net-
works in Glioblastoma
Ph.D. Student: Michael Tørngren Henriksen
Supervisors: Assoc. Prof. Meg Duroux, Aalborg University
The main body of this thesis consists of the following four papers, where two
are published, one is under review and one is in preparation.
[1] Henriksen M, Johnsen K B, Andersen H H, Pilgaard L, Duroux M,
“MicroRNA expression signatures determine prognosis and survival in
glioblastoma multiforme - a systematic review,” Molecular Neurobiology,
vol. 50, no. 3, pp. 896–913, 2014.
[2] Henriksen M, Johnsen K B, Olesen P, Pilgaard L, Duroux M, “MicroRNA
expression signatures and their correlation with clinicopathological fea-
tures in glioblastoma multiforme,” Neuromolecular Medicine, vol. 16, no. 3,
pp. 565–577, 2014.
[3] Henriksen M, Duroux L, Zachar V, Duroux M, “Brain-specific fatty acid
binding protein transcriptional regulatory network,” BBA - Gene Regu-
latory Mechanisms, (under review), 2016.
[4] Henriksen M, Duroux L, Pilgaard L, Agger R, Moos T, Zachar V, Duroux
M, “The elusive expression of FABP7 and its association to the molecu-
lar subtype of GBM,” (in preparation).
In addition to the main papers, contribution has been made to the following
publications.
[5] Møller H G, Rasmussen A P, Andersen H H, Johnsen K B, Henriksen
M, Duroux M, “A systematic review of microRNA in glioblastoma mul-
tiform: micro-modulators in the mesenchymal mode of migration and
invasion,” Molecular Neuropathology, vol. 47, no. 1, pp. 131–144, 2013.
xix
Thesis Details
[6] Pilgaard L, Mortensen J H, Henriksen M, Olesen P, Sørensen P, Laursen
R, Vyberg M, Agger R, Zachar V, Moos T, Duroux M, “Cripto-1 ex-
pression in glioblastoma multiform,” Brain Pathology, vol. 24, no. 4, pp.
360–370, 2014.
Conference papers and proceedings.
[7] Henriksen M, Johsen K B, Olesen P, Pilgaard L, Duroux M, “Glioblas-
toma miRNA signatures linked to progression free survival,” 8th Inter-
national MicroRNAs Europe - 2013 meeting, Cambridge, UK, 2013.
[8] Henriksen M, Duroux L, Pilgaard L, Zachar V, Duroux M, “Down-
regulation of FABP7 in glioblastoma primary cultures,” Brain tumor
2013, Berlin, Germany, 2013.
[9] Mortensen J H, Pilgaard L, Henriksen M, Olesen P, Sørensen P, Agger
R, Vyberg M, Moos T, Zachar V, Duroux M, “Cripto-1 is differentially
expressed in glionlastoma and resides in the vascular niche,” Brin tumor
2013, Berlin, Germany, 2013.
This thesis has been submitted for assessment in partial fulfilment of the PhD
degree. The thesis is based on the published or submitted scientific papers,
which are listed above. Parts of the papers are used directly or indirectly in
the extended summary of the thesis. As part of the assessment, co-author
statements have been made available to the assessment committee and are
also available at the Faculty. The thesis is not in its present form acceptable
for open publication but only limited and closed circulation as copyright may
be ensured.
xx
Contents
Curriculum Vitae ix
Preface xi
Acknowledgement xiii
Abstract xv
Dansk Resumé xvii
Thesis Details xix
List of Figures xxvii
List of Tables xxix
List of Abbreviations xxxi
General Introduction 1
1 Introduction 3
1 Glioblastoma Pathology . . . . . . . . . . . . . . . . . . . . . . . 3
2 Biology of Glioblastoma . . . . . . . . . . . . . . . . . . . . . . . 4
3 Glioblastoma Molecular Subtypes . . . . . . . . . . . . . . . . . 6
3.1 Characteristics of the Proneural Molecular Subtype . . . 6
3.2 Characteristics of the Classical Molecular Subtype . . . 7
xxi
Contents
3.3 Characteristics of the Neural Molecular Subtype . . . . . 7
3.4 Characteristics of the Mesenchymal Molecular Subtype 7
4 Glioma and Stemness . . . . . . . . . . . . . . . . . . . . . . . . . 8
5 The Tumour Microenvironment . . . . . . . . . . . . . . . . . . . 10
The Tumour Microenvironment . . . . . . . . . . . . . . . . . . . . . . 10
The Tumour Microenvironment . . . . . . . . . . . . . . . . . . . . . . 11
5.1 The Angiogenic Niche . . . . . . . . . . . . . . . . . . . . 11
5.2 The Hypoxic Niche . . . . . . . . . . . . . . . . . . . . . . 12
5.3 Cell-to-Cell Communication: The Extracellular Com-
munication Niche . . . . . . . . . . . . . . . . . . . . . . . 12
6 Aims of thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Methodology 15
2 17
1 Collection of Tumour Specimens . . . . . . . . . . . . . . . . . . 17
2 Tumour Tissue Processing . . . . . . . . . . . . . . . . . . . . . . 18
3 Culture Conditions . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4 RNA Isolation and Quantification . . . . . . . . . . . . . . . . . 19
5 Quantitative Real-Time Polymerase Chain Reaction Analysis . 20
6 Microarray and miRNA Arrays . . . . . . . . . . . . . . . . . . . 21
7 Western Blotting Analysis . . . . . . . . . . . . . . . . . . . . . . 22
8 Immunohistochemistry . . . . . . . . . . . . . . . . . . . . . . . . 23
9 Bioinformatics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
10 Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
I MicroRNA in Glioblastoma 27
3 Introduction 29
1 The Essential of MicroRNA . . . . . . . . . . . . . . . . . . . . . 29
2 The Biogenesis of MicroRNA . . . . . . . . . . . . . . . . . . . . 30
xxii
Contents
3 The Expression of MicroRNA in Glioblastoma Multiforme . . . 31
4 Overall and Progression-Free Survival as Clinical Endpoints in
Glioblastoma Multiforme . . . . . . . . . . . . . . . . . . . . . . 32
4 MicroRNA Expression Signatures Determine Prognosis and Survival
in Glioblastoma Multiforme - A Systematic Overview 35
1 Prognostic MicroRNA Signatures in Glioblastoma Multiforme . 37
1.1 MicroRNA Signatures Derived from Database Mining . 38
2 MicroRNA Signatures Derived from Independent Tissue Cohorts 41
3 MicroRNA Reported to be Protective or Risk-Asso-ciated . . . . 47
3.1 Clinically Protective MicroRNAs . . . . . . . . . . . . . . 47
3.2 Risk-Associated MicroRNAs . . . . . . . . . . . . . . . . 48
4 MicroRNAs Included in Several Signatures . . . . . . . . . . . . 48
4.1 Functional Analysis of the MicroRNAs Included in Sev-
eral Signatures . . . . . . . . . . . . . . . . . . . . . . . . 53
5 Perspectives on MicroRNA-Based Therapies for the Treatment
of Glioblastoma Multiforme . . . . . . . . . . . . . . . . . . . . . 55
6 Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . . . 56
5 MicroRNA Expression Signatures and Their Correlation with Clini-
copathological Features in Glioblastoma Multiforme 59
1 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
1.1 Clinical Data . . . . . . . . . . . . . . . . . . . . . . . . . 61
1.2 MicroRNA Expression Profile Determines Patients Sur-
vival . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
1.3 MicroRAs Dysregulated Between Long- and Short-Term
Surviving Patients are Reported to Confer Risk or Pro-
tection or Modulate the Mesenchymal Mode of Migra-
tion and Invasion in GBM . . . . . . . . . . . . . . . . . . 63
1.4 Expression of miR-125b and Neural Stem Cell Marker
Nestin Correlate with Patient Survival . . . . . . . . . . 66
1.5 Exosome-Packaging Motifs in the Mature Sequences of
Differentially Expressed microRNAs Indicate a Role in
Paracrine Signalling . . . . . . . . . . . . . . . . . . . . . 67
2 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
xxiii
Contents
3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
II Brain-Specific Fatty Acid Binding Protein 75
6 Introduction 77
7 Brain-Specific Fatty Acid Binding Protein Transcriptional Regula-
tory Network 81
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
2.1 Mapping FABP7 Transcriptional Regulatory Elements
and Transcription Factors . . . . . . . . . . . . . . . . . . 83
2.2 FABP7 Regulation in Astrocytic Tumour and Associ-
ated Transcription Factor Regulatory Network . . . . . . 85
3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
8 The Elusive Expression of FABP7 and its Association to the Molecu-
lar Subtype of GBM 87
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
2.1 Differential expression of FABP7 and transcriptional reg-
ulatory factors . . . . . . . . . . . . . . . . . . . . . . . . . 89
2.2 Molecular subtypes and FABP7 expression . . . . . . . . 90
3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
General Discussion 93
9 95
1 The Role of MicroRNA in Glioblastoma . . . . . . . . . . . . . . 95
2 MicroRNA Defined as Risk-associated vs Protective as Predic-
tors of Clinical Outcome . . . . . . . . . . . . . . . . . . . . . . . 96
3 MicroRNA Expression, Prognosis and Linking this to Clinical
Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
4 The Potential of MicroRNA Modulating the Tumour Niche . . 98
xxiv
Contents
5 FABP7: A Complex Regulatory Landscape . . . . . . . . . . . . 98
6 Piecing Together the Biological Dots: FABP7 Linked to Mole-
cular Subtype . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
7 Refining the Transcriptional Regulatory Landscape to Include
the Role of MicroRNA and FABP7 Expression . . . . . . . . . . 100
8 Tying Part One and Two Together . . . . . . . . . . . . . . . . . 100
9 Future Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Appendices 103
A Supplement to chapter five 105
References 107
xxv
Contents
xxvi
List of Figures
1.1 The three core pathways found in GBM . . . . . . . . . . . . . . 9
3.1 The biogenesis of miRNA . . . . . . . . . . . . . . . . . . . . . . 31
5.1 Dendrogram based on miRNA expression in tumour samples . 62
5.2 Kaplan–Meier survival diagram based miRNA expression pro-
file. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
5.3 Graphical representation of differentially expressed miRNAs . 64
5.4 Exosome-packaging motifs of miR-125b . . . . . . . . . . . . . . 67
6.1 Expression pattern of FABP7 . . . . . . . . . . . . . . . . . . . . 79
7.1 A map of FABP7 transcription factors from peer-reviewed lit-
erature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
7.2 Position of ENCODE transcription factors at FABP7 locus and
upstream inter-genic region . . . . . . . . . . . . . . . . . . . . . 85
7.3 Small interaction network of the eleven newly identified FABP7
TFs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
8.1 The distribution of molecular subtypes among the TFs regulat-
ing FABP7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
xxvii
List of Figures
xxviii
List of Tables
1.1 Overview of the molecular heterogeneity of the molecular sub-
types . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.1 Overview of patient samples . . . . . . . . . . . . . . . . . . . . 18
2.2 List of primers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
4.1 Studies performed on dataset obtained from public databases . 39
4.2 Studies performed on independent tissue cohorts . . . . . . . . 43
4.3 miRNAs reported to be protective or risky-associated . . . . . . 49
4.4 miRNA signatures correlating with survival in GBM . . . . . . 52
4.5 Functional characteristics of miRNAs found in several signatures 54
5.1 Univariate analysis using the log-rank test . . . . . . . . . . . . 62
5.2 MicroRNAs reported to be protective or risk-associated . . . . . 65
5.3 MicroRNAs linked to MMMI . . . . . . . . . . . . . . . . . . . . 65
5.4 MicroRNAs connected to long-term-survival and EXOmotifs . 68
A.1 MicroRNAs upregulated in cluster 1 and upregulated in GBM 105
A.2 MicroRNAs upregulated in cluster 1 and downregulated in GBM105
A.3 MicroRNAs upregulated in cluster 1 and disputed regulation
in GBM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
A.4 MicroRNAs upregulated in cluster 1 and no reported dysreg-
ulation in GBM . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
xxix
List of Tables
xxx
List of Abbreviations
5 M
5ALA 5-aminolevulinic acid MDGI mammary derived growth inhibitor
MDM2 MDM2 proteooncogene, E3 ubiquitin
protein ligase
A MDM4 MDM4, p53 regulator
Ago2 v-akt murine thymoma viral oncogene
homolog
MEIS meis homeobox 1
AKT argonaut protein 2 MEM menimum essential medium eagle
AP1 activator protein 1 MERTK MER proto-oncogene, tyrosine kinase
MET MET proto-oncogene, receptor tyro-
sine kinase
B MeV multiexperiment viewer
BACE1 beta-site amyloid beta precursor
protein-cleaving enzyme 1
MGMT o-6-methylguanine-DNA methyltrans-
ferase
BCA bicinchoninic acid miRNA microRNA
BMF bcl2 modifying factor MLANA melan-A
bZIP basic leucine zipper MMMI mesenchymal mode of migration and
invasion
MMP matrix metalloproteinase
C mRNA messenger RNA
CaCo-2 human colon carcinoma cells MS multiple sclerosis
CASP caspase MSCs mesenchymal stem cells
CAT chloramphenicol acetyltransferase
CCND2 cyclin D2 N
CD34+ CD34 positive NEFL neurofilament, light polypeptide
CD38− CD38 negative NEP neuroepithelial
CD133+ CD133 positive NES nestin
CDC25A cell division cycle 25A NF1 neurofibromin 1
CDK cyclin-dependent kinase NFKB nuclear factor of kappa light polypep-
tide gene enhancer in B-cells
CDKN1A cyclin-dependent kinase inhibitor 1A
(p21)
NICD notch intercellular domain
CDKN1C cyclin-dependent kinase inhibitor 1C
(p57)
NKX2-2 NK2 homeobox 2
CDKN2A cyclin-dependent kinase inhibitor 2A
(p14)
cDNA complementary DNA O
CEA carcinoembryonic antigen gene fmily OLIG2 oligodendrocyte lineage transcription
factor 2
CEBPA CCAAT/enhancer binding protein, al-
pha
OMIM online mendelian inheritance in man
CEBPB CCAAT/enhancer binding protein,
beta
OS overall survival
CGGA chinese glioma genome atlas
CHD5 chromodomain helicase DNA binding
protein 5
P
CHI3L1 chitinase 3-like 1 p14 CDKN2A
ChIP chromatin immunoprecipitation p16 CDKN2A
xxxi
List of Abbreviations
ChIP-
Seq
ChIP-sequencing p21 CDKN1A
Chr chromosome p53 tumour protein p53
CNS central nervous system p57 CDKN1C
CpG is-
land
cytosine-phosphate-guanine island p38MAPK MAPK14
CSC cancer stem cells PACT protein activator of PKR
CTCF CCCTC-binding factor Pasha partner of drosha
Cx43 connexin 43 PAX6 paired box 6
PBS phosphate-buffered saline
D PBX1 pre-B-cell leukemia homeobox 1
DAB 3,3’-diaminobenzidine PCR polymerase chain reaction
DGCR8 DiGeorge critical region 8 PDCD4 programmed cell death 4 (neoplastic
transformation inhibitor)
DLL3 delta-like 3 PDGFRA platelet-derived growth factor recep-
tor alpha
DMEM Dulbecco’s modification of Eagle’s
MEM
PI3K phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit alpha
DNA deoxyribonucleic acid PIAS3 protein inhibitor of activated STAT3
PIC pre-initiation complex
E PFS progression-free survival
E2A transcripton factor 3 PKNOX1 PBX/knotted 1 homeobox 1
E2F3 E2F transcription factor 3 PNS peripheral nervous system
EDTA ethylenediaminetetraacetic acid POU2F1 POU class 2 homeobox 1
EGF epidermal growth factor POU3F1 POU class 3 homeobox 1
EGFR epidermal growth factor receptor POU3F2 POU class 3 homeobox 2
EGFRvIII epidermal growth factor receptor vari-
ant III
POU3F3 POU class 3 homeobox 3
EMT epithelial-mesenchymal transition PPIA cyclophilin A
ENCODE the encyclopedia of DNA elements PTEN phosphatase and tensin homolog
ERBB2 erb-b2 receptor tyrosine kinase 2
ERBB3 erb-b2 receptor tyrosine kinase 3 Q
ERK extracellular signal-regulated kinases qRT-PCR quantitative real-time polymerase
chain reaction
ETS E26 transformation-specific
R
F RAD21 double-strand-break repair protein
FABP fatty acid binding protein Ran-GTP guanosine triphosphate-bound ras-
related nuclear protein
FABP1 liver fatty acid binding protein RANO revised assessment in neuro-oncology
FABP2 intestinal fatty acid binding protein RB retinoblastoma
FABP3 heart fatty acid binding protein RBCC RING finger, B-box zinc-finger, coiled-
coil region
FABP4 adipocyte fatty acid binding protein RBPJ recombination signal binding protein
for immunoglobulin kappa J region
FABP5 epidermal fatty acid binding protein RECK reversion inducing cysteine rish pro-
tein with kazal motifs
FABP7 brain fatty acid binding protein RELB v-rel avian reticuloendotheliosis viral
oncogene homolog B
FBXO3 f-box protein 3 RELN reelin
FFPE formalin-fixed paraffin-embedded RIPA radioimmunoprecipitation assay
FGFR3 fibroblast growth factor receptor 3 RISC RNA-induced silencing complex
FOS FBJ murine osteosarcoma viral onco-
gene homolog
RNA ribonucleic acid
FOXA forkhead box, subgroup A RTK receptor tyrosine kinase
FOXO forkhead box, subgroup O
S
G SAM significance analysis of microarray
G-CIMP glioma CpG island methylator pheno-
type
SDS sodium dodecyl sulfate
G-CSF colony stimulating factor SLC12A5 solute carrier family 12 member 5
GABRA1 gamma-aminibutyric acid A receptor,
alpha 1
SMC3 structural maintenance of chromo-
somes 3
xxxii
List of Abbreviations
GABRB2 gamma-aminobutyric acid A receptor,
beta 2
SNCG synuclein gamma
GAPDH glyceraldehyde-3-phosphate dehydro-
genase
SOX2 SRY-box 2
GBM Glioblastoma Multiform SPSS statistical package for the social sci-
ences
GFAP glial fibrillary acidic protein STAG2 stromal antigen 2
GP130 glycoprotein 130 STAT3 signal transducer and activator of
transcription 3 (acute-phase response
factor)
GRCh37 genome reference consortium human
genome (build 37)
SYT1 synaptotagmin 1
GTP guanosine-5’-triphosphate
T
H TAZ tafizzin
HepG2 human liver cancer cell line TBP TATA-box binding protein
HGF heptocyte growth factor TCGA the cancer genome atlas
HIF1 hypoxia inducible factor 1 TF transcription factor
hMSH2 muts protein homolog 2 TGFB transforming growth factor beta 1
hnRNPA2B1 heterogeneous nuclear ribonucleopro-
tein A2/B1
TIMP3 TIMP metallopeptidase inhibitor 3
HOX homeobox TLR2/4 toll-like receptor 2/4
HRE hormone response element TMZ temozolomide
TNFRSF1A tumour necrosis factor receptor super-
family member 1A
I TP53 tumour protein p53
IDH1 isocitrate dehydrogenase 1 TRADD TNFRSF1A-associated via death do-
main
iHOP information hyperlinked over proteins TRBP tar RNA binding protein
IL interleukin TRIM28 tripartite motif containing 28
IL6 interleukin 6
IL8 interleukin 8 U
IL10 interleukin 10 UTR untranslated region
K V
Ki67 marker of proliferation ki67 (MKI67) VEGF vascular endothelial growth factor
KPBS phosphate-buffered saline with potas-
sium
VAK volume, age, karnofsky performance
score
KRAB krûppel associated box VEGFA vascular endothelial growth factor A
L W
LOH loss of heterozygocity WHO world health organisation
M Y
MAD median absolute deviation YWHAZ tyrosine3/tryptophan 5-
monooxygenase activation protein
MAPK14 mitogen-activated protein kinase 14
MAZ myc-associated zinc finger protein
MBP myelin basic protein
MCP macrophage chemo-attractant protein
xxxiii
List of Abbreviations
xxxiv
General Introduction
1

1
Despite advances in our knowledge about glioblastoma (GBM) pathology,
clinical challenges still lie ahead with respect to treatment of GBM due to
high prevalence, poor prognosis and frequent tumour relapse [77, 108, 159,
246, 297, 298]. This is in part due to the invasive nature, a hallmark of GBM,
which makes it a difficult task at tumour resection. Early treatment and
proper characterisation of the tumour is therefore of critical impact [191].
This chapter gives a general introduction to GBM pathology and ends
with the aims of the thesis. There is a chapter on methodology, which de-
scribes the methods outlined in the papers. Following this, the thesis is di-
vided into two parts, each of which with an introduction relevant for the
chapter and papers presented. The thesis is closed by a general discussion
and conclusion.
1 Glioblastoma Pathology
Cancer can arise in all types of tissue. Although it is composed of a hetero-
geneous group of diseases, these diseases all share a common feature; ab-
normal cells growing past their natural limitations. Hanahan and Weinberg
proposed six hallmarks of cancer in 2001, which encapsulate the fundamental
basics of malignant transformation [133]. These basic hallmarks are defined
as: (1) self-sufficiency in growth signals, (2) insensitivity to anti-growth sig-
nals, (3) tissue invasion and metastasis, (4) limitless replicative potential, (5)
sustained angiogenesis and (6) evading apoptosis. During the last decade, a
better understanding of these hallmarks has been enabled through remark-
able progress in cancer research, which has led to modifications and expan-
sion of the original concept [134].
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The number of genetic alterations needed for tumourigenesis is still un-
known [379]; however, it is evident that several disruptions to the cellular cir-
cuitry are required for carcinogenesis. These genetic alterations can happen
either in the form of activation or inactivation of specific genes contributing to
the carcinogenic process [379]. Glioma, similar to other cancers, spawns from
an accumulation of genetic alterations, such as epigenetic modifications, mu-
tations, amplification and modification of the gene function, which change
the signalling pathways leading to the cancer phenotype [134]. Of all cen-
tral nervous system (CNS) malignancies, approximately 30 % are attributed
to glioma, while 80 % of primary brain tumours alone are of glioma origin
[121].
Malignant glioma are tumours of the neoplastic glial cells and can, ac-
cording to the World Health Organisation (WHO), be classified as astrocy-
toma, oligodendroglioma, mixed oligoastrocytoma and ependymoma, which
are based on histological similarities [252]. Additional stratification based
on histopathological criteria, specified by nuclear atypia, mitotic index, mi-
crovascular proliferation and necrosis, can further subclassify the gliomas
into low grade (WHO grades 1 and 2) or high grade (WHO grades 3 and 4)
[252].
The four grades of astrocytomas are; pilocytic astrocytoma (grade 1), dif-
fuse astrocytoma (grade 2), anaplastic astrocytoma (grade 3) and glioblas-
toma (GBM) (grade 4). Of primary brain tumours, GBM is the most common
and accounts for 15 %, while 55 % of all gliomas are GBMs [121]. Although
the number of malignant glioma cases per year is fairly low, it is considered
one of the most aggressive forms of human cancer [434].
2 Biology of Glioblastoma
One of the enabling characteristics of cancer is genomic instability [379]. The
ability of gliomas to circumvent the receptor-driven pathways to reduce the
dependence on ligand activation facilitates their inappropriate cell division,
survival and motility.
These genetic alterations have been supported by the Cancer Genome At-
las (TCGA), a comprehensive study of GBM initiated in 2008 with reports on
alterations such as copy number, acquired DNA sequence, gene expression
patterns and DNA methylation [274]. Akin to previous literature, these anal-
yses verified three major pathways involved in GBM: (1) the tumour protein
p53 (TP53) pathway, (2) the retinoblastoma (RB) pathway and (3) receptor
tyrosine kinase (RTK) signalling, see figure 1.1.
The mutation of TP53 was one of the first genetic alterations associated
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with glioma [290]. TP53 encodes p53, a transcription factor involved in cell
cycle arrest [131, 416], which upon DNA damage is activated leading to tran-
scriptionally regulation of potential effector genes [154, 231]. Although muta-
tion in the TP53 gene is relatively rare in primary GBM, loss of TP53 function
is observed in approximately 50 % of primary and in over 75 % of secondary
GBM [461].
The RB pathway control proliferation through the binding of RB with
transcription factors in the E2F family, essential for inactivation of genes in-
volved in cell cycle progression [354]. Perturbations of the RB pathway is
found in more than 50 % of primary gliomas [25, 137, 274, 344, 402], how-
ever, on its own the RB pathway is incapable of facilitating sufficient cell cycle
control required for cellular transformation, pointing to other pathways im-
portant for the prevention of gliomagenesis [11, 156, 157, 165, 337, 372, 403,
404, 451].
Activation of receptor tyrosine kinases (RTKs), such as Epidermal growth
factor receptor (EGFR) and Platelet-derived growth factor receptor alpha
(PDGFRA), seems to be the most important among the many mechanisms
at play in GBM. EGFR is affected by the most common genetic alteration in
primary glioma at chromosome 7p12 92, with EGFR gene amplification oc-
curring in 40 to 50 % of GBM [85, 244, 245, 252, 440]. The most commonly
described event in primary GBM is encoding of a truncated form of EGFR
missing exon 2 to 7 generating EGFR variant III (EGFRvIII) [86, 226, 436],
facilitating constant activation of downstream pathways. This is further en-
hanced by the loss of Phosphatase and tensin homolog (PTEN), a major tu-
mour suppressor shown to have a significant role in high grade glioma, found
to be inactivated in 50 % of high-grade gliomas [202, 298, 398]. Amplification
has also been found to happen at chromosome 12q13-15 affecting both the
RB and TP53 pathway [97, 172, 183, 252] and at chromosome 4q12 affection
several RTKs [352].
In addition to alterations in the three core pathways of GBM, Isocitrate
dehydrogenase 1 (IDH1) mutation, O-6-methylguanine-DNA methyltrans-
ferase (MGMT) promoter methylation and loss of heterozygosity (LOH) are
reported. IDH1 is involved in energy metabolism [133] and mutation of this
gene is largely associated with secondary GBM, where it is an early and
frequent genetic alteration [14, 133, 296, 312, 371, 382, 421], while only oc-
casionally found in primary GBM [14, 133, 218]. It has though been found
that mutation of IDH1 is an independent and positive prognostic marker
[133, 218, 225, 421]. In regard to prognostic markers for GBM, the methyla-
tion status of MGMT has been found to be one of the most important. MGMT,
a DNA repair enzyme that facilitates removal of DNA adducts [387], has been
found to have a CpG (cytosine-phosphate-guanine) island situated at its tran-
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scriptional start site [277]. Methylation of the CpG island has been found to
transcriptionally silence MGMT transcription [147, 433]. Due to the toxic na-
ture of DNA modifications and the property of temozolomide, an alkylating
agent that is the current standard of care for GBM patients, the expression of
MGMT correlates with sensitivity to temozolomide [143]. The methylation of
MGMT thus positively correlates with better outcome for patients receiving
temozolomide.
With the application of genome-wide analysis, common pathways mu-
tated in GBM have been uncovered, with several of the characteristics of
GBM represented in molecular subclasses identified within this disease.
3 Glioblastoma Molecular Subtypes
Identification of molecular subclasses through genome-wide mRNA expres-
sion analysis [120] has fundamentally changed the understanding of GBM
and emphasised that glioma, which represents few histopathological WHO
grade cases, is a molecular heterogeneous disease [34, 106, 169, 242, 294, 316,
407].
Through the TCGA, Verhaak et al. [407] characterised four subtypes: Pro-
neural, Neural, Classical and Mesenchymal, which were associated with dis-
tinct genetic alterations, such as copy number alterations and genetic muta-
tions, table 1.1.
3.1 Characteristics of the Proneural Molecular Subtype
The proneural subtype was found to, especially, have alterations of PDGFRA
and point mutations in IDH1 [35, 122, 407]. Amplification of PDGFRA was
observed in all GBMs, though to a higher degree in the proneural subtype.
IDH1 mutations, on the other hand, were almost exclusively present in this
subtype. Mutations in the IDH1 gene has been associated with young pa-
tients [312, 453] corresponding with the proneural subtype having the largest
percentage of young patients [293, 316, 407]. Both PDGFRA alterations, IDH1
mutation and younger age have all previously been shown to be preva-
lent in secondary GBM which also is enriched in the proneural subtype
[10, 108, 201, 431, 453]. Secondary GBM has also previously been shown, in
comparison to primary GBM, to have prevalence for promoter methylation,
especially in the RB and MGMT gene [288, 297]. Methylation of cytosines
generally occurs in conjunction with CpG di-nucleotide repeats, or CpG is-
lands [58]. Hypermethylation of CpG islands within promoters are a general
trait of cancers and widely reported in glioma [93, 198, 293]. Recently, a sub-
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set of GBMs have been identified to have a glioma-CpG island methylator
phenotype (G-CIMP), displayed as a concentration of CpG island hyperme-
thylations at a large number of loci, which represent 30 % of the proneural
subtype [293]. In addition, mutation in or LOH of TP53 was more frequent
in the proneural subtype, a characteristic of GBM [274], while paired loss of
chromosome 10 and gain of chromosome 7, another GBM trademark, was
less prevalent in the proneural subtype. The paired chromosome 10 loss and
chromosome 7 gain was, however, present in all of the classical subtype [407].
3.2 Characteristics of the Classical Molecular Subtype
This subtype also showed amplification of EGFR along with point or vIII
EGFR mutations together with loss of PTEN and Cyclin-dependent kinase
inhibitor 2A (CDKN2A), however, it also has a recognisable absence of TP53
mutation. Classical tumours exhibiting EGFR amplification was associated
with CDKN2A alterations which occurred nearly exclusively together with
alteration of the RB pathway suggesting that the RB pathway in these tu-
mours is almost solely affected through the CDKN2A deletion. The classical
subtype was also characterised by high expression of the neural precursor
and stem cell marker Nestin (NES), together with the Notch and Sonic hedge-
hog signalling pathways [407].
3.3 Characteristics of the Neural Molecular Subtype
The neural subtype is the only subtype with no real characteristics and to date
no unique molecular alterations. It was defined based on the expression of
neural markers such as Neurofilament, light polypeptide (NEFL), Gamma-
aminobutyric acid A receptor, alpha 1 (GABRA1), Synaptotagmin 1 (SYT1)
and Solute carrier family 12 member 5 (SLC12A5) and classified together
with normal brain tissue samples [407].
3.4 Characteristics of the Mesenchymal Molecular Subtype
Lastly, Verhaak et al. [407] identified a subtype with mesenchymal charac-
ter. This subtype exhibited mutations and/or loss of Neurofobromin 1 (NF1)
and co-mutation with PTEN; both related to the V-akt murine thymoma viral
oncogene homolog (AKT) pathway (A pathway which is involved in sur-
vival, migration, cell cycle progression and metabolism, promoted by the
phosphorylation of AKT [80, 185, 317, 412]). The mesenchymal subtype
was represented by expression of mesenchymal markers such as Chitinase
3-like 1 (CHI3L1) and MET proto-oncogene, receptor tyrosine kinase (MET)
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[316, 407]. Increased activity of both mesenchymal and astrocytic markers
(CD44 and MER proto-oncogene, tyrosine kinase (MERTK)) is suggestive of
an epithelial-to-mesenchymal transition (EMT), which has been associated
with trans- and dedifferentiated tumours [393]. Furthermore, increased ex-
pression of genes in the tumour necrosis factor super family pathway and
Nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB)
pathway, like Tumor necrosis factor receptor superfamily member 1A (TN-
FRSF1A), v-rel avian reticuloendotheliosis viral oncogene homolog B (RELB)
and TNFRSF1A-associated via death domain (TRADD), is probably due to
a higher overall necrosis and associated inflammatory response in the mes-
enchymal class [407].
4 Glioma and Stemness
One of the most problematic features of GBM is the recurrent nature of can-
cer. The fact that a small population of cancer cells with limitless replica-
tive potential can reconstitute a glioma tumour suggests that gliomas arise
from stem or progenitor cells [11, 472, 479]. The concept of a subpopu-
lation of tumour-initiating cells has profoundly changed the view on solid
tumours and is another example on the heterogeneity of cancer. The first
indication of a subpopulation of tumour-initiating cells within cancer was re-
ported for acute myeloid leukaemia with the characteristics of CD34+/CD38-
[31]. The presence of tumour initiating cells, first described by several groups
[144, 172, 363], was identified by Singh et al. [364] who identified a population
of CD133+ cells in GBM. However, later studies have questioned the aspect of
CD133+ as the tumour-initiating cells in the brain [19, 20, 52, 296, 421] thus,
the search for novel markers [220], with a range of possible markers for brain
cancer stem cells has been, such as Nestin (NES) [23], sex determining region
Y-box 2 (SOX2) [112] and activated NOTCH [95], along with brain fatty acid
binding protein (FABP7), a protein tightly linked to the invasive nature of
GBM. FABP7 is highly upregulated in GBM cancer stem cells [248] and was
early on recognised as a gene involved in GBM biology and cell migration
[280].
The notion that these tumour-initiating cells, drive carcinogenesis with
the capacity to self-renew has lead to the hypothesis of CSCs [76, 219, 389].
This hierarchical model is based on the subset of cells, forming a minority of
the tumour mass, as the critical subpopulation of GBM. An alternative model
has a less hierarchical structure, in which the majority of cells have a low but
equal possibility for functioning as tumour-initiating cells [409]. In recent
years, the interrelation between CSC and the tumour microenvironment has
been shown to be capable of influencing cell fate in GBM [18, 141, 151].
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Fig. 1.1: The three core pathways found in GBM. The dark blue indicates the core protein(s)
of the module, red indicate proteins affecting the expression of the core protein(s) upstream,
light blue indicate proteins downstream of the core protein(s), and green indicate microRNAs.
Modified from [274] to include microRNAs [444]. Abbreviations: AKT = v-akt murine thymoma
viral oncogene homolog 1 ; CCND2 = cyclin D2 ; CDK2 = cyclin-dependent kinase 2 ; CDK4 =
cyclin-dependent kinase 4 ; CDK6 = cyclin-dependent kinase 6 ; CHD5 = chromodomain helicase
DNA binding protein 5 ; ERK = mitogen-activated proein kinase 1 (MAPK1) ; FOXO = forkhead
box O ; MDM2 = MDM2 proto-oncogene, E3 ubiquitin protein ligase ; MDM4 = MDM4, p53
regulator ; NF1 = neurofibromin 1 ; p14 = cyclin-dependent kinase inhibitor 2A (CDKN2A) ; p16
= cyclin-dependent kinase inhibitor 2A (CDKN2A) ; p21 = cyclin-dependent kinase inhibitor 1A
(CDKN1A) ; p53 = tumor protein 53 ; Pi3K = phosphatidylinositol-4,5-bisphosphate 3-kinase ;
PTEN = phosphatase and tensin homolog ; RB = retinoblastoma.
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Table 1.1: Overview of the molecular heterogeneity of the molecular subtypes. ∗ Molecular markers specified by Verhaak et al. [407]. Abbreviations:
AKT2 = v-akt murine thymoma viral oncogene homolog ; CASP1/4/5/8 = caspase 1/4/5/8 ; CDKN2A = cyclin-dependent kinase inhibitor 2A ; CEBPB
= CCAAT/enhancer binding protein, beta ; CHI3L1 = chitinase 3-like 1 ; Chr = chromosome ; CpG = cytosine-phosphate-guanine ; DLL3 = delta-like
3 ; ERBB3 = erb-b2 receptor tyrosine kinase 3 ; EGFR = epidermal growth factor receptor ; EGFRvIII = EGFR variant III ; FBXO3 = F-box protein
3 ; FGFR3 = fibroblast growth factor receptor 3 ; GABRB2 = gamma-aminobutyric acid A receptor, beta 2 ; GBM = glioblastoma ; IDH = isocitrate
dehydrogenase ; LOH = loss of heterozygocity ; MBP = myelin basic protein ; NES = nestin; NF1 = neurofibromin 1; NKX2-2 = NK2 homeobox 2 ; OLIG2
= oligodendrocyte lineage transcription factor 2 ; PDGFRA = platelet-derived growth factor receptor alpha ; PTEN = phosphatase and tensin homolog ;
RELB = v-rel avian reticuloendotheliosis viral oncogene homolog B ; TAZ = tafazzin ; TLR2/4 = toll-like receptor 2 ; TNFRSF1A = tumor necrosis factor
receptor superfamily member 1A ; TP53 = tumour protein p53 ; TRADD = TNFRSF1A-associated via death domain ; SNCG = synuclein gamma ; SOX2
= SRY-box 2 ; STAT3 = signal transducer and activator of transcription 3 (acute-phase response factor)
Subtype Proneural Classical Neural Mesenchymal
Amplification PDGFRA EGFR, NES, Notch, Sonic
Hedgehog
Loss PTEN, CDKN2A NF1
Mutation IDH PTEN
Signature mutation LOH TP53 EGFRvIII NF1
Genomic features CpG-islands Chr10 loss, Chr 7 gain
Proteomic features CD44, TRADD, RELB, TN-
FRSF1A
Transcriptional regulators STAT3, CEBPB, TAZ
Clinical features Young patients, Secondary
GBM
Necrosis, Inflammatory in-
filtrates
Markers∗ DLL3, NKX2-2, SOX2,
ERBB3, OLIG2
FGFR3, PDGFRA, EGFR,
AKT2, NES
FBXO3, GABRB2, SNCG,
MBP
CASP1/4/5/8, ILR4,
CHI3L1, TRADD, TLR2/4,
RELB
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5 The Tumour Microenvironment
The tumour microenvironment constitutes the supporting network for tu-
mour growth GBM is composed of a multitude of astrocytes, endothelial
cells and cells of the immune and inflammatory system [40, 41], along with
blood vessels [103–105], signalling molecules [318] and the extracellular ma-
trix [28, 84]. In addition to the genetic alteration in determining cancer aetiol-
ogy, the autocrine and paracrine signalling influences on the tumour milieu
is perhaps of equal importance.
For example, cell-to-cell communication is paramount, and investigations
into the mechanisms of EGFR overexpression in GBM revealed that EGFRvIII
overexpression facilitated secretion of two cytokines, namely Interleukin 6
(IL6) and leukaemia inhibitor factor, which lead to activation of EGFR in non
EGFRvIII cell through phosphorylation of Glycoprotein 130 (GP130) [174],
illustrating the signalling between subpopulations in GBM. The intercommu-
nication is also in play when normal cells are recruited to the tumour centre
and during phenotypic changes [134, 187, 199], leading to the secretion of
growth factors, which facilitate and maintain neoplastic transformation [24]
or drive angiogenesis [187].
5.1 The Angiogenic Niche
Angiogenesis is crucial for tumour progression and malignant gliomas are
among the most angiogenic of tumours to alleviate the hypoxic conditions
as a consequence of rapid growth [88, 448]. The priming of endothelial cells
may arise from the release of secreted factors such as vascular endothelial
growth factor (VEGF) [335], from both tumour cells and endothelial cells
[99], while differentiation of CSC into endothelial cells has also been shown
to be a contributing factor [336]. Endothelial cells also expand the population
of CSCs in the perivascular niche by secreting nitric oxide [47], while VEGF
has been shown to be secreted by CSCs to support their local vascular niche
[13], establishing a CSC niche. This is enhanced by the release of Notch
ligands from endothelial cells essential for CSC maintenance [96, 478]. The
hypoxic nature might not only facilitate angiogenesis, but also increase the
attainment of stem-like characteristics within the tumour [140] which can
lead to tumour cells migrating away from the hypoxic niche [71]. The ability
for CSCs to migrate and infiltrate has lead to the suggestion that the invasive
edge might be where a population of CSCs reside [219].
11
Chapter 1. Introduction
5.2 The Hypoxic Niche
The hypoxic environment within the tumour is involved in the inflammatory
response [287] with Hypoxia inducible factor 1 (HIF1) and NF-κB (NF-κB)
activation facilitating release of cytokines capable of attracting inflammatory
cells, which in return secrete VEGF [87]. Within the brain, microglia is the pri-
mary immune effector and they contribute to a large fraction of tumours [12,
124, 283, 284, 432]. The recruitment of microglia to the glioma microenviron-
ment is facilitated by secretion of several factors, such as macrophage chemo-
attractant protein 1 and 3 (MCP1, MCP3), Colony stimulating factor (G-CSF)
and Heptocyte growth factor (HGF) [196, 228, 270, 301, 380]. Microglia beside
secreting VEGF, and thereby stimulating angiogenesis, also releases epider-
mal growth factor (EGF) and proteases affecting tumour proliferation and
invasion, respectively [12, 69, 101, 129, 152]. Although gliomas are capable
of immunosuppression of microglia through secretion of for example Trans-
forming growth factor beta (TGFB), Interleukin 10 (IL10) or prostaglandin E2
[12, 102, 166, 195, 204, 209, 302, 417], reports suggest inhibition of growth by
microglia is also present [111, 271]. Immunosuppression within the CNS can
also be facilitated by astrocytes [204]. They are activated glial cells, a process
known as reactive gliosis, which occur upon injury of the CNS generating a
scar-like structure around the affected region crucial for the confinement of
inflammation within the demarcated tissue [369, 370].
5.3 Cell-to-Cell Communication: The Extracellular Communica-
tion Niche
The communication interplay between the microenvironment and cancer cells
is complex and the question whether cancer cells activate the microenviron-
ment or vice versa might partly be answered by the information carried by
extracellular vesicles such as exosomes [193]. They are a class of nanoparti-
cles that are secreted by the majority of cell types [74, 177, 214, 263, 314, 319,
330, 348, 481], and are able to transport biological active cargo between cells,
including proteins, lipids, mRNA and miRNA [4]. They are 30 to 120 nm
in diameter and have a complex surface structure composed of special lipids
and transmembranous proteins, which facilitate specific interaction and fu-
sion with the recipient cells but also help avoiding uptake by the reticuloen-
dothelial system [413].
The interplay between cancer cells and microenvironment through secre-
tion of extracellular vesicles, exosomes, might facilitate the transfer of onco-
genes (e.g. β-catenin [43], Carcinoembryonic antigen gene family (CEA), Erb-
b2 receptor tyrosine kinase 2 (ERBB2), Melan-A (MLANA) [5] and LMP-1
[408]) and onco-microRNAs [203, 300, 390] (e.g. let-7, miR-1, miR-15, miR-16
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and miR-375) with the latter being a more persistent and long-lasting modu-
lation of the recipient cells.
6 Aims of thesis
The overall objective of this thesis was to gain a better understanding of
the molecular mechanisms that underpin the invasive nature of GBM. The
dysregulation of key signalling pathways plays a role in tumorgenesis and
relapse [160] giving rise to GBM hallmarks [134]. One of the most prominent
hallmarks of GBM is the invasive or infitrative nature which can in part be
due to a population of cells called cancer stem cells, which supports the
tumour growth in a heterogenous hypoxic niche [15]. Gene regulation, pre-
and post-transcriptional (microRNA), and how this can be linked in some
way to the expression of stem cell like proteins that are dysregulated has
been the main focus point in this thesis.
This has lead to the following aims.
[1] To present a comprehensive overview of all the available literature on
the expression profiles and function of microRNA in GBM.
[2] To present a comprehensive overview of all the available literature, eval-
uating miRNA signatures as a function of prognosis and survival in
GBM.
[3] To combine clinicopathological findings with molecular profiling of
GBM tumours and to identify connections between these features that
may have the potential of predicting survival and illuminate aspects of
GBM pathogenesis.
[4] To provide an up-to-date account of transcriptional regulatory elements,
factors and DNA-binding proteins of the FABP7 gene, which is reported
in the literature or extracted from public electronic databases.
[5] To investigate the expression of FABP7 in GBM and to correlate it to the
expression of known regulatory elements or the molecular subtype.
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The methods applied in the work of this thesis are described in detail for the
specific paper. This section is meant as an overview of the methodological
procedures. Some of the methods are similar for all papers (e.g., culture
conditions), while others are specific for a certain paper (like, miRNA array).
In this section some additional comments will be presented.
1 Collection of Tumour Specimens
The basis for the research papers (Chapter 5 and 8 was the investigation into
the regulatome of surgically resected GBM specimens. These were collected
from the Department of Neurosurgery at Aalborg University Hospital from
November 2010 to June 2012. The study was reviewed and approved by the
regional Committee on Biomedical Research Ethics (N-20100069) in North-
ern Jutland, Denmark prior to execution of the experiments, and all patients
provided informed consent for the use of tumour samples. The diagnoses
were confirmed by immunohistochemistry against Nestin (NES), Marker of
Proliferation Ki67 (Ki67) and Glial Fibrillary Acidic Protein (GFAP) using the
routine methodology at the Institute of Pathology, Aalborg University Hospi-
tal, and all relevant clinical information was extracted from patient journals.
Though 47 patients were initially enrolled in the study, fewer tumour samples
were included for further analysis due to inclusion criteria.
For the investigation of the clinicopathological link to microRNA signa-
tures fourteen patients fulfilled the inclusion criteria of the study: diagnosed
with primary GBM, first-time resection, and before having received any sort
of treatment. These stringent inclusion criteria were chosen because determi-
nation of a prognostic miRNA signature should be possible after first tumour
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resection. Median age of the patients was 61 years (range 27–85), and the
gender ratio (men/women) was around 1:2 (five men: nine women). Surgery
consisted of resection with (71 %) or without (29 %) tumour visualisation by
5-aminolevulinic acid (5ALA)-induced fluorescence. Due to limited amounts
of tissue, not all samples were applicable for downstream analysis. All sam-
ples are listed in table 2.1
Table 2.1: Overview of patient samples.
Tumour Status Recurrence OS Gender Age 5’ALA Diagnosis Nestin Ki67 Cluster Molecular
subtype
C4 0 0 112 F 53 No GBM + +++ Long C
C9 1 0 69 M 74 No GBM + NA Short M
C11 0 1 75 F 65 Yes GBM + +++ Long P
C12 1 0 20 F 60 Yes GBM + +++ Short C
C13 0 1 74 F 54 Yes GBM + +++ Short M/P
C15 1 1 207 M 61 Yes GBM NA NA Long C
C16 1 1 48 M 43 Yes GBM +++ +++ Short C/M
C17 1 0 14 F 79 Yes GBM +++ ++ Short N
C18 1 0 22 F 75 No GBM +++ +++ Short N
C21 0 1 51 F 61 Yes GBM + ++ Long N
C22 0 1 49 M 40 Yes GBM +++ +++ Long N
C24 0 0 44 F 27 Yes GBM + +++ Long M
C25 1 0 10 M 75 No GBM +++ +++ Short M
C27 1 0 5 F 85 Yes GBM +++ ++ Long M
Status: 0 signify alive and 1 deceased; Recurrence: 0 signify no recurrence and 1 recurrence; Gender:
F = female, M = male; GBM = glioblastoma; Molecular subtype: C = classical; P = proneural; M =
Mesencumal; N = neural
In order to consolidate the finding in the tissue cohort, two public data-
bases were access. 146 glioma samples corresponding to newly diagnosed
glioma cases with a minimum of 80 % tumour nuclei and a maximum of 50
% necrosis were obtained from TCGA on May 2014 (https://tcga-data.
nci.nih.gov/tcga/, [274]). For a detailed description of the data see the
TCGA Data Primer, available at https://wiki.nci.nih.gov/display/TCGA/
TCGA+Data+Primer, as well as supplementary methods from McLendon et al.
[274]. The TCGA data set for expression had already been processed and nor-
malised (level 3). Gene expression profiles of 219 glioma samples were ob-
tained from the Rembrandt database on May 2014 (https://caintegrator.
nci.ni-h.gov/rembrandt/home.do/, [289]).
2 Tumour Tissue Processing
For the investigation into the regulation of FABP7 (Chapter 8), primary cell
cultures were generated in order to investigate the gene expression. Primary
cells were generated from glioma tissue by homogenising the tissue in a Me-
dimachine (BD, Franklin Lakes, NJ, USA). Briefly, the tissue was rinsed in
PBS, weighted and divided into smaller pieces. These small clumps of tissue
18
3. Culture Conditions
were processed piece by piece in a Medimachine for 1 minute together with
Accutase (Millipore, Billerica, MA, USA). When all tissue was processed, the
homogenised suspension was filtered through a 100 µm nylon cell strainer
(BD, Franklin Lakes, NJ, USA). The cell suspension was centrifuged, and
the red blood cells were lysed using an erythrocytes lysis buffer containing
155mM NH4Cl, 5.7mM K2HPO4 in 0.1mM EDTA-Na. Cells were counted
and 5000 cells/cm2 were seeded in Collagen Type I (BD, Franklin Lakes, NJ,
USA) coated culture flasks.
3 Culture Conditions
For the investigation into the regulation of FABP7 (Chapter 8), immortalised
cell lines were utilised in order to investigate the gene expression. The cell
lines U251 and U87 were grown in Dulbecco’s modification of Eagle’s MEM
(DMEM) (Lonza, Basel, Switzerland) supplemented with 10 % (v/v) foetal
calf serum (Invitrogen, Carlsbad, CA, USA) and 1 % (v/v) penicillin/strepto-
mycin (Invitrogen, Carlsbad, CA, USA). Primary cell cultures were grown in
DMEM-F12 (Lonza, Basel, Switzerland) supplemented with 10 % (v/v) foetal
calf serum (Invitrogen, Carlsbad, CA, USA) and 1 % (v/v) penicillin/strepto-
mycin (Invitrogen, Carlsbad, CA, USA). Cells were cultured at 37 ◦C in a
humidified atmosphere containing 5 % CO2.
4 RNA Isolation and Quantification
Total RNA was isolated from fresh GBM tumour samples using the Aurum
Total RNA Isolation kit (Bio-Rad, CA, USA) according to the manufacturer’s
instruction. Except for the first few initial steps, which are specific for the
given starting material, the procedure share a common protocol and all cen-
trifugations steps are performed at maximum speed at room temperature.
Briefly, for cultured adherent cells, they were detached from the flask and
transferred to a 2 ml capped microcentrifuge tube and centrifuged for 2
minutes. The supernatant were discarded and 350 µl lysis solution (supple-
mented with 1 % β-mercaptoethanol) were added to each tube. The solution
was pipetted up and down several times in order to thoroughly lyse the cells.
350 µl of 70 % ethanol was then added to each tube and mixed thoroughly.
For tissue, a small chunk was added to 700 µl lysis solution and the solu-
tion was homogenised for 30 to 60 seconds and thereafter centrifuged for 3
minutes. The supernatant was transferred to a new tube and 700 µl of 70 %
ethanol was added and mixed thoroughly. After lysis, no matter the starting
material, the lysate was added to a RNA binding column and centrifuged
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for 30 seconds. The flow through was discarded and 700 µl low stringency
wash buffer was added. The RNA binding columns were centrifuged for 30
seconds and the flow through discarded. 80 µl diluted DNase I was added to
the membrane stack at the bottom of the column and incubated at room tem-
perature for 30 minutes in order to allow digestion. 700 µl high stringency
wash buffer was added and centrifuged for 30 seconds and the flow through
discarded. 700 µl low stringency wash buffer was added and the columns
were centrifuged for 1 minute and the flow through discarded. The RNA
binding columns were centrifuged for an additional 2 minutes to allow for
removal of residual wash buffer. Finally, 60 µl of the elute solution was added
onto the membrane stack and allowed to incubate for 1 minute at room tem-
perature. Thereafter, the RNA was eluted by centrifugation for 2 minutes.
RNA concentration and quality were assessed by spectrophotometry using a
NanoDrop (NanoDrop products, Thermo Scientific, DE, USA).
5 Quantitative Real-Time Polymerase Chain Reac-
tion Analysis
To assess the expression of specific genes in regard to the regulation of FABP7
(Chapter 8), quantitative real-time polymerase chain reaction (qRT-PCR) was
applied. This platform semi-quantify the relative expression levels through
the aid of standard curves produced by a four-fold serial dilution derived
from a pool of all cDNA samples. It uses a SYBRGreen dye, which binds
double stranded DNA in a sequence independent manner. This therefore
requires primers to be designed to be highly specific. All primers (Table 2.2)
were designed using the open source software primer 3 with a relative high
melting temperature (60 to 69 ◦C), to be approximately 20 base pairs of length
with a GC content of minimum 45 % and produced by TAG Copenhagen
(Copenhagen, Denmark) and all primer pair candidates were put through a
primer optimisation to find the optimal annealing temperature.
Table 2.2: List of primers.
Gene Forward Reverse Temperature
EGFR GCAGCTGCCAAAAGTGTGAT CAGATGATTTTGGTCAGTTTCTGGC 63◦
FABP7 GGCGTGGGCTTTGCCACTAGG TGTGCTGAGAGTCCTGATGACCAC 65◦
NFIA TGTCACAGACACCAATAGCTGCA CTTTGTGGAGCTCGTAGAGGAT 60◦
NFIB GAATCCTCCAGGTTACCTTG GTTATGGGCGTTCTGGATAC 60◦
NFIC TGCGTGAGCGAGATGCAGAG TGGAAGTCGGTCGTGTCCAG 60◦
NFIX CCCAACGGGCACTTAAGTTT GCAACAGGAGTCTGTGATAC 60◦
PAX6 CCTGGAGAAAGAGTTTGAGAGA AGAAAACCATACCTGTATTCTTGC 60◦
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For the qRT-PCR, 250 ng of RNA was reverse transcribed using the iS-
cript cDNA synthesis kit (BioRad, Hercules, CA, USA) following the manu-
facturer’s recommendations. PCR amplification was performed using 25 µl
1:50 dilution of cDNA as template. Quantitative real-time polymerase chain
reaction (qRT-PCR) analysis was done on a My-Cycler real-time PCR system
(Bio-Rad, Hercules, CA, USA). The final PCR reaction mix included a final
volume of 25 µl containing 0.188 µM of each primer, 12.5 µl cDNA using
the SYBR Green PCR supermix (Bio-Rad, Hercules, CA, USA). The thermal
cycling protocol involved initial denaturation at 95 ◦C for 3 minutes and was
followed by 50 cycles of denaturation at 95 ◦C for 15 seconds and primer
annealing and elongation for 30 seconds at a predetermined optimal temper-
ature (Table 2.2). To test for specificity of the product, a melt curve function
of the IQ5 Optical System Software 2.1 (Bio-Rad, Hercules, CA, USA) was ap-
plied. Furthermore, PCR runs producing standard curves with a correlation
coefficient R2 > 0.98 were preferred. For normalisation purposes, the geomet-
ric mean of two reference genes, cyclophilin A (PPIA) and tyrosine 3/Tryp-
tophan 5-monooxygenase activation protein (YWHAZ), was used [100, 206].
6 Microarray and miRNA Arrays
Gene expression across all tumour samples included was done through mi-
croarray. This was done in an effort to assess the gene expression profile
across multiple samples to evaluate the correlation between FABP7 and its
transcription factors. HumanHT-12 V3 Expression BeadChip (Illumina, CA,
USA) arrays were performed at AROS Applied Biotechnology, Aarhus, Den-
mark to investigate the expression of 34602 unique mRNA transcripts in the
fourteen GBM tumour samples. The arrays were quantile normalised and
evaluated with R using the Bioconducter [116] R-package lumi for beadarrays
[81], and the expression of relevant target genes of differentially expressed
miRNAs was determined [82]. In short, quantile normalisation is the effort
of making the distribution of probe intensities equal across multiple arrays.
This is based on the notion that two data vectors will produce a straight di-
agonal line in a quantile-quantile plot if they are equal. This is extended to
n dimension in which case if all n data vectors are plotted in n dimensions it
will give a straight line described by the unit vector [ 1√n , ...,
1√
n ]. By project-
ing the points of the n dimensional quantile plot onto the diagonal it would
make a set of data that has the same distribution. Let ~qk = [qk1, ..., qkn] for
k = 1, ..., p be vector of the kth quantile for all n arrays and ~d = [ 1√n , ...,
1√
n ]]
be the unit diagonal, then the projection of ~q onto ~d is described by
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proj~d ~qk =
[
1
n
n
∑
j=1
qkj, ...,
1
n
n
∑
j=1
qkj
]
.
The equation is the equivalent of substituting the data in the original
dataset with the value of the mean quantile, thereby generating arrays with
the same distribution. The normalised data was clustered in order to find
any similarities between the samples. Agglomerative hierarchical clustering
was performed using Multiexperiment Viewer (MeV) from the TM suite of
micro array tools [341], by using a Eucledian complete linking algorithm.
In order to investigate the expression of microRNA in the tumour sam-
ples generated, microRNA expression profiling was performed using the Taq-
Man Low Density Array Cards A and B (Life Technologies, NY, USA). These
analyses were performed in collaboration with AROS Applied Biotechnology,
Aarhus, Denmark. The cards contained assays for 750 mature human miR-
NAs present in the Sanger miRBase v19.0. The Ct value of an endogenous
control gene (MammU6) was used for normalisation, and a cut off of 40 was
set as threshold for the Ct value. In order to define miRNA patterns, hier-
archical clustering identified clusters based on expressional similarity. First,
the miRNAs with most varying levels of expression were identified based on
median absolute deviation (MAD) with a cut off at the first quartile. MAD
is a robust statistic and a measure of dispersion in univariate samples, which
is more resilient to outliers than the standard deviation. A similarity matrix
was then generated containing all pairwise similarities between samples. Fi-
nally, the Euclidean distance and complete linkage was applied to compute
the similarities.
7 Western Blotting Analysis
Although gene analysis have revealed the level of transcription, that does
not entail translation, wherefore western blotting was employed in order to
get an idea of the protein expression level of FABP7. Cytoplasmic and nu-
clear extracts were prepared using Radioimmunoprecipitation assay (RIPA)
buffer containing 0.1 % (v/v) Sodium dodecyl sulfate (SDS), 50 mM Tris-
HCl (pH 7.4), 1 % (v/v) Igepal, 0.25 % (w/v) Sodium deoxycholate, 1 mM
Ethylenediaminetetraacetic acid (EDTA), 150 mM Sodium chloride (NaCl),
and one Complete Mini Protease Inhibitor Cocktail tablet (Roche Diagnos-
tics, Indianapolis, IN, USA) per 10 ml total lysis solution. Protein concentra-
tions were determined using the bicinchoninic acid assay (BCA) Protein As-
say Reagent (Pierce; Thermo Science, Wilmington, DE, USA). 50 µg of total
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protein extracts were heat denatured, electrophoresed through a 12 % (w/v)
polyacrylamide-SDS gel and transferred onto a nitrocellulose membrane us-
ing the iBlot transfer apparatus (Invitrogen). Membranes were blocked us-
ing Phosphate-buffered saline (PBS) containing 5 % skimmed milk (Fluka;
Sigma-Aldrich, St. Louis, MO, USA) and 0.5 % tween-20 (Sigma-Aldrich,
St. Louis, MO, USA) and incubated at 4 ◦C overnight with 1 µg/ml rabbit
polyclonal FABP7 antibody or mouse monoclonal β-actin antibody (1:5000)
(Sigma-Aldrich, St. Louis, MO, USA; A1978). The FABP7 antibody was gen-
erated after immunisation by full-length recombinant protein in rabbits and
isolating the serum (Eurogentec, Seraing, Belgium). The serum was affinity
purified over a protein-A sepharose column (Pierce; Thermo Science, Wilm-
ington, DE, USA). Membranes were then incubated at room temperature
for half an hour with horseradish peroxidase-(HRP)-conjugated secondary
polyclonal antibody either goat anti-rabbit (1:10000) (Santa Cruz Biotechnol-
ogy, Inc., Dallas, Texas, USA; sc-2004) or rabbit anti-mouse (1:10000) (DAKO,
Glostrup, Denmark; P0260). The antibody-antigen complex was visualised
using enhanced chemiluminescence (Amersham ECL Plus; GE Healthcare,
Chalfont St. Giles, UK). Signal acquisition was accomplished using a Kodak
Image Station 4000 mm Pro (Carestream Health Denmark, Brøndby, Den-
mark). ImageJ (National Institutes of Health, Bethesda, MD, USA) was used
to quantify the intensity of western blot bands, normalising to β-actin level.
8 Immunohistochemistry
The investigation of expression was also conducted in xenografted tumours.
These were done to get a better understanding of the expression of FABP7
in a tumour microenvironment. An intracranial tumour xenograft model
was established using the GBM stem cell line, C16 (generated in-house from
resected GBM tumour tissue) as previously described. After tumour estab-
lishment for 21 days, the brains were removed and immediately immersed
into 3.7 % paraformaldehyde for fixation. After 24 hours, the fixative was re-
moved, and the brains were washed three times in Phosphate-buffered saline
with potassium (8 g NaCl, 0.2 g KCl, 1.15 g Na2HPO4, 0.2 g KH2PO4, pH
7.4-7.6 (KPBS)) followed by immersion into a 30 % sucrose solution. The
brains remained immersed in sucrose for 48 hours. Immunohistochemical
staining was performed on 40 µm sections of the brains. Briefly, all sections
were blocked for 30 minutes in incubation buffer (3 % swine serum and 0.3
% Triton X-100 in KPBS) and incubated overnight with a primary antibody
against FABP7 (Hycult Biotech, HP9029). After this incubation, the sections
were washed and incubated with a biotinylated secondary antibody, followed
by incubation with a peroxidase-conjugated avidin–biotin enzyme complex
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(Vectastain Elite ABC System, Vector Labs, CA, USA) before reaction with
3,3’-diaminobenzidine (DAB). Afterwards, sections were mounted on slides
and analysed by bright field microscopy.
9 Bioinformatics
In order to get an overview of the field of microRNA in relation to glioblas-
toma, survival, prognosis and progression (Chapter 4) a comprehensive liter-
ature search was conducted. As described in Henriksen et al. [145],
‘a Medline database search on “microRNA, glioblastoma, sur-
vival, prognosis and progression” (typed: “(microRNA OR miRNA)
AND (glioblastoma OR glioma) AND (survival OR prognosis OR
progression)”) was performed (date of last search entry: Novem-
ber 26, 2013). The results contained a total of 270 papers; 125 of
these were chosen based on title and abstract content. Of the re-
maining, 100 papers were cell culture studies and 45 were reviews
or review-like and were therefore excluded. A total of 125 papers
were reviewed for miRNA expression level in GBM correlated to
survival and/or progression, 25 involved database studies, and
35 contained studies on GBM tissue (not database-derived). The
miRNA profiles, often presented in the form of signatures, were
extracted from the papers. This review summarises the studies
investigating miRNAs in GBM and explores their correlation to
clinical outcome and highlights the functional characteristics of
the miRNAs linked to protection (i.e., longer survival) or risk (i.e.,
shorter survival). The miRNAs that are included in the signature
of more than one study and involved in the progression of GBM
have been identified, and their functional role, if known, is dis-
cussed.’ (Henriksen et al. [145])
In order to link microRNAs to clinicopathological features (Chapter 5)
text data mining of functional characteristics of miRNA target interactions
was downloaded through miRTarBase (accessed January 25, 2014) [162]. Tar-
gets for selected miRNAs were examined for correlation with the miRNA
clustering (Mann–Whitney U test; p <0.05), where only targets differentially
expressed were considered. These were further investigated for connection to
GBM through various literature databases using combinations of keywords
including: “gene name of target,” “gene nomenclature of target,” “glioblastoma
multiforme,” “GBM” and “glioma.” Gene nomenclature was used according
to the HUGO Gene Nomenclature Committee at the European Bioinformat-
ics Institute (www.genenames.org). Furthermore, a systematic review of all
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known mRNA targets of miRNAs in GBM was consulted [282].
A number of previous studies have provided miRNA signatures asso-
ciated with survival or progression in GBM and reported that individual
miRNAs of these signatures could be regarded as either protective or risk-
associated, most often based on determination of the hazard ratio (reviewed
in Henriksen et al. [145]). In addition, the miRNAs were analysed for any
modulating properties on the MMMI [282, 474]. The miRNAs determined in
this study were analysed with respect to miRNAs known to be in these two
categories, and dysregulation of known validated targets mRNAs were ana-
lysed in the microarray analysis data. The presence of exosome-packaging-
associated motifs (EXO-motif) was investigated in all differentially expressed
miRNAs by analysing all mature sequences for their content of four individ-
ual EXO-motifs (GGAG, UGAG, CCCU and UCCU), as recently reported in
Villarroya-Beltri et al. [411].
In order to gain a complete overview of the literature with respect to reg-
ulation of FABP7 (Chapter 7), a comprehensive compilation of the literature
on FABP7 promoter and transcriptional regulation was conducted, integrat-
ing data from man and rodents. To this end, iHOP (http://www.ihop-net.
org/; [153]), OMIM (http://www.omim.org/; [273]) and UniProt (http://
www.uniprot.org/; [392]) databases were instrumental. This literature re-
view was complemented with a survey of a dedicated meta-database with
author-curated information the Transcription Factor Encyclopaedia [460] and
from results produced by The Encyclopedia of DNA Elements (ENCODE,
http://www.genome.gov/10005107; http://genome.ucsc.edu/ENCODE/).
ENCODE is a project launched and coordinated by the National Human
Genome Research Institute which is aimed at identifying the functional el-
ements in the human genome, using various human cell lines and state-
of-the-art analytical methods like chromatin immunoprecipation (ChIP) fol-
lowed by DNA sequencing (ChIP-Seq) in the case of TF binding sites [391].
At the time of our survey, 56 cell lines and 161 transcription factors were
included in ENCODE. Investigation of the human FABP7 gene using UCSC
Genome Browser (http://genome.ucsc.edu/, [192]) on genome assembly ver-
sion GRCh37/hg19, revealed several additional DNA binding proteins. Here,
we will only discuss TFs identified by ENCODE showing multiple interaction
sites or with a signal higher than 0.5 (an index between 0 and 1 correspond-
ing to the relative level of enrichment for the TF with respect to the highest
signal monitored in the cell line analysed). TFs which have been shown
experimentally to regulate FABP7 transcription will be presented first, and
TFs discovered by the ENCODE project will be presented afterwards as data
showing their regulatory effect on FABP7 transcription is currently not avail-
able. However, the functions of these new TFs will be discussed in the context
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of brain biology, development and neoplastic pathology, as they might shed
additional light on FABP7 regulation.
10 Statistics
Prior to clustering, the most differentially expressed miRNAs across all tu-
mour samples were identified using the MAD. The non-parametric Mann–
Whitney U test in TM4 MultiExperiment Viewer, determined statistical sig-
nificance of aberrantly expressed miRNAs between the two clusters. Survival
analyses were based on Kaplan–Meier plot with univariate testing performed
by means of the log-rank test and Fisher’s Exact test using GraphPad Prism
5. A p value <0.05 was considered as significant.
Statistical significance of differences in expression between two groups
was determined by the non-parametric Mann-Whitney U test using Multiex-
periment Viewer (MeV) from the TM suite of micro array tools [341], while
for three groups Kruskal-Wallis was performed in SPSS (version 22). Pearson
correlation was used to correlate expressions between two genes and Fisher’s
Exact test was used to correlated expression of transcription factor and cofac-
tor with expression of FABP7, both using SPSS (version 22). A p value of <
0.05 was considered as significant.
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Over a decade ago, the human genome-sequencing consortium [217] released
a final draft of the human genome. This sparked the characterisation of
the human transcriptome in resent years due to novel techniques, which
has uncovered an unforeseen finding. Opposed to previously believed, a
considerable wider part of the human genome is ubiquitously transcribed
with up to 70 % being transcribed while only 2 % is translate into proteins
[22, 39, 54, 89, 186]. While genetic alteration within the coding sequences has
been demonstrated to affect cell development and carcinogenesis, expand-
ing our understanding of this severe disease, emerging evidence reveal that
alterations within the non-coding sequences likewise contributes to carcino-
genesis [272].
1 The Essential of MicroRNA
A family of these non-coding RNA molecules are microRNAs (miRNAs),
which are small, approximately 22 nucleotides in length, single-stranded and
endogenous molecules. They are considered interfering, due to their abil-
ity to bind within the 3’ untranslated regions (3’UTRs) of mRNA transcripts
leading to a lowered post-transcriptional gene expression [17, 213]. A sin-
gle miRNA is able to target several different gene transcripts since perfect
complementarity between the miRNA and its mRNA target is not required
[303, 394]. They are considered as micro modulators of various processes in
the normal cellular homeostasis, thus their dysregulation have been linked
to several pathological conditions, like autoimmune, cardiovascular and neu-
rodegenerative diseases, along with most cancer types [1, 37, 267, 410, 477].
Furthermore, there has recently been a great scientific effort in comparing
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aberrant expression of miRNAs in pathological specimens or biofluids to
non-pathological samples [423]. These efforts have provided interesting per-
spectives in terms of novel diagnostic and prognostic approaches based on
miRNAs, and is the first step in uncovering the role of individual miRNAs
in the context of different diseases, eventually leading the way for the de-
velopment of novel miRNA-based therapies or miRNA-based biomarkers of
disease.
2 The Biogenesis of MicroRNA
The biogenesis of miRNA is initiated by the transcription of miRNA genes
by RNA polymerase II/III, giving rise to the primary transcript, pri-miRNA,
which is characterised by polyadenylation and capping (Figure 3.1). Due to
intrastrand base-pairing, the pri-miRNA transcript folds into a hairpin loop
structure [438]. The loop structure of the pri-miRNA is next endonucleolyti-
cally cleaved inside the cell nucleus by a micro-processor complex formed by
the RNase III enzyme Drosha and the DiGeorge critical region 8 (DGCR8),
also known as Pasha (Partner of Drosha) in D. melanogaster og C. elegans. The
resulting pre-miRNA is transported out of the cell nucleus by Exportin-5 in a
Ran-GTP dependent manner [458]. Once in the cell cytoplasm, the RNAse III
enzyme known as Dicer cleaves the pre-miRNA aided by the double-stranded
RNA-binding domain proteins Tar RNA binding protein (TRBP) and protein
activator of PKR (PACT) and the core component Argonaut protein 2 (Ago2)
leading to a miRNA duplex, of which only one strand (called the guide-
strand) is incorporated into the RNA-induced silencing complex (RISC), the
cytoplasmic effector machine of miRNA. The other strand, termed passenger-
strand, is subsequently degraded, though in some cases the passenger-strand
is incorporated into a RISC of its own thus remaining functional. The choice
of which strand that is incorporated into the RISC is based on the asym-
metry in the miRNA duplex [347] or the thermodynamic stability of the two
strands, where the strand with least thermodynamic stability in its 5’ end will
be incorporated into the RISC [194]. Post-transcriptional mRNA-silencing is
achieved mostly via imperfect complementarity binding between the miRNA
strand with associated RISC accessory proteins, and the target mRNA, result-
ing in translational inhibition [437]. Interestingly, miRNAs are also secreted
into the extracellular space and plasma via lipoproteins, exosomes and mi-
cro vesicles, hereby participating in the intercellular communication. This
is important in relation to the nature of sampling material, because miRNA
patterns of circulating micro particles might be a useful diagnostic and/or
prognostic marker of on-going pathological processes [53, 376].
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Fig. 3.1: The biogenesis of miRNA requires RNA polymerase II/III for the transcription of
pri-miRNA. The pri-miRNA product is then cleaved by the Drosha-DGCR8 complex into pre-
miRNA. The pre-miRNA is exported to the cytoplasm by Exportin-5 in the presence of Ran-GTP
co-factor. Once in the cytoplasm, the pre-miRNA is cleaved by the Dicer-TRBP complex into a
miRNA duplex, which is unwound into two products: a guide strand bound to Ago2, which
is incorporated into the RISC, and a passenger strand, which is degraded. Finally, the miRNA
binds to its target mRNAs resulting in mRNA target cleavage, translational repression, or mRNA
decay. A more novel fate of the miRNAs is the selective secretion via microvesicles or exosomes.
Ran = Ras-related nuclear protein ; GTP = guanosine-5’-triphosphate ; TRBP = TAR (HIV-1) RNA
binding protein ; Ago2 = Argonaute protein 2 ; RISC = RNA-induced silencing complex. From
Henriksen et al. [145].
3 The Expression of MicroRNA in Glioblastoma Mul-
tiforme
As mentioned elsewhere:
‘[Presently, nearly every analysis of tumour tissue] ... by mi-
RNA profiling has ... [revealed] a distinct miRNA ... [profile
in comparison] to normal tissue [254], ... [which] can be fur-
ther associated with prognostic factors and disease progression
[38, 384, 454]. ... The [vast] number of studies pertaining to
miRNA expression and functional characterisation [in GBM] has
grown and miRNA signatures are refining ... [the] classification
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[of GBM], differentiating between the different grades and stages,
providing key regulatory links to disrupted signalling pathways
such as those facilitating cell growth ... [, which] has lead to a
more in depth understanding about GBM pathology [197].
[Previous studies have shown that expression of miRNA] in tu-
mour samples seem lower, and this could be a function of cellular
differentiation status [254, 415]. [Based on our systematic litera-
ture review [282]] it appears that the most common dysregulation
of miRNA in GBM is observed to be overexpression. ... For ex-
ample, miR-17, miR-21, miR-93, miR-221 and miR-222 have been
intensively investigated with respect to both their expression and
functionality, but the functional properties of the vast majority re-
main completely unknown.
The most extensively investigated miRNA is miR-21, which
is consistently reported to be overexpressed in GBM in a grade-
specific manner [44, 48, 57, 60, 62, 79, 109, 114, 126, 168, 211, 212,
215, 221, 234, 239, 240, 268, 310, 328, 333, 334, 343, 346, 355, 361,
447, 462, 473, 475, 476]. At least for GBM, miR-21 appears to be
the major anti-apoptotic and pro-survival factor that is linked to
shorter progression-free survival [46, 215, 325].
Expression ... [profiles] of miRNA in patient tissue and inves-
tigation of their putative function using in vitro primary cultures
and in vivo studies have provided an insight not only into the
genes that are regulated by respective miRNA, but also the path-
ways that are disrupted, many of which are hallmarks of GBM
biology (reviewed by Lakomy et al. [215]). The pattern of miRNA
expression, whether it is up- or downregulated, is now becoming
a recognised tool in addition to gene expression profiling to strat-
ify GBM patients into different groups [197]. Here, the miRNA
cohorts are smaller and miRNA signatures pertaining to overall
or progression-free survival are starting to evolve, albeit they are
still very much dependent on the individual patient history, tu-
mour size, age and treatment regimen.’ (Henriksen et al. [145])
4 Overall and Progression-Free Survival as Clinical
Endpoints in Glioblastoma Multiforme
As previously described:
‘in the literature, both overall survival (OS) and progression-free
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survival (PFS) are widely used end points to assess the predictive
factor of a given miRNA signature; however, the two terms do
not provide equal information [73, 323, 331]. When evaluating a
treatment response, OS is used as a measure of the end result in-
cluding the complete disease history and possible other factors af-
fecting the lifespan. The PFS is more specific in its measure of the
effect of a specific treatment in the form of tumour control or ra-
diographic response. Reviewing the literature and trying to draw
conclusions are therefore challenging when both OS and PFS are
applied [56]. The response assessment criteria for GBM has been
developed over the course of several decades as a result of tech-
nology advances in imaging and expanded knowledge on tumour
biology. Before 1990, the Levin and WHO Oncology Response Cri-
teria, which primarily was based on contrast-enhanced computer
tomography, was the standard assessment methods [230]. These
were substituted by the standardised McDonald Criteria, which
took into account that contrast enhancement could be affected by
clinical factors such as the use of corticosteroids [266]. The Mc-
Donald Criteria incorporated the clinical assessment (neurology
status) of the patient in the designation of response to therapy
as being a complete response, partial response, or stable or pro-
gressive disease. With the arrival of magnetic resonance imaging
and new therapeutic options, the response assessment criteria was
developed further and standardised with regard to all aspects of
imaging, timing, and evaluation techniques. Especially the intro-
duction of bevacizumab, a monoclonal antibody targeting VEGF-
A and a resulting increased risk of pseudoprogression interpreted
as disease progression stimulated the modification and lead to the
Revised Assessment in Neuro-Oncology (RANO) Criteria in 2010
[33, 55, 107, 171]. Because of this development over the last twenty
years, caution should be taken in the comparison of particular PFS
data.’ (Henriksen et al. [145])
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1. Prognostic MicroRNA Signatures in Glioblastoma Multiforme
Determination of disease prognosis is most often based on histological
classification combined with information on patient age and tumour size
and location. These factors have all been defined as indicators of patient sur-
vival and treatment outcome, but due to the sustained poor overall survival
of GBM patients, new arrays of prognostic indicators have been requested
to aid in the clinical decision making [246]. In recent years, several mo-
lecular biomarkers have been characterised including chromosomal aberra-
tions, methylation status of the methyl guanine methyl transferase (MGMT)
promoter, mutations in important genes (isocitrate dehydrogenase 1 (IDH1),
EGFR, and p53), and dysregulation of miRNAs [49]. LOH in chromosomes
9p and 10q is associated with decreased survival, while co-deletion of 1p and
19q correlates with better treatment response and longer survival [49]. Hy-
permethylation of the MGMT promoter leads to lower expression levels of
MGMT, which sensitizes GBM tumours to chemotherapeutic treatment and
thus is associated with a significantly better patient outcome [94, 142]. Im-
provement of the disease condition is also observed in patients with mu-
tation in the IDH1 gene, which is most often found in secondary GBM.
Furthermore, the expressional profile of specific microRNA signatures also
correlates with overall survival, time to progression and treatment success
[215, 429, 453].
Based on studies derived from clinical data in databases and indepen-
dent tissue cohorts where smaller samples sizes were investigated, miRNA
associated to longer survival (protective) and miRNA with shorter survival
(risk-associated) have been identified and their signatures based on different
prognostic attributes are described.
Here, these studies are stratified into those based on publicly available
databases and those conducted on independent tissue cohorts. These data
sets have been extensively reviewed and combined to derive a signature or
pattern of miRNAs, which has a prognostic potential. The miRNAs reported
to have a protective or risk-associated profile have been highlighted in rela-
tion to GBM. Finally, the studies that have reported a miRNA signature with
respect to prognosis have been compared to find common miRNA profile
across the different studies.
1 Prognostic MicroRNA Signatures in Glioblastoma
Multiforme
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1.1 MicroRNA Signatures Derived from Database Mining
A total of 25 studies were based on database entries. For the individual
studies, the database accessed, cohort size, cohort factor and normalisation
methodology along with miRNA signature were documented (Table 4.1). The
majority of the studies used TCGA (cancergenome.nih.gov). However, four
studies used the Chinese Glioma Genome Atlas (CGGA) (www.cgga.org.cn),
which uses the Illumina Human v2.0 miRNA Expression BeadChip microar-
ray platform [265, 388, 429, 445]. The study by Ma et al. [265] evaluated
two large cohorts of data, the CGGA with 198 samples containing low-grade
gliomas and 91 GBMs and an additional cohort of 128 samples, with low-
grade gliomas and 68 GBMs to validate the array data. High expression of
miR-196b was conferring poor prognosis when stratifying the patients into
high miR-196b expression and low miR-196b expression groups. Following a
similar experimental setup, Wu et al. [445] looked at 91 GBM patients taken
from the array data and validated their findings in a cohort of 60 GBM pa-
tients. Here, they focused on miR-328, showing that a low level of expression
was conferring poor prognosis. The TCGA dataset has also been used for
developing a new method for predicting the outcome based on miRNA ex-
pression; however, only one of the studies provided the miRNA identified
[241].
While a few studies gave rise to a defined multiple-miRNA signature,
eight of the studies looked at a single miRNA. For example, two studies eval-
uated the functionally well-characterised miRNA, miR-10b. Gabriely et al.
[110] showed that miR-10b was expressed in GBM tissue while not present
in normal brain tissues. Using TCGA data, they investigated the associa-
tion between the expression of miR-10b and clinical outcome and found that
miR-10b correlated with survival although with stratified conditions, the as-
sociation was insignificant. When the correlation with survival for miR-10b
was assessed together with miR-10a, however, the association with survival
was significant regardless of stratification; hence, high levels of miR-10 con-
ferred poor survival. [128] also found a correlation between high levels of
miR-10b and poor survival by analysing the TCGA data and further reported
on a functional role of miR-10b in GBM stem cells.
Since the majority of the studies use the TCGA dataset in analysing the
expression of miRNAs in GBM, the platform for generating the data was the
same. The only differences seen were in the downstream analysis, other clini-
cally prognostic factors, and the type of filtering applied. Expression analysis
was conducted on Agilent 8 × 15 K Human miRNA microarrays, with data
available at four levels. The first level is the raw non-normalised data from
the array (level 1), and the second level (level 2) is the processed normalised
signal. The third level (level 3) is the segmented data, assemblies of the pro-
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Table 4.1: Studies performed on dataset obtained from public databases. For each study, the cohort size, the database utilized, the date of accession,
and the cohort factor of investigation are stated. The type of normalization used and the levels of data are described; level 1 is the raw data, level 2 or 3
are normalized data from TCGA. Finally, the number of miRNAs investigated is reported. VAK = Volume, Age, Karnofsky performance score; MGMT
= methyl guanine methyl transferase; TMZ = temozolomide; EGFR = epidermal growth factor receptor; IDH1 = isocitrate dehydrogenase 1; FOS = FBJ
murine osteosarcoma viral oncogene homolog; GBM = glioblastoma multiforme
Reference Cohort size Database Accessed Cohort factor Normalisation Validation No. of miRNAs
studied
Bozdag et al. [32] 385 TCGA Jul, 2011 Age-specific
signature
Level 3 19
Dai et al. [66] 465 TCGA In vitro tissue 1
Delfino et al. [73] 253 TCGA Dec, 2009 miRNA biomark-
ers of glioblas-
toma survival
Quantile normalised,
collapsed within mi-
croRNA, and log2
transformed
45
Gabriely et al.
[110]
261 TCGA Level 2 In vitro tissue 1
Genovese et al.
[115]
290 TCGA Level 3 In vitro xenograft-
ing
8
Guessous et al.
[128]
TCGA In vitro tissue 1
Haapa-Paananen
et al. [130]
308 TCGA Level 3 Used to validate
signature found
in cell culture
8
Hua et al. [163] 580 TCGA Antagonistic
activity on cell
proliferation and
"stemness"
12
Kim et al. [197] 261 TCGA Classification Level 3 - Mean cen-
tered, and the STD was
normalised to 1 per ar-
ray
121
Lee et al. [224] 491 TCGA Sep, 2011 Level 3 In vitro tissue 1
Li et al. [241] 371 TCGA Method develop-
ment
Tissue 5
Ma et al. [265] 198 CGGA Assess prognostic
value
Tissue 1
Qiu et al. [321] 480 TCGA Level 3 In vitro tissue 1
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Qiu et al. [322] 480 TCGA Jul, 2013 Signature for
GBM survival
Level 3 6
Srinivasan et al.
[374]
222 TCGA Jul, 2010 Signature for
GBM survival
Level 1 - Quantile
normalised and log2
transformed
10
Suzuki et al. [383] 478 TCGA Mar, 2012 Method develop-
ment
Level 3 - Mean cen-
tered, and the STD was
normalised to 1 per ar-
ray
Divided into a
training set and a
testing set
Tao et al. [388] 220 CGGA FOS expression Illumina BeadStu-
dio Data Analysis
Software
Tissue, In vitro
xenografting
2
Wang et al. [429] 170 TCGA IDH1 mutation
signature
Level 3 23
Wang et al. [428] 198 CGGA In vitro tissue 1
Wu et al. [445] 198 CGGA Grade specific
miRNAs
Tissue 1
Xiao et al. [452] 378 TCGA miRNA-mRNA
modules
11
Yin et al. [459] 188 TCGA EGFR amplifica-
tion
In vitro tissue 1
Zhang et al. [468] 424 TCGA Feb, 2011 TMZ and MGMT Level 3 In vitro tissue 9
Zhang et al. [469] 345 TCGA Signature for
GBM survival
Tissue 5
Zinn et al. [480] 255 TCGA Oct, 2011 VAK classification Level 2 - Multi array
algoritm
No 8
40
2. MicroRNA Signatures Derived from Independent Tissue Cohorts
cessed data from single samples, and grouped by probed loci to form larger
contiguous regions. The fourth level (level 4) is the summary, a quantified
association across classes of samples and associations based on molecular ab-
normalities, sample characteristics and/or clinical variability. Not all studies
state the level of data they use, but most use the third level. Only one study,
looking at a ten-miRNA signature, used level 1 and quantile-normalised the
expression data. Here, they segregated patients in to high- and low-risk
groups and identified seven miRNAs associated with high risk of disease
progression and three miRNAs that were found to be protective [374]. A
more elaborate study by Delfino et al. [73] used quantile-normalised data (al-
though it does not specify the level of the data set analysed) and identified
45 miRNAs in the TCGA data across race, gender, recurrence, and therapy
linked to survival. Using level 2 data with multiarray algorithm normali-
sation, Zinn et al. [480] looked at 78 patients and included a Volume (tu-
mour volume), Age, and Karnofsky Performance Score (VAK) classification
to dichotomize the patients into VAK A (good prognosis) and VAK B (poor
prognosis). A total of five miRNAs were associated with short-term survival
(miR-566, miR-505, miR-345, miR-484, and miR-92b), and three miRNAs were
associated with long-term survival (miR-511, miR-369-3p, and miR-655).
Though the normalisation was not standard for all studies along with
the variation in cohort size, most of them used normalised data from the
TCGA database and therefore had the same material. The cohort size, how-
ever, ranges from 170 to 580 (mean = 329 ± 121) and is a function of the
cohort factors that are investigated. For example, factors such as age, grade,
MGMT methylation, chemotherapy regimen, IDH1 mutation, or grade sub-
classification are just some examples of where the investigation is based on
prior knowledge of clinical data correlated with expression and survival
[32, 197, 429, 445, 468]. In addition to the TCGA, a number of the studies
have used independent GBM tissue validation cohorts for identifying differ-
entially expressed miRNAs with respect to cohort factors [265, 445, 469].
2 MicroRNA Signatures Derived from Independent
Tissue Cohorts
The studies performed on independent sample sets can generally be char-
acterised as being validation of database findings, validation of literature
findings, or novel array-based determination of miRNA profiles of clinical
interest in GBM (Table 4.2). A total of 35 studies identified miRNA signa-
tures associated to survival, and many of these have used tissues to validate
signatures previously found in datasets described in the last section and con-
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tained in Table 4.1. The majority of studies (n = 30) use PCR-based methods
when validating miRNA expression, while several studies use different types
of arrays. The PCR-based methods require normalisation, and most of the
studies use RNU6B, though there are a few studies that use others, such as
hsa-miR-16 or RNU5A [326, 473].
The starting material used in the studies was either tissue or formalin-
fixed paraffin-embedded (FFPE) tissue with a variable cohort size (min = 12,
max = 253, mean = 91 ± 59). With regard to sample preparation, de Biase
et al. [70] have shown that there is no difference in the miRNA expression ob-
tained from tissue and FFPE tissue, and some studies also use both types to
validate their findings. Twenty-five studies focused on single-miRNA candi-
dates, while the remainder focused on expression profiles of several miRNAs
(min = 1, max = 30, mean = 3 ± 5).
While most of the studies focus on smaller miRNAs signatures, Niyazi
et al. [291] present a larger cohort of miRNA as a putative survival signature.
They used a top-down approach, where they filtered the miRNAs based on
the variance in expression across the samples and chose the 30 most dysreg-
ulated miRNAs. These miRNAs were used to stratify the samples into two
patterns, which correlated with short- and long-term survival. This approach
was also applied in several database studies, limiting the number of miRNAs
down to a specific signature [241, 468, 469, 473]. Others looked at pre-selected
miRNAs already linked to GBM pathogenesis in the literature [173, 326, 463].
Zhang et al. [463] found that miR-221 and miR-222 expression was signifi-
cantly increased in high-grade gliomas compared with low grade, positively
correlated with degree of glioma infiltration. This corresponded well to the
fact that overexpression of miR-221 and miR-222 increased cell invasion [215].
In addition, Quintavalle et al. [326]showed that miR-221 and miR-222 were
upregulated in GBM patients and that they target MGMT mRNA thereby
inducing greater temozolomide-mediated cell death.
Of all the studies, twelve of them utilised both databases and indepen-
dent tissue cohorts. They all link an expression of one or more miRNAs
to survival; however, some studies categorise a given miRNA to be protec-
tive or risk-associated. Three studies used hazard ratio to assess whether
a specific miRNA was protective or risk-associated, while Wang et al. [429]
used a Significance Analysis of Microarray (SAM) and Li et al. [241] used the
Cox-regression coefficient to designate the miRNAs [241, 374, 429, 468]. Inter-
estingly, large variations can be found in the choice of control tissues across
the individual studies, ranging from purchased RNA from normal brains to
tissues from epilepsy patients or patients with cerebral trauma. Such differ-
ences in control tissues might also be a factor in the incoherency between
the miRNA signatures found in the different studies (Table 4.2). In addition,
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Table 4.2: Studies performed on independent tissue cohorts. For each study, the cohort factor of investigation, the cohort size, the methodology
and the choice of control tissue are stated. The method of normalisation, whether it is validated, and the number of miRNAs reported in the study
are described. TMZ = temozolomide; MGMT = methyl guanine methyl transferase; EGFR = epidermal growth factor receptor; RT-qPCR = real-time
quantitative polymerase chain reaction; GBM = glioblastoma multiforme; AVM = arteriovenous malformation
Reference Cohort factor Cohort size Method Control Normalisation Validation No. of miRNAs
studied
Chang et al. [45] 128 RT-qPCR 10 × non-
neoplastic brain
tissue
RNU6B 1
Chen et al. [50] 43 In situ hy-
bridisation
RT-qPCR
Normal brain tis-
sue
In vitro 1
Dai et al. [66] 19 RT-qPCR 3 × severe trau-
matic brain injury
In vitro 1
Gabriely et al.
[110]
RT-qPCR Normal brain tis-
sue
In vitro xenograft-
ing
1
Gao et al. [113] 151 RT-qPCR 15 × severe trau-
matic brain injury
RNU6B 1
Guan et al. [126] Grade specific
miRNAs
92 PCR array
(TaqMan Hu-
man miRNA
array v1.0
(PE Applied
Biosystems))
RT-qPCR
1 × epilepsy and
1 × no tumour
RNU44 and RNU48 1
Guessous et al.
[128]
20 RT-qPCR 5 × normal brain
tissue
RNU6B In vitro 1
He et al. [139] 112 RT-qPCR 10 × non-
neoplastic brain
tissue from de-
compressive
craniectomy after
brain injury
RNU6B 1
Hermansen et al.
[149]
193 In situ hy-
bridisation
Not described RNU6B 1
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Hou et al. [161] 102 RT-qPCR 20 × non-
neoplastic brain
tissue from de-
compressive
craniectomy after
suffering brain
injury
RNU6B 1
Ilhan-Mutlu et al.
[173]
Progression -
compare paired
primary and
secondary
15 RT-qPCR 3 × epilepsy RNU6B 7
Jiang et al. [179] 253 RT-qPCR
and In situ
hybridisation
3 × died in traffic
accident
RNU6B 1
Jiang et al. [178] 166 RT-qPCR 10 × non-
neoplastic brain
tissue from de-
compressive
craniectomy after
brain injury
RNU6B 1
Lakomy et al.
[215]
Methylation and
TMZ
38 RT-qPCR 6 × normal AVM
and commercial
RNA from adult
brain
8
Lee et al. [224] RT-qPCR Non-neoplastic
brain tissue
RNU6B In vitro 1
Li et al. [241] Method develop-
ment
160 Numan v2.0
miRNA ex-
pression
BeadChip
Not decribed Log transform 5
Li et al. [235] 128 RT-qPCR Paired adjacent
non-neoplastic
brain tissue
RNU6B 1
Lu et al. [255] 108 RT-qPCR 20 × dead from
traffic accident
RNU6B 1
Lu et al. [256] 108 RT-qPCR 20 × dead from
traffic accident
RNU6B 1
Ma et al. [265] Assess prognostic
value
128 RT-qPCR Not decribed 1
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Niyazi et al. [291] Signature for
GBM survival
35 Biochip "Ge-
niom Biochio
MPEA homo
sapiens"
(Febit)
Not described 30
Qiu et al. [321] 25 RT-qPCR 14 × non-
neoplastic brain
tissue
RNU6B In vitro 1
Quintavalle et al.
[326]
MGMT and com-
mon classification
34 RT-qPCR Not described RNU5A, β-actin 2
Speranza et al.
[373]
NEDD expression RT-qPCR Not described RNU6B Proliferation and
invasion assay,
transfection
1
Sun et al. [381] 168 RT-qPCR, Taq-
man miRNA
array
21 × cerebral
trauma samples
RNU6B 1
Tao et al. [388] FOS expression 50 In situ hy-
bridisation
3 × normal brain RNU6B In vitro xenograft-
ing
2
Wang et al. [424] 108 RT-qPCR 20 × normal con-
trols no patholog-
ical lesions
RNU6B 1
Wang et al. [428] 30 RT-qPCR Severe traumatic
brain injury
In vitro xenograft-
ing
1
Wu et al. [445] Grade-specific
miRNAs
100 RT-qPCR Not described RNU6B Validation set 1
Wu et al. [446] 128 RT-qPCR, Taq-
man miRNA
array
10 × cerebral
trauma samples
RNU6B 1
Yin et al. [459] EGFR amplifica-
tion
55 RT-qPCR,
SNP-chip
analysis
Not described RNU48 Transfection, pro-
liferation, migra-
tion, luciferase as-
say
1
Zhang et al. [463] 50, 22 In situ hy-
bridisation,
RT-qPCR
Not described RNU6B Transwell assay,
wound healing
assay, transfec-
tion, xenografting
2
Zhang et al. [468] TMZ and MGMT 82 Illumina Hu-
man v2.0 mi-
RNA Expres-
sion BeadChip
Not described 9
45
C
hapter
4.
Zhang et al. [469] Signature for
GBM survival
117 Illumina Hu-
man v2.0 mi-
RNA Expres-
sion BeadChip
Not described Average expression Validation set 5
Zhi et al. [473] Signature for
GBM survival
124 RT-qPCR 60 × normal adja-
cent tissue
hsa-miR-16 Split into training
and validation set
3
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only few studies specify their use of the terms OS and PFS, which also makes
direct comparison difficult.
3 MicroRNA Reported to be Protective or Risk-Asso-
ciated
3.1 Clinically Protective MicroRNAs
In the group of the protective miRNAs (n = 22), only two miRNAs, miR-
544 and miR-1227, have not been described previously in relation to miRNA
alterations in GBM pathogenesis. Eleven of the protective miRNAs were sig-
nificantly increased in studies comparing GBM specimens to normal brain
tissue, while only six were significantly downregulated. Surprisingly, three
of these miRNAs are well described as miRNAs with an oncogenic poten-
tial and have several validated targets considered to be tumour suppressor
genes. This includes the extensively investigated miR-17-5p, which in vitro
has been shown to increase angiogenesis and growth when overexpressed
and decrease viability and proliferation when inhibited, making it unlikely
that this miRNA, at least solely, should be considered protective [75]. As
to miR-19a, miR-19b, and miR-106a, there is currently an inconsistency in
the literature regarding their role in GBM development. The functional data
available on miR-106a shows that overexpression by transfection of GBM cell
lines causes a significant decrease in proliferation and an increase in apop-
tosis, likely mediated by the suppression of E2F1, supporting the notion of
it being tumour suppressive [455]. More in line with what would be ex-
pected, miRNAs with previously investigated tumour suppressive capabil-
ities are present on the list whereby miR-128a and miR-181d are most no-
table. miR-128 has been investigated in thirteen studies demonstrating its
wide range of oncogenic mRNA targets and its ability to inhibit angiogenesis
and proliferation and even to significantly decrease total tumour volume in
vivo [57, 63, 119, 212, 215, 221, 234, 328, 358, 414, 447, 462, 470, 475]. Similarly,
although, less extensively investigated is miR-181d, which has been shown
to target the oncogenes Bcl-2 and K-Ras whereby apoptosis is increased and
proliferation decreased. miR-181d transfection is demonstrated to decrease
in vivo tumour size and has been shown to increase the susceptibility to the
chemotherapeutic agent, temozolomide [207, 427].
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3.2 Risk-Associated MicroRNAs
Within the cohort of miRNAs described as risk-associated (n = 22), nine have
not been previously associated with miRNA modulation in GBM. Of the thir-
teen miRNAs mentioned in the literature, ten are overexpressed in GBM
specimen, three are underexpressed, and four have been functionally char-
acterised. miR-34a is well studied in numerous GBM cell lines and shown to
increase cell differentiation and decrease total tumour volume in a xenograft
mouse model of GBM [127, 459]. The less investigated miR-146b is similarly
known to decrease in vitro invasiveness, migration, proliferation, and tu-
mour volume in mice [189, 449]. Both miR-34a and miR-146b are, in terms of
isolated functional characteristics, not associated with risk of GBM progres-
sion (Table 4.3). The oncogenic miRNAs, miR-221 and miR-222, clinically
associated with risk, have been studied in relation to a diverse list of can-
cers including GBM. They inhibit a number of common gene targets such as
PUMA and P57 both involved in apoptosis. When overexpressed in vitro,
both miR-221 and miR-222 potentiate classic cancer hallmarks, i.e., prolifera-
tion, angiogenesis, and invasion. In vivo studies have revealed that miR-221
or miR-222 overexpression is associated with increased tumour growth, a sit-
uation that can be reversed with administration of corresponding antagomirs
[275, 464].
Out of 44 miRNAs reported to be protective or risk-associated, only eight
were not previously described as significantly modulated in GBM samples.
This demonstrates a relatively broad coverage in terms of the miRNAs inves-
tigated purely to assess miRNA modulation in GBM pathogenesis without
correlating the data to clinical outcome (Table 4.3). No general patterns apply
to these cohorts of protective and risk- associated miRNAs, as such, several
miRNAs, which are described as oncogenic from a functional standpoint, are
present within the cohort of protective miRNAs and vice versa. This compar-
ison between in vitro functionality and clinical implication of GBM-related
miRNAs illustrates that although a specific miRNA may have a specific set of
functional characteristics when artificially over or underexpressed in isolated
in vitro models, this is not necessarily a good indicator for the multifacto-
rial clinical progression of GBM. For more elaborate details of the functional
characterisation of miRNAs involved in GBM, please refer to [282].
4 MicroRNAs Included in Several Signatures
Based on the multiple-miRNA signatures identified from both tissue and
database studies pertaining to survival, the miRNAs found in multiple stud-
ies were identified (Table 4.4). Most of the miRNA found in signatures are
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Table 4.3: miRNAs reported to be protective (pale green) or risky-associated (pale magenta).
MicroRNAs described as either protective (pale green) or risk-associated (pale magenta) com-
pared with their corresponding functional characteristics. The terms overexpressed and under-
expressed refers to miRNA expression data comparing GBM samples to normal brain tissue.
Disputed expression signifies that different studies present contradictory results. The numbered
brackets are numbers of studies supporting the observation.
miRNA Reference Function in GBM Validated tar-
gets
Reference
hsa-miR-9 [424] Overexpressed (5),
oncogenic proper-
ties
CAMTA1 Huse et al. [168],
Lages et al. [212],
Malzkorn et al.
[268], Rao et al.
[328], Schraivogel
et al. [345]
hsa-miR-17-5p [374, 424] Overexpressed (9),
oncogenic proper-
ties
CAMTA1,
CTGF,
POLD2,
PTEN, TGFβ-
RII
Dews et al.
[75], Ernst et al.
[92], Lages et al.
[212], Lavon et al.
[221], Malzkorn
et al.
[268], Rao et al.
[328], Schraivo-
gel et al.
[345], Wuchty
et al. [447]
hsa-miR-19a [424] Disputed expres-
sion in GBM (6)
CTGF Dews et al.
[75], Ernst et al.
[92], Lavon et al.
[221], Malzkorn
et al. [268], Rao
et al.
[328], Wuchty
et al. [447]
hsa-miR-19b [424] Disputed expres-
sion in GBM (4)
Ernst et al.
[92], Lavon et al.
[221], Rao et al.
[328], Wuchty
et al. [447]
hsa-miR-20a [374, 424] Overexpressed (5),
oncogenic proper-
ties
TGFbeta-RII,
CTGF
Dews et al.
[75], Lages et al.
[212], Lavon et al.
[221], Malzkorn
et al.
[268], Wuchty
et al. [447]
hsa-miR-99a [424] Overexpressed (2),
oncogenic proper-
ties
Rao et al.
[328], Wuchty
et al. [447]
hsa-miR-106a [374, 424] Disputed expres-
sion in GBM (5)
E2F1 Lavon et al. [221],
Rao et al. [328],
Yang et al. [455],
Zhi et al. [473? ]
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hsa-miR-128a [424] Underexpressed
(13), tumour sup-
pressive
WEE1,
p70S6K1,
Msi1, E2F3a,
Bmi-1, EGFR,
PDGFRα
Ciafre et al.
[57], Cui et al.
[63], Godlewski
et al.
[119], Lakomy
et al. [215], Lavon
et al. [221], Li et al.
[234], Rao et al.
[328], Shi et al.
[358], Vo et al.
[414], Wuchty
et al. [447], Zhang
et al. [462? ? ? ]
hsa-miR-128b [424] Underexpressed (7) WEE1 Ciafre et al.
[57], Lavon et al.
[221], Li et al.
[234], Skalsky
and Cullen
[365], Wuchty
et al. [447], Zhang
et al. [462? ]
hsa-miR-139 [395, 424] Underexpressed (5) Lages et al.
[212], Lavon et al.
[221], Silber et al.
[361], Skalsky
and Cullen
[365], Wuchty
et al. [447]
hsa-miR-181d Zhang et al.
[468, 471]
Underexpressed (1),
tumour suppressive
Bcl-2, K-Ras Kreth et al. [207],
Wang et al. [427]
hsa-miR-183 [424] Underexpressed (2) Huse et al.
[168], Jiang et al.
[179], Lavon et al.
[221], Wu et al.
[441], Wuchty
et al. [447]
hsa-miR-217 [424] Overexpressed (2) Lavon et al.
[221], Wuchty
et al. [447]
hsa-miR-301 [424] Overexpressed (2) Lavon et al.
[221], Wuchty
et al. [447]
hsa-miR-324-5p [424] Overexpressed (1) Li et al. [234]
hsa-miR-328 Wu et al.
[445]
Underexpressed (2) Lavon et al. [221],
Malzkorn et al.
[268]
hsa-miR-374 [424] Overexpressed (1) Lages et al. [212],
Rao et al. [328]
hsa-miR-497 [424] Overexpressed (1) Wuchty et al.
[447]
hsa-miR-524-5p Li et al.
[241], Zhang
et al. [471]
Overexpressed (1) Wuchty et al.
[447]
hsa-miR-544 Li et al. [241] Overexpressed (1) Wuchty et al.
[447]
hsa-miR-628-5p Li et al. [241] Rao et al. [328]
hsa-miR-1227 Zhang et al.
[471]
No studies
hsa-miR-15a Tian et al.
[395]
Overexpressed (4) Malzkorn et al.
[268], Rao et al.
[328], Wuchty
et al. [447], Zhang
et al. [462]
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hsa-miR-31 Srinivasan
et al. [374]
No studies
hsa-miR-34a [424] Underexpressed (5),
tumour suppressive
SIRT1, c-Met,
Notch1/2,
PDGFRA,
Msi1
Guessous et al.
[127], Li et al.
[238], Luan et al.
[259], Silber et al.
[362], Vo et al.
[414]
hsa-miR-34b [424] No studies
hsa-miR-146b Srinivasan
et al. [374]
Underexpressed (5),
tumour suppressive
Katakowski et al.
[189], Xia et al.
[449]
hsa-miR-148a [424][374] Overexpressed (1) Huse et al. [168]
hsa-miR-155 [424] Overexpressed (6) Dong et al.
[79], Lages et al.
[212], Lavon et al.
[221], Meng et al.
[276], Rao et al.
[328], Wuchty
et al. [447]
hsa-miR-193a [374] Overexpressed (1) Lavon et al.
[221], Wuchty
et al. [447]
hsa-miR-200b [374] Overexpressed (2) Wuchty et al.
[447]
hsa-miR-221 [374, 424] Overexpressed
(11), oncogenic
properties
P27, Akt,
PUMA,
P57, PTPµ,
Cx43, TIMP3,
MGMT
Conti et al. [60],
He et al. [138], Lu
et al. [258], Med-
ina et al. [275],
Quintavalle et al.
[324], Zhang et al.
[462, 464, 466? ? ?
]
hsa-miR-222 [374, 424] Overexpressed (9),
oncogenic proper-
ties
P27, Akt,
PUMA,
P57, PTPµ,
Cx43, TIMP3,
MGMT
Ciafre et al.
[57], Medina
et al. [275], Quin-
tavalle et al.
[324], Wang et al.
[426], Zhang et al.
[462, 464, 466? ? ]
hsa-miR-297 Zhang et al.
[469]
No studies
hsa-miR-299-3p Zhang et al.
[469]
Underexpressed (1) Lavon et al. [221]
hsa-miR-346 Zhang et al.
[469]
No studies
hsa-miR-518b Zhang et al.
[469]
Overexpressed (1) Wuchty et al.
[447]
hsa-miR-541* Zhang et al.
[469]
No studies
hsa-miR-551a Zhang et al.
[469]
No studies
hsa-miR-566 Zhang et al.
[469]
Overexpressed (1) Wuchty et al.
[447]
hsa-miR-661 Zhang et al.
[469]
Overexpressed (1) Wuchty et al.
[447]
hsa-miR-768-3p [424] Overexpressed (1) Wuchty et al.
[447]
hsa-miR-936 Zhang et al.
[469]
No studies
hsa-miR-1238 Zhang et al.
[469]
No studies
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Table 4.4: miRNA signatures correlating with survival in GBM. Overview of the miRNA signa-
tures reported in database studies and independent tissue cohort studies correlated with survival
or progression of GBM. The miRNAs marked in bold were detected in two or more studies.
Reference microRNA
Bozdag et al. [32] Ebv-miR-BART1-5p, Ebv-miR-BHRF1-2, Hcmv-miR-UL70-5p,
hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-147, hsa-miR-223,
hsa-miR-302c, hsa-miR-325, hsa-miR-422b, hsa-miR-453, hsa-
miR-507, hsa-miR-552, hsa-miR-558, hsa-miR-620, hsa-miR-649,
hsa-miR-661
Hua et al. [163] hsa-miR-19a, hsa-miR-93, hsa-miR-221, hsa-miR-222
Lakomy et al. [215] hsa-miR-21, hsa-miR-128a, hsa-miR-181c, hsa-miR-195, hsa-
miR-196a, hsa-miR-196b, hsa-miR-221, hsa-miR-222
Li et al. [241] hsa-miR-15a, hsa-miR-139-5p, hsa-miR-524-5p, hsa-miR-544,
hsa-miR-628-5p
Niyazi et al. [291] hsa-let-7a, hsa-let-7f, hsa-let-7g, hsa-let-7i, hsa-miR-26a*, hsa-
miR-29b, hsa-miR-30b, hsa-miR-124, hsa-miR-129-3p, hsa-miR-
136, hsa-miR-195, hsa-miR-210, hsa-miR-374b, hsa-miR-409-
3p, hsa-miR-487b, hsa-miR-539, hsa-miR-555, hsa-miR-578, hsa-
miR-590-3p, hsa-miR-595, hsa-miR-720, hsa-miR-1260, hsa-miR-
1282, hsa-miR-1286, hsa-miR-1305, hsa-miR-2113, hsa-miR-3065-
3p, hsa-miR-3132, hsa-miR-3163, hsa-miR-4286
Qiu et al. [322] hsa-miR-130a, hsa-miR-155, hsa-miR-210, hsa-miR-323, hsa-
miR-326, hsa-miR-329
Srinivasan et al. [374] hsa-miR-17-5p, hsa-miR-20a, hsa-miR-31, hsa-miR-106a, hsa-
miR-146b, hsa-miR-148a, hsa-miR-193a, hsa-miR-200b, hsa-
miR-221, hsa-miR-222
Wang et al. [429] hsa-miR-9, hsa-miR-17-5p, hsa-miR-19a, hsa-miR-19b, hsa-
miR-20a, hsa-miR-34a, hsa-miR-34b, hsa-miR-99a, hsa-miR-
106a, hsa-miR-128a, hsa-miR-128b, hsa-miR-139, hsa-miR-148a,
hsa-miR-155, hsa-miR-183, hsa-miR-217, hsa-miR-221, hsa-
miR-222, hsa-miR-301, hsa-miR-324-5p, hsa-miR-374, hsa-miR-
497, hsa-miR-768-3p
Zhang et al. [468] hsa-miR-181d, hsa-miR-297, hsa-miR-299-3p, hsa-miR-346, hsa-
miR-541*, hsa-miR-551a, hsa-miR-661, hsa-miR-936, hsa-miR-
1238
Zhang et al. [469] hsa-miR-181d, hsa-miR-566, hsa-miR-524-5p, hsa-miR-518b,
hsa-miR-1227
Zhi et al. [473] hsa-miR-21, hsa-miR-106a, hsa-miR-181b
Zinn et al. [480] hsa-miR-92b, hsa-miR-345, hsa-miR-369-3p, hsa-miR-484, hsa-
miR-505, hsa-miR-511, hsa-miR-566, hsa-miR-655
specific for the given study. Thirteen of the miRNAs were identified in more
than one study; however, no miRNAs were identified in more than three
studies. Through miRNA array analysis, Niyazi et al. found a 30-miRNA
signature in an independent cohort, which divided the samples into short-
and long-term survival [291]. Furthermore, Zhang et al. and Srinivasan et al.
used similar methods and the same database, but the overlap between these
studies was poor [374, 469].
It is striking that the database studies do not reveal better coherency; how-
ever, this could be attributed to the cohort factors studied or the filtering of
the miRNAs during the analysis. The tissue studies represent independent
cohorts; however, many of the database studies have validated their results in
independent cohorts, whereby the cohort factors could be the prime source
for the lack of overlap. Additionally, Ilhan-Mutlu et al. [173] chose to inves-
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tigate seven well-characterised miRNAs (miR-10b, miR-21, miR-181b, miR-
181c, miR-195, miR-221, miR-222) and found that none of them correlated
with survival contradicting other studies [374, 424]. Therefore, the thirteen
miRNAs identified in more than one signature could be more applicable in
their prediction of survival and of great interest in relation to GBM prognosis.
4.1 Functional Analysis of the MicroRNAs Included in Several
Signatures
The majority of the thirteen miRNAs included in more than one signature
have been functionally characterised in GBM and associated with the expres-
sion of validated target genes (Table 4.5). The most well-characterised mi-
RNA in GBM is miR-21, which functions as an oncogenic miRNA. miR-21 has
numerous validated target genes that it represses in GBM and therefore it is
interesting that this miRNA is included in two signatures. The target genes of
miR-21 include genes associated with proliferation (e.g., PTEN and PDCD4),
invasiveness (e.g. TIMP3 and RECK), and susceptibility to chemo and ra-
diation therapy (e.g., hMSH2), factors, which are all characteristics of GBM
tumours [46, 109, 114, 475]. The same characteristics of GBM tumour growth
are also modulated by miR-221 and miR-222, both of which appear in three
signatures. Being less well characterised than miR-21, miR-221 and miR-222
still have several validated target genes including some important tumour
suppressor genes such as p27, p57, TIMP3, and Cx43 [135, 258, 275, 463].
In addition to the oncogenic miRNAs identified in more than one signa-
ture, different tumour suppressor miRNAs were also found in several signa-
tures. miR-195 has validated target genes, including some cyclins and E2F3,
which are associated with cell proliferation [167, 467]. Hence, a low expres-
sion of this miRNA should in theory correlate with a favourable clinical out-
come, which is in fact reflected in the clinical data [215]. Another interesting
miRNA shown in more than one signature is miR-136, which has very little
functional characterisation, but the current validated target genes include the
important oncogene, Bcl-2 [457]. Several of the thirteen miRNAs (miR-155,
miR-17-5p, miR-181b, miR-195, miR-20a, miR- 21, miR-221, and miR-222) are
known to modulate the MMMI, which is an important characteristic of GBM
cells [282, 474]. Three of the miRNAs identified in more than one signature
have no functional characterisation and could possibly reveal numerous rel-
evant target genes to substantiate the importance of the thirteen miRNAs in
future determination of patient prognosis.
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Table 4.5: Functional characteristics of miRNAs found in several signatures. MiRNAs found
in several signatures and their functional characteristics. Each miRNA is noted along with their
validated targets, their functional role, and how many signatures they appear in. Regarding the
functional role, 1 designate the functional role of the miRNA when it is overexpressed and 2 the
functional role when it is inhibited in vitro or in vivo.
microRNA Validated
targets
Functional role when,
1: Overexpressed,
2: Inhibited
No. of
signatures
included
Reference to
functional stud-
ies
hsa-miR-106a E2F1,
SLC2A3
1: Proliferation↓,
Apoptosis↑
2 Munoz et al. [286],
Yang et al. [455]
hsa-miR-136 AEG-1, Bcl-2 1: Apoptosis↑ 2 Yang et al. [457]
hsa-miR-148a No val-
idated
targets
No functional analysis
performed
2
hsa-miR-155 GABRA-1,
FOXO3a
1: Proliferation↑,
Apoptosis↓, Invasion↑
3 D’Urso et al. [83],
Ling et al. [247]
hsa-miR-17-5p POLD2,
TGFβ-RII,
CTGF,
CAMTA1,
PTEN
1: Angiogenesis↑,
Growth↑, Invasion↑,
Migration↑,
Chemosensitivity↓
2: Viability↓, Apoptosis↑,
Proliferation↓
2 Dews et al. [75],
Ernst et al. [92],
Li and Yang [236],
Malzkorn et al.
[268], Schraivogel
et al. [345]
hsa-miR-181b FOS, MEK1,
IGF-1R
1: Xenograft growth↓,
Chemosensitivity↑,
Invasion↓, Proliferation↓,
Migration↓
2 Shi et al. [359], Tao
et al. [388], Wang
et al. [422]
hsa-miR-195 E2F3,
CCND3,
Cyclin D1,
Cyclin E1
1: Invasion↓,
Proliferation↓, Xenograft
growth↓
3 Yang et al. [457],
Zhang et al. [467]
hsa-miR-20a TGFβ-RII,
CTGF
1:Angiogenesis↑,
Growth↑
2: Viability↓,
Proliferation↓
2 Dews et al. [75],
Ernst et al. [92]
hsa-miR-21 RECK,
TIMP3,
APAF1,
ANP32A,
SMARCA4,
Caspases,
PTEN,
Cdc25A,
HNRPK,
TAp63,
Spry2,
LRRFIP1,
PDCD4,
hMSH2
1:Invasiveness↑,
Radiosensitivity↓
2: Invasiveness↓,
Apoptosis↑, Viability↓,
Proliferation↓, In vivo
tumour volume↓,
Chemosensitivity↑,
Radiosensitivity↑
2 Chan et al.
[44], Chao et al.
[46], Ciafre et al.
[57], Corsten et al.
[62], Gabriely
et al. [109], Gaur
et al. [114], Han
et al. [132], Kwak
et al. [211], Li et al.
[239, 240], Papa-
giannakopoulos
et al. [310], Ren
et al. [333, 334],
Schramedei et al.
[346], Shi et al.
[355], Zhou et al.
[476? ]
hsa-miR-210 No val-
idated
targets
No functional analysis
performed
2
hsa-miR-221 P27, Akt,
PUMA, P57,
PTPµ, Cx43,
TIMP3,
MGMT
1: Proliferation↑,
Invasiveness↑, In vivo
tumour volume↑,
Apoptosis↓, Migration↑
2: Proliferation↓,
Apoptosis↑, in vivo
tumour volume↓,
Radiosensitivity↑
3 Hao et al. [135],
Li et al. [237], Lu
et al. [258], Lukiw
et al. [262], Med-
ina et al. [275],
Quintavalle et al.
[324, 326], Zhang
et al. [463, 464]
54
5. Perspectives on MicroRNA-Based Therapies for the Treatment of Glioblastoma
Multiforme
hsa-miR-222 P27, Akt,
PUMA, P57,
PTPµ, Cx43,
TIMP3,
MGMT
1: Proliferation↑,
Invasiveness↑, In vivo
tumour volume↑,
Apoptosis↓, Migration↑
2: Proliferation↓,
Apoptosis↑, In vivo
tumour volume↓,
Radiosensitivity↑
3 Hao et al. [135],
Li et al. [237], Lu
et al. [258], Med-
ina et al. [275],
Quintavalle et al.
[324, 326], Zhang
et al. [463, 464? ]
hsa-miR-566 No val-
idated
targets
No functional analysis
performed
2
5 Perspectives on MicroRNA-Based Therapies for the
Treatment of Glioblastoma Multiforme
Given the fact that several miRNA signatures associated with OS or PFS have
been identified and that these miRNAs have functional characteristics with
importance in GBM progression, a therapeutic concept taking advantage of
such correlations seems inherent. The use of miRNA-based therapies in the
treatment of GBM is still in its primary phases with exciting basic research
being published frequently [396].
Approaches for utilizing miRNAs in such treatment regimens includes
both inhibition of oncogenic miRNAs (e.g., miR-21) or overexpression of tu-
mour suppressor miRNAs (e.g., miR-146b) with different types of carriers to
facilitate delivery directly to the tumour tissue [125, 190]. Systemic admin-
istration of a liposome-encapsulated tumour suppressor miRNA, miR-7, led
to a significant tumour size reduction in a xenograft mouse model of GBM.
In addition, several key oncogenes were downregulated upon the tumour
suppressor miRNA delivery [425]. Another more sophisticated type of lipid-
based delivery was exploited by Griveau et al. [125] where locked nucleic
acid miRNA inhibitors against miR-21 conferred increased radiosensitivity in
U87MG cells. miRNA carriers have also been generated with polymer- based
technology, using poly(amido amine) to encapsulate miR-7 for delivery to
U251 cells, which resulted in a higher transfection efficiency than liposomal
delivery [251].
Of particular interest in solving the problems with efficient drug deliv-
ery to the brain, both in malignancies and neurodegenerative diseases is the
use of exosomes as drug carriers [227]. Exosomes are endogenous vesicular
structures with a diameter ranging from 40 to 120 nm produced by all cells
in the body [4]. They are characterised by expression of specific proteins in
the membrane (especially tetraspanins) and their ability to deliver proteins,
mRNA and miRNAs [413]. The delivered mRNAs and miRNAs are fully
functional and can be translated into protein or inhibit mRNA targets in the
recipient cells [188, 406].
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The potential of exosomes to deliver functional RNAs to cells was utilised
by Alvarez-Erviti et al. [3], who provided interesting evidence as to how
exosomes might be used to deliver drugs across the ever troubling blood-
brain barrier. Immature dendritic cells were transfected to produce exosomes
that expressed a neuron-specific targeting peptide on their surfaces to facil-
itate specific delivery of the exosome cargo. These exosomes successfully
delivered both GAPDH- and BACE1-siRNA across the blood-brain barrier
resulting in specific gene silencing in the neuronal tissue. Using a some-
what similar approach, Ohno et al. [299] showed that exosomes targeted to
EGFR could deliver the tumour suppressor miRNA, let-7a, to a xenograft
breast cancer model after intravenous administration. Furthermore, let-7a
suppressed the growth of the tumour underscoring the relevance of using
exosomal delivery in malignant diseases.
Evidence is now emerging showing that exosomal delivery of interfer-
ing RNAs could be relevant in the treatment of GBM. GBM cell lines were
shown to be resistant to treatment with anti-miRs against the oncogenic mi-
RNA, miR-9, described in Table 4.3. However, if these GBM cells were co-
cultured with anti-miR-transfected mesenchymal stem cells (MSCs) or cul-
tured in the presence of anti-miR-transfected MSC-exosomes, miR-9 was sig-
nificantly downregulated. This decrease in miR-9 expression made the GBM
cells more susceptible to treatment with the chemotherapeutic drug, temo-
zolomide [286]. [190] also produced exosomes in MSCs, which were trans-
fected with a miR-146b expression vector. The resulting miR-146b-containing
exosomes were injected into xenograft GBM tumours, leading to a significant
reduction in tumour volume compared to vehicle-treated controls. Interest-
ingly, it has previously been shown that miR-146b negatively correlates with
survival in GBM [374]. The use of exosomes in the treatment of GBM may
have a great potential and should be substantiated with more evidence in-
cluding choice of relevant miRNA cargo and direct targeting of GBM cells to
facilitate intravenous administration.
6 Concluding Remarks
This review presents the studies investigating the expression of specific miR-
NAs or miRNA signatures with respect to their correlation to clinical pro-
gression of GBM. A large part of the studies utilise data from the same data-
bases (TCGA or CGGA), but they do not necessarily reveal the same results.
This is because the extracted data and the filtering based on clinical informa-
tion differ across individual studies, which makes comparison difficult (Table
4.1). The studies using individual tissue cohorts also reveal different miRNA
signatures with only some consistency between them. Such varying results
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may be caused by several factors, including miRNAs investigated, type of
array platform utilised, cohort size and especially the choice of control tissue.
Comparing miRNA expression data to control tissue obtained from another
type of diseased brain (i.e., epilepsy) might be problematic because it may
induce variations in the miRNA expression data compared to studies using
non-diseased normal brain tissue.
Furthermore, imperfect description of terminology with regard to OS and
PFS may also add complexity to the comparison of the different miRNA sig-
natures. Several studies report some miRNAs to have a protective or risk-
associated profile with respect to their correlation with clinical outcome in
GBM. Interestingly, several of these miRNAs have validated functions in vitro
and in vivo, which are opposite to the way that they should mediate either
protection or risk. Therefore, the in vitro and in vivo studies available for
numerous miRNAs are not necessarily good indicators for the multifactorial
clinical progression of GBM (Table 4.3). However, many of the miRNAs re-
ported to be either protective or risk-associated or the miRNAs included in
several signatures do in fact have validated targets and functional characteris-
tics, which are in line with their correlation to clinical progression or survival
of GBM (Tables 4.3, 4.4, and 4.5). Having been associated with disease pro-
gression or survival in several studies, these miRNAs may be valuable for
future determination of patient prognosis and could possibly serve as targets
for miRNA-based therapies, which hold a great potential in the treatment of
this severe malignant disease.
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1. Results
The increased interest devoted to the development of miRNA-based prog-
nostic signatures to aid in the clinical decision-making has revealed a large
number of available miRNA signatures correlating with disease outcome and
survival, but the level of coherency between the different signatures was low,
see Chapter 4 [145]. Interestingly, the great use of TCGA data did not re-
veal any particular coherency across the studies, possibly due to the different
types of data that can be extracted from this database. The type of control
tissue varied between the studies and was often derived from other diseased
brains. Interestingly, several of the miRNAs found to be associated with ei-
ther risk or protection have multiple targets validated in model cell culture
systems opposite to what would be expected from such an association. This
could point to the fact that these in vitro evaluations may not be good in-
dicators for the multifactorial clinical progression of GBM. Some miRNAs
were present in several signatures, suggesting that they could be of interest
both in prognosis and as therapeutic targets [145]. However, a combination
of molecular profiling (e.g., with miRNA signatures) and clinicopathological
findings is seldom seen.
This present study aims to combine clinicopathological findings with mo-
lecular profiling of GBM tumours and to identify connections between these
features that may have the potential of predicting survival and illuminate
aspects of GBM pathogenesis.
1 Results
1.1 Clinical Data
Tissue from fourteen GBM tumours isolated from patients was examined
(Appendix A). Median overall survival of the patient cohort was 57 weeks,
ranging from 5 to 207 weeks. Median age was 61 years (range 27–85). The
gender ratio (men/women) was 1:2 (five men/ nine women). Surgery con-
sisted of resection with (79 %) or without (21 %) tumour visualisation by
5ALA-induced fluorescence. Six tumour samples exhibited increased posi-
tivity of the neural stem cell marker, NES, while nine tumour samples had
high expression of the proliferation indicator, Ki67, determined at the time of
pathological diagnosis. All clinical features were analysed with the univariate
log-rank test to identify any correlations to patient survival. These analyses
revealed that age [p = 0.0497, Hazard ratio = 0.2230 (95 % CI 0.04982–0.9980)],
NES expression [p = 0.0169, Hazard ratio = 7.799 (95 % CI 1.445–42.09)] and
tumour recurrence [p = 0.025, Hazard ratio = 0.176 (95 % CI 0.038–0.804)]
were all predictors of patient outcome, while no correlations could be found
between any other clinical feature and patient survival (Table 5.1).
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Table 5.1: Univariate analysis using the log-rank test.
Factor p value Hazard ratio 95% CI
Gender 0.839 0.854 0.186-3.926
Age 0.035 0.198 0.044-0.889
5ALA 0.365 2.563 0.335-19.63
Nestin 0.008 10.30 1.845-57.47
Recurrence 0.025 0.176 0.038-0.804
Ki67 0.175 0.202 0.020-2.041
1.2 MicroRNA Expression Profile Determines Patients Survival
The fourteen GBM tumour samples were tested by the TaqMan Low Density
Array Cards to analyse the expression of 750 mature human miRNAs across
two cards (A and B). Based on MAD, miRNAs were filtered with a threshold
set at the first quartile calculated for all miRNAs with a MAD above zero.
This resulted in 287 miRNAs, which had different expression levels across
the fourteen tumour samples. These 287 miRNAs were used to make a hi-
erarchical clustering of the samples, resulting in two distinct clusters (Figure
5.1) The two clusters were analysed by Kaplan–Meier estimation and uni-
variate analysis for their correlation with respect clinical data such as overall
survival. This analysis showed that the miRNA pattern clustering defined
two groups of patients based on the clinical data, which corresponded to ei-
ther long-term or short-term survival [p = 0.030, Hazard ratio = 5.235 (95 %
CI 1.170–23.43)] (Figure 5.2).
Fig. 5.1: Dendrogram presenting the hierarchical clustering of the tumour samples based on
the expression profile of 287 miRNAs. The clustering was made based on the median absolute
deviation, Euclidean distance and complete linking. Tumor numeration: C = tumour sample
coding
Comparing the miRNA patterns between the two clusters defined a to-
tal of 161 miRNAs (cluster 1 vs. cluster 2), which had significantly different
expression levels with a twofold change as a cut off. These upregulated miR-
NAs of cluster 1, indicative of long-term survival, were grouped based on
current evidence of their aberrant expression profile in GBM tissue compared
to normal brain tissue [282]. The grouping showed that miRNAs upregulated
in tumour samples from patients with long-term survival could be associated
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Fig. 5.2: Kaplan–Meier survival diagram for cluster 1 (n = 7) or cluster 2 (n = 7) based on
hierarchical clustering of the tumour samples miRNA expression profile. Univariate analysis
showed that the patients in cluster 1 had significantly longer survival than those in cluster 2
(log-rank test, p = 0.030)
both with up- and downregulation in GBM. A small number of miRNAs had
a disputed role in GBM pathogenesis, while almost a third of all the miRNAs
identified in this experiment had no reported dysregulation in GBM. In addi-
tion, both validated oncogenic and tumour suppressor miRNAs were found
between these long-term survival-associated miRNAs (Figure 5.3; Appendix
A Tables A.1-A.4).
1.3 MicroRAs Dysregulated Between Long- and Short-Term Sur-
viving Patients are Reported to Confer Risk or Protection or
Modulate the Mesenchymal Mode of Migration and Invasion
in GBM
Several of the miRNAs found to be dysregulated between short- and long-
term surviving patients were previously reported to be involved in the tu-
mourigenesis and progression of GBM. Some of these miRNAs have been
reported to confer either risk or protection with regard to GBM patient sur-
vival, as was recently reviewed [145]. Thirteen of the miRNAs with increased
expression between the two clusters were previously found to confer either
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Fig. 5.3: Graphical representation of the 161 differentially expressed miRNAs between cluster
1 and 2. a The fold change between cluster 1 and 2 with each miRNA color-coded corresponding
to previously reported dysregulations in GBM as upregulated (red), downregulated (green),
disputed (yellow) and not reported (blue). b Pie chart depicting the distribution of miRNAs
within the four color-coded groups.
risk or protection. For each of these miRNAs, functionally verified targets
were identified through miRTarBase, and the expression of these targets was
analysed using microarray gene expression analysis. Target genes with sig-
nificantly different expression between the two clusters were identified and
correlated to miRNAs with these genes proposed as their functional targets
(presented in Table 5.2). The same analysis was performed to identify sixteen
miRNAs known to regulate the MMMI (Table 5.3) [282]. In total, three of
these genes (E2F3, CTGF, Akt2) associated with the miRNAs conferring risk
or protection or modulate the MMMI have been shown previously to be im-
portant validated targets of miRNAs responsible for disease progression in
GBM (highlighted in bold).
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Table 5.2: MicroRNAs reported to be protective or risk-associated, and those targets that have
been functionally characterised and differentially expressed between cluster 1 and 2.
microRNA Proposed func-
tion
Target genes
hsa-miR-20a Protective ARFGEF2, BACH1, E2F3, GATA6, IL17RC, IRF2,
PLEKHM3, PPARG, RBL1, RBL2, RPL18A
hsa-miR-99a Protective GNAL, KIRREL, PPP5C, RNF187, TUBG1
hsa-miR-128 Protective CDKN1B, E2F3, ETS1, FAB126B, FAM83G, GCN1L1,
HERC4, HSP90AA1, OGFOD1, RFC1, SELE, SERTAD4,
SKIV2L, TATDN2, TOP3A
hsa-miR-139-3p Protective
hsa-miR-139-5p Protective
hsa-miR-328 Protective
hsa-miR-374b Protective MRPL19, RANBP6
hsa-miR-628-5p Protective
hsa-miR-31 Risky CASR, CXCL12, DKK1, ETS1, NFATC2IP, PPIL2, SELE,
TXNDC5
hsa-miR-34a Risky ACSL4, ATXN2L, CDKN2A, CDON, CFL1, E2F3,
EHD1, EIF4G1, EMP1, FOXP1, GRM7, HIST1H1D,
HIST1H2BO, HIST1H4L, MAP3K9, OGFOD1,
PPP1R10, PPP3R1, PUM2, STAT1, TATDN2, TRAIP,
VAMP2, VPS37B, XRN1, ZAP70
hsa-miR-146b-5p Risky AKT3
hsa-miR-200b Risky CREB1, E2F3, ETS1, FLT1, FN1
hsa-miR-222 Risky CDKN1B, ETS1, FAB126B, FAM83G, GCN1L1, HERC4,
HSP90AA1, OGFOD1, RFC1, SELE, SERTAD4,
SKIV2L, TATDN2, TOP3A
Table 5.3: MicroRNAs linked to MMMI, and those targets that have been functionally charac-
terised and differentially expressed between cluster 1 and 2.
microRNA Proposed func-
tion
Target genes
hsa-miR-26b Tumour suppres-
sor
ABCF1, ACVR1B, ASTN2, ATF3, ATXN2L, BCL11B,
BNC1, BRDT, C22orf29, CATSPERB, CDIPT, CEND1,
CNOT4, CNPY3, CXCL6, DDX60, DHX30, DRD3,
DSC1, DYNC2LI1, EEF1A1, EFNA2, EGR3, EIF4A1,
ENTPD7, EXOC6B, FANCC, FBLN5, FN1, FOXE1,
GKN1, GNB5, GPR107, HIST1H1D, IBSP, IL17RC,
IL1RL1, INPP5B, INSR, ISOC2, KCNQ2, KIAA1107,
KREMEN2, KRTAP5-7, LAMA3, LRPAP1, MAFG,
MAGEA9, MED22, METTL9, NACC2, NOP2, NSF,
NXPH4, ODAM, ODF2, OTC, PEX5L, PHLDA2,
PHLPP2, PNOC, PODXL, POU4F1, PPP3R1, PSMD5,
PAB11FIP1, RAB3A, RAD54L2, RNF187, RORC,
RSAD2, SCP2, SIPA1, SLC17A5, SLC35C1, SLC6A9,
SV2B, SYNE1, TAGLN, TAZ, TGFB1I1, UPF3B, ZNF35
hsa-miR-29b Tumour suppres-
sor
BMP1, CDC42, COL1A1, COL3A1, CTNNBIP1
hsa-miR-34a Tumour suppres-
sor
ACSL4, ATXN2L, CDKN2A, CDON, CFL1, E2F3,
EHD1, EIF4G1, EMP1, FOXP1, GRM7, HIST1H1D,
HIST1H2BO, HIST1H4L, MAP3K9, OGFOD1,
PPP1R10, PPP3R1, PUM2, STAT1, TATDN2, TRAIP,
VAMP2, VPS37B, XRN1, ZAP70
hsa-miR-124 Tumour suppres-
sor
hsa-miR-125a-5p Tumour suppres-
sor
ERBB2, MMP11, NIN, PDPK1, PREPL, PUM2, SRGAP2
hsa-miR-137 Tumour suppres-
sor
CDC42, CTBP1, NCOA2
hsa-miR-184 Tumour suppres-
sor
AKT2
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hsa-miR-195 Tumour suppres-
sor
E2F3, BCL2L11, CDC42
hsa-miR-218 Tumour suppres-
sor
hsa-miR-326 Tumour suppres-
sor
ATXN2L, CD9, ERBB2
hsa-miR-27b Oncogenic CTSB, EYA4, NPEPPS, PPARG, RAPGEF1
hsa-miR-93 Oncogenic CDC42, DHX30, EEF1A1, EIF4A1, HYOU1, MAFG,
PAMR1, WASH3P, ZNF703
hsa-miR-143 Oncogenic COL1A1
hsa-miR-145 Oncogenic CTGF, ERG, NEDD9, PODXL, STAT1, TPRG1
hsa-miR-222 Oncogenic CDKN1B, ETS1, FAB126B, FAM83G, GCN1L1, HERC4,
HSP90AA1, OGFOD1, RFC1, SELE, SERTAD4,
SKIV2L, TATDN2, TOP3A
hsa-miR-125b Disputed BACH1, CDKN2A, E2F3, EEF1A1, ERBB2, ETS1,
KIF24, MAPK14, MYO19, PLEKHA8, PPP1R12C,
RPLP0, RPS6KA1
1.4 Expression of miR-125b and Neural Stem Cell Marker Nestin
Correlate with Patient Survival
Since a positive correlation between NES expression in GBM tumour tissue
and the degree of malignancy has been reported, a univariate log-rank test
was performed to determine any differences in NES expression between the
two clusters, showing that the level of NES expression negatively correlated
with patient survival (p = 0.008). Next, the differentially expressed miRNAs
were scrutinised for known negative regulators of NES expression. From this
analysis, miR-125b was found to have significant aberrant expression between
the two clusters and to have Nestin as a validated mRNA target (determined
with miRTarBase). Univariate analysis of the distribution of miR-125b ex-
pression showed that miR-125b expression alone positively correlated with
patient survival (log-rank test, p = 0.018). Interestingly, the gene expression
level of Nestin determined from the microarray analysis did not differ signif-
icantly between the two clusters, and no correlation between such expression
and patient’s survival could be found (log-rank test, p = 0.318).
In theory, the expression of a single miRNA and the protein product of its
validated targets should be negatively correlated. Thus, the tumour samples
were grouped to determine such a correlation (low miR-125b + high NES vs.
high miR-125b + low NES). A Fisher’s Exact test showed that the frequency of
high miR-125b + low NES was significantly higher in the patients with long-
term survival (n = 9, p = 0.039), and hence, this combination of molecular
characteristics also correlated with patient survival (log-rank test, p = 0.003).
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1.5 Exosome-Packaging Motifs in the Mature Sequences of Dif-
ferentially Expressed microRNAs Indicate a Role in Para-
crine Signalling
It was recently published that a number of miRNAs possess specific exosome-
packaging motifs (EXO-motifs) in the mature sequence that guides them to-
ward packaging and secretion in exosomes [411]. Therefore, all miRNAs with
a significantly different expression between long- and short-term-surviving
patients were investigated for their contents of these particular EXO-motif
sequences. This analysis revealed that 61 out of 161 differentially expressed
miRNAs possessed EXO-motifs in their mature sequences, indicating a role
of these miRNAs in the paracrine communication between individual cells in
GBM tumors (Table 5.4). Among the 61 miRNAs bearing EXO-motifs, miR-
NAs known to be upregulated or downregulated in GBM accounted for ∼30
% each. Approximately ten per cent had a disputed function, while the last
∼30 % has no validated dysregulation or function in GBM. Several validated
tumour suppressor miRNAs contained EXO-motifs, including two miRNAs
(let-7a and miR-146b) that have previously been overexpressed in donor cells
to be loaded into exosomes [188, 299]. Interestingly, miR-125b, whose expres-
sion in combination with Nestin expression correlated with patient survival,
contained three individual EXO-motifs along its mature sequence (Figure 5.4;
Table 5.4).
Fig. 5.4: The mature sequence of miR-125b containing three individual exosome-packaging mo-
tifs
2 Discussion
In this study, we have combined clinicopathological data with molecular pro-
filing to identify an inverse relationship between the expression of the neural
stem cell marker, Nestin, and miR-125b - a relationship that correlated with
survival in a cohort of primary GBM patients having not yet undergone treat-
ment.
Several miRNA signatures that correlate to clinical progression or overall
survival in GBM have been defined through the recent years. The coherency
between these individual signatures is low, even though a large number of
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Table 5.4: MicroRNAs upregulated in long-term-surviving patients containing exosome-packaging motifs in their mature sequences.
microRNA miRBase accession Mature sequence No. of EXO-
motifs
microRNAs in cluster
hsa-let-7a MIMAT0000062 ugagguaguagguuguauaguu 1 let-7a-1 / let-7f-1 / let-7d
hsa-let-7b MIMAT0000063 ugagguaguagguugugugguu 1 let-7a-3 / 4763 / let-7b
hsa-let-7e MIMAT0000066 ugagguaggagguuguauaguu 2 99b / let-7e / 125a
hsa-let-7f MIMAT0000066 ugagguaguagauuguauaguu 1 let-7a-1 / let-7f-1 / let-7d
hsa-let-7g MIMAT0000414 ugagguaguaguuuguacaguu 1 -
hsa-miR-28-3p MIMAT0004502 cacuagauugugagcuccugga 2 -
hsa-miR-30a MIMAT0000087 uguaaacauccucgacuggaag 1 -
hsa-miR-30b MIMAT0000420 uguaaacauccuacacucagcu 1 30d / 30b
hsa-miR-30c MIMAT0000244 uguaaacauccuacacucucagc 1 30e / 30c-1
hsa-miR-93-3p MIMAT0004509 acugcugagcuagcacuucccg 1 106b / 93 / 25
hsa-miR-98 MIMAT0000096 ugagguaguaaguuguauuguu 1 98 / let-7f-2
hsa-miR-125a MIMAT0000443 ucccugagacccuuuaaccuguga 3 99b / let-7e / 125a
hsa-miR-125b MIMAT0000423 ucccugagacccuaacuuguga 3 -
hsa-miR-126-3p MIMAT0000445 ucguaccgugaguaauaaugcg 1 -
hsa-miR-127-3p MIMAT0000446 ucggauccgucugagcuuggcu 1 337 / 665 / 431 / 433 / 127 /
432 / 136
hsa-miR-129-1-3p MIMAT0004548 aagcccuuaccccaaaaaguau 1 -
hsa-miR-129-3p MIMAT0004605 aagcccuuaccccaaaaagcau 1 -
hsa-miR-139-3p MIMAT0004552 uggagacgcggcccuguuggagu 3 -
hsa-miR-140 MIMAT0000431 cagugguuuuacccuaugguag 1 -
hsa-miR-143-3p MIMAT0000435 ugagaugaagcacuguagcuc 1 143 / 145
hsa-miR-145 MIMAT0000437 guccaguuuucccaggaaucccu 1 143 / 145
hsa-miR-146a MIMAT0000449 ugagaacugaauuccauggguu 1 -
hsa-miR-146b MIMAT0002809 ugagaacugaauuccauaggcu 1 -
hsa-miR-150 MIMAT0000451 ucucccaacccuuguaccagug 1 -
hsa-miR-151 MIMAT0004697 ucgaggagcucacagucuagu 1 -
hsa-miR-151-3p MIMAT0000757 cuagacugaagcuccuugagg 2 -
hsa-miR-181a MIMAT0000256 aacauucaacgcugucggugagu 1 181a-2 / 181b-2
hsa-miR-181c MIMAT0000258 aacauucaaccugucggugagu 1 181c / 181d
hsa-miR-181c-3p MIMAT0004559 aaccaucgaccguugaguggac 1 181c / 181d
hsa-miR-184 MIMAT0000454 uggacggagaacugauaagggu 1 -
hsa-miR-186 MIMAT0000456 caaagaauucuccuuuugggcu 1 -
hsa-miR-197 MIMAT0022691 cggguagagagggcagugggagg 1 -
hsa-miR-204 MIMAT0000265 uucccuuugucauccuaugccu 2 -
hsa-miR-326 MIMAT0000756 ccucugggcccuuccuccag 2 -
hsa-miR-328 MIMAT0026486 gggggggcaggaggggcucaggg 1 -
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hsa-miR-337 MIMAT0004695 gaacggcuucauacaggaguu 1 493 / 337 / 665 / 431 / 433 /
127 / 432
hsa-miR-338 MIMAT0004701 aacaauauccuggugcugagug 2 1250 / 338 / 3065 / 657
hsa-miR-339-3p MIMAT0004702 ugagcgccucgacgacagagccg 1 -
hsa-miR-345 MIMAT0000772 gcugacuccuaguccagggcuc 1 -
hsa-miR-362 MIMAT0000705 aauccuuggaaccuaggugugagu 2 532 / 188 / 500a / 362 / 501 /
500b / 660 / 502
hsa-miR-376c MIMAT0022861 gguggauauuccuucuauguu 1 1193 / 543 / 495 / 376c / 376a-
2 / 654 / 376b / 376a-1 / 300 /
1185- 1 / 1185-2 / 381 / 487b /
539 / 889 / 544a / 655
hsa-miR-377 MIMAT0004689 agagguugcccuuggugaauuc 1 487a / 382 / 134 / 668 / 485 /
323b / 154 / 496 / 377 / 541 /
409 / 412 / 369 / 410 / 656
hsa-miR-381 MIMAT0022862 agcgagguugcccuuuguauau 1 376c / 376a-2 / 654 / 376b /
376a-1 / 300 / 1185-1 / 1185-2
/ 381 / 487b / 539 / 889 / 544a
/ 655 / 487a / 382 / 134 / 668
/ 485
hsa-miR-410 MIMAT0026558 agguugucugugaugaguucg 1 323b / 154 / 496 / 377 / 541 /
409 / 412 / 369 / 410 / 656
hsa-miR-433 MIMAT0026554 uacggugagccugucauuauuc 1 337 / 665 / 431 / 433 / 127 /
432 / 136
hsa-miR-484 MIMAT0002174 ucaggcucaguccccucccgau 1 -
hsa-miR-485-3p MIMAT0002176 gucauacacggcucuccucucu 1 381 / 487b / 539 / 889 / 544a
/ 655 / 487a / 382 / 134 / 668
/ 485 / 323b / 154 / 496 / 377
/ 541 / 409
hsa-miR-487b MIMAT0026614 gugguuaucccuguccuguucg 2 376c / 376a-2 / 654 / 376b /
376a-1 / 300 / 1185-1 / 1185-2
/ 381 / 487b / 539 / 889 / 544a
/ 655 / 487a / 382 / 134 / 668
/ 485 / 323b
hsa-miR-491 MIMAT0002807 aguggggaacccuuccaugagg 2 -
hsa-miR-501 MIMAT0002872 aauccuuugucccugggugaga 3 532 / 188 / 500a / 362 / 501 /
500b / 660 / 502
hsa-miR-504 MIMAT0002875 agacccuggucugcacucuauc 1 -
hsa-miR-512-3p MIMAT0002823 aagugcugucauagcugagguc 1 512-1 / 512-2 / 1323 / 498 /
520e
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hsa-miR-517c-3p MIMAT0002866 aucgugcauccuuuuagagugu 1 518d / 516b-1 / 518a-2 / 517c
/ 520h / 521-1 / 522
hsa-miR-519a MIMAT0002869 aaagugcauccuuuuagagugu 1 20 h / 521-1 / 522 / 519a-1 /
527 / 516a-1 / 1283-2 / 516a-2
/ 519a-2
hsa-miR-539 MIMAT0003163 ggagaaauuauccuuggugugu 2 376c / 376a-2 / 654 / 376b /
376a-1 / 300 / 1185-1 / 1185-2
/ 381 / 487b / 539 / 889 / 544a
/ 655 / 487a / 382 / 134 / 668
/ 485 / 323b
hsa-miR-551b MIMAT0004794 gaaaucaagcgugggugagacc 1 -
hsa-miR-589 MIMAT0004799 ugagaaccacgucugcucugag 2 -
hsa-miR-598 MIMAT0026620 gcggugaucccgauggugugagc 1 -
hsa-miR-769 MIMAT0003886 ugagaccucuggguucugagcu 2 -
hsa-miR-885 MIMAT0004947 uccauuacacuacccugccucu 1 -
hsa-miR-1244 MIMAT0005896 aaguaguugguuuguaugagaugguu 1 -
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studies have been compiled from data extracted from similar databases and
smaller scale tissue cohorts [145]. The 161-miRNA signature associated with
long-term survival contained in this study included several miRNAs found
in other prognostic signatures of PFS and OS in GBM. Since the overall co-
herency across the currently available signatures is poor, an additional step of
complexity must exist with regard to miRNA dysregulation and its predictive
qualities for clinical outcome in GBM. This aspect with respect to complex-
ity on the usage of miRNA-based biomarkers was recently investigated in
an elaborate study by Li et al. [241]. They identified a number of so-called
hub miRNAs, which are center points in large, complex regulatory networks
of miRNAs and mRNAs, and hence, their dysregulation between high-grade
gliomas and normal brain tissue is associated with dysregulation of impor-
tant cellular characteristics such as proliferation. Thus, these hub miRNAs
had strong prognostic value with respect to patient outcome compared to
dysregulated non-hub miRNAs [241].
The differences between miRNAs found to be associated with long-term
survival in this study compared to similar studies, and between all available
studies performed on GBM tissue in general, could possibly be due to dif-
ferences in methodology (i.e., array- vs. PCR-based platforms) and varying
cohort sizes. Furthermore, several subtypes of GBM together with inter- and
intratumoral clonal heterogeneity have been defined [375, 407]. This study
only includes data from fourteen GBM patients stringently cut back from 47
patients, but we believe that our inclusion criteria of patients being diagnosed
with primary GBM resected from the first surgery before having received any
treatment is very relevant, because miRNA expression is reported to change
after treatment with temozolomide [401]. This might interfere with the qual-
ity of the currently published data.
Categorisation of the differentially expressed miRNAs showed that a large
number of them had validated functions in GBM, while approximately a
third of them had no determined functionality. Some miRNAs have been
previously reported to confer either risk or protection with respect to clin-
ical prognosis, while others have been associated with MMMI. Microarray
analysis of gene expression showed that a number of validated targets of
these miRNAs were differentially expressed between the long- and short-
term survival clusters. Three of these genes (E2F3, CTGF and Akt2) have
been identified as important miRNA targets in GBM; E2F3 is inhibited by
tumour suppressor miR-128 to decrease proliferation, CTGF is regulated by
the miR-17–92 cluster resulting in increased proliferation and angiogenesis
and upregulation of miR-184 leads to decreased Akt2 expression, lowered in-
vasiveness and increased apoptosis [63, 92, 268]. In addition, most of the val-
idated gene targets of the long-term survival-associated miRNAs are found
in other types of cancer, e.g., miR-125b was found to directly target E2F3 in
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bladder cancer [164].
Since the scope of this study was to link miRNA signatures to clinico-
pathological findings and determine their correlation with clinical outcome
in GBM, we chose to investigate the neural stem cell marker, NES, because
this protein was upregulated in several patients and could be correlated to
OS [65]. NES is an intermediate filament, which is expressed both in pro-
liferating and differentiating cells of the CNS during neural development.
It is widely used as an early neural marker, but it can also be detected in
progenitor cells in other parts of the body [175]. The expression of NES sus-
tains through life, especially in areas, where the cellular composition contains
cells with proliferative and stem-like properties, which is also the reason why
NES is increasingly used as a marker for cancer stem cells [158, 435]. In GBM,
NES is widely used in the clinic as a determinant of tumour grade [399]. It is
recognised as an important mediator of stemness, and a lowered expression
is known to decrease tumour volume in vivo [257, 442]. Brain tumour initiat-
ing cells with the ability to self-renew and to generate clonal tumour spheres
were also shown to express NES [363]. The fact that we see an inverse cor-
relation between NES expression and patient survival corresponds well with
the evidence presented above.
To find a molecular link between the NES expression and patient sur-
vival, we examined our miRNA signature to identify possible regulators of
NES. The examination revealed that miR-125b, which has previously been
shown to target NES in neural stem and progenitor cells, was differentially
expressed between the long- and short-term-surviving patients [64]. This mi-
RNA is of particular interest, because its role in GBM pathogenesis is highly
disputed. MiR-125b inhibited all-trans retinoic acid-induced cell death in
U343 cells, decreased the sensitivity to temozolomide and positively corre-
lated with tumour grade [180, 419, 443, 450]. Currently, it has been shown
to directly target Bmf, MAZ, E2F2, PIAS3, connexin 43, and p38MAPK in
association with GBM [180, 356, 368, 442, 443, 450]. All of these features sug-
gest this miRNA to be oncogenic. However, in CD133- positive GBM stem
cells, the true functional role of miR-125b is still debated. MiR-125b has been
endowed with oncogenic potential, because it increases migration of CD133-
positive GBM cells together with a concordant increase in the expression of
MMP2/9 [356]. Its expression is also increased in highly invasive SU3 GBM
stem cells compared with U251 cells [418]. Interestingly though, miR-125b
has been characterised as the most downregulated miRNA between CD133-
positive and CD133-negative GBM cells and to decrease the proliferation of
CD133-positive GBM cells due to its direct targeting of transcription factor
E2F2 [442]. The decrease in GBM stem cell proliferation was also associated
with a decreased expression of CDK6 and CDC25A [356]. Recently, it has
been reported that miR-125b was downregulated in three primary GBM stem
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cell lines and targeted Lin28, hereby inhibiting GBM growth both in vitro and
in vivo [419, 420]. These results did not correspond to a previous report by
the same group, where only one CD133-positive GBM stem cell line was ex-
amined [356, 420]. An assessment of the staining patterns of four CD133
antibodies possibly recognising different epitopes on CD133 splice variants
showed that the distribution of CD133 and concurrent cell morphology rarely
corresponded between the different antibodies used [148]. This might explain
some of the contradicting results reported on the role of miR-125b in GBM
stem cells.
The direct targeting of NES by miR-125b is only validated in neural pro-
genitor cells, but one study on GBM did report an inverse correlation between
miR-125b and the expression of NES and CD133, a results which is also re-
flected in this study [64, 442]. In fact, co-expression of Nestin and CD133
was recently proposed as relevant cancer stem cell markers in GBM, which
could indicate that GBM stem cells may be differentially regulated between
long- and short-term-surviving patients [65]. In GBM-associated endothelial
cells, the expression of miR-125b is downregulated, which may be due to the
inhibitory effects of VEGF on this miRNA, hereby defining a role of miR-
125b in tumour angiogenesis [368]. The role of miR-125b and how it varies
across studies and between CD133-positive and CD133-negative GBM cells
illustrates how complex the regulation of this miRNA must be. Therefore,
miR-125b may be of great importance with regards to increase the under-
standing of GBM pathogenesis and how it may be valuable as a therapeutic
target.
Exosomes are a family of nanoparticles with a diameter in the range of
30 to 120 nm that are secreted by all cell types of the body, and capable
of carrying cargos like RNA, proteins, lipids, etc. to be shared between
cells [4, 332, 413]. They can be isolated from several types of extracellu-
lar fluids including blood, urine, amniotic fluid, and saliva, but also from
cell-conditioned medium [413, 439]. The growing interest of paracrine sig-
nalling between cancer cells has resulted in interesting new evidence on how
cancer exosomes modulate cancer cell characteristics and the tumour niche
[313, 327, 360]. For example, exosomes derived from hypoxic regions of GBM
tumours or from GBM cells grown under hypoxic culture conditions potently
induced angiogenesis [208]. Exosomes from GBM tumours and cell lines are
known to contain a great number of miRNAs that can be shared between
GBM cells, and to possess a nanofilament network, which facilitates interac-
tion with the cell membrane and subsequently increase the cellular exosome
uptake [188, 351, 366]. In a recent paper, specific exosome-packaging motifs
in mature miRNA sequences was shown to bind sumoylated hnRNPA2B1
to facilitate loading into the exosome compartment [411]. The results of the
present study showed that 61 miRNAs possessed these so-called EXO-motifs,
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suggesting them to play a role in the paracrine signalling within tumours.
This is supported by the fact that all miRNAs (miR-214, miR-146b, miR-
122 and let-7a) artificially overexpressed to obtain enriched exosomes possess
these EXO-motifs [51, 190, 299, 308]. Four of the 61 miRNAs containing EXO-
motifs (let-7b, miR-30a, miR-30b and miR-125a) have also been shown to be
abundant in glioma microvesicles [233]. Interestingly, miR-125b contained
three individual EXO-motifs in its mature sequence, and hence, this miRNA
is possibly communicated between GBM cells to inhibit expression of specific
genes including the neural stem cell marker NES. Thus, it may be valuable
to investigate the ongoing intercellular communication in GBM tumours to
understand how miRNA signatures are generated and regulated, and which
underlying functions are responsible for the phenotype and patient outcome.
Such work could possibly identify GBM exosomes and their contents as novel
therapeutic targets or biomarkers of disease [208, 269, 292].
3 Conclusion
The clustering of miRNAs to define signatures and their prognostic value is
not a stand-alone entity with respect to predicting survival. It is very clear
that evidence needs to be critically analysed preferentially combining clini-
copathological findings with molecular profiling, which we have attempted
to achieve in a smaller cohort of patients meeting stringent inclusion cri-
teria. The inverse relationship between NES and miR-125b expression and
their correlation to patient survival in GBM illustrate this eloquently. The in-
triguing finding that many of the differentially expressed miRNAs contained
exosome-packaging motifs in their mature sequences suggest that we must
expand our view to encompass the complex intercellular communication in
order to identify molecular prognostic biomarkers and to increase our knowl-
edge in the field of GBM pathogenesis.
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Early-on it was established that brain fatty acid binding protein (FABP7) is ex-
pressed in human malignant anaplastic astrocytoma and GBM tumour biop-
sies, as well as in some but not all malignant glioma cell lines [118]. Likewise,
FABP7 was identified as one of the most overexpressed genes in surgical sam-
ples of GBM [242] as well as in GBM cancer stem cells [248]. Genetic manip-
ulations of FABP7 expression in malignant glioma cell lines [243, 280] as well
as glial stem cell derived neurospheres [72] showed this gene to be directly
implicated in tumour proliferation and invasiveness, with similar conclusions
drawn in a study on melanoma cell lines and tumours in vivo [367].
FABP7 is a member of a larger family group of fatty acid binding proteins
(FABPs), which was first discovered in 1972 by Ockner et al. [295]. They are
small cytosolic proteins, 14.15 kDa in size, and though they have a distinct
primary structure, their tertiary structure is highly conserved.
FABPs consist of a β-barrel composed of ten antiparallel ß-strands capped
by a helix-turn-helix motif. The β-barrel contains the lipid-binding cavity,
rich in polar and hydrophobic amino acids, which binds various amphiphilic
ligands, like fatty acids, bile aids or retinoids [136, 216, 260, 261, 279]. Initially,
it was thought that the expression of the individual FABPs was confined to
specific tissues, thus the FABPs were named after their first tissue of isolation.
Although each FABP is primary expressed in a certain tissue, they exhibit
a broader tissue distribution than originally thought, which has lead to a
numerical nomenclature for the different FABPs [26, 150, 305, 378].
Even though FABPs are widely expressed in various tissues, their expres-
sion is under tight spatiotemporal regulation by regulatory elements posi-
tioned both distally and proximally to the transcriptional start site. For in-
stance, high levels of FABP3 in muscle tissue have been shown to be ade-
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quately regulated by the -400 bp promoter region, while the 1.2 kb 5’ flank-
ing region in necessary for expression in heart tissue [320]. Interestingly,
knockdown of the predominantly expressed FABP can spark an increase in
expression of lesser expressed FABPs as has been seen for FABP5 which in
adipocytes is increase upon negative alteration in FABP4 expression [59, 91,
353], while the metabolism is relatively unaltered probably due to common
functions in adipocytes [353, 377]. In contrast to this, both FABP4 and FABP5
is also expressed in macrophages where alterations in FABP4 expression does
not affect FABP5 suggesting a distinct function for FABP4 and FABP5 in
macrophages [91, 223].
In relation to the brain, three different FABPs are expressed, FABP3, FABP5
and FABP7, at varying stages of CNS development (Figure 6.1) [305]. In
mouse, FABP7 is expressed during embryogenesis from E10 (Theiler stage
17) in radial glial cells found in the ventricular zone of most regions of the
developing CNS, as well as in the trigeminal ganglion and the spinal dor-
sal root ganglia of the peripheral nervous system (PNS) [6, 8, 181, 210, 430].
FABP7 expression intensifies during neurogenesis in radial glial cells of the
developing cortex to reach a maximum at E14-E17, and gradually decreases
after birth, to be expressed at low levels in specific regions of the adult organ-
ism where niches of neural progenitors subside, such as the subventricular
zone of the lateral ventricle and the dentate gyrus subgranular zone of the
hippocampus.
In the CNS, FABP7 expression typically marks glial cells: radial glia in
the neocortex and differentiated glia such as cerebellar Bergmann glia, reti-
nal Müller cells, and cortical immature astrocytes [210]. FABP7 expression
is normally not associated with neuroepithelial (NEP) cells, which are the
precursors of radial glia during cortical neurogenesis, although a study in rat
suggested otherwise [8]. Likewise, FABP7 expression is down-regulated in
cells deriving from the radial glial lineage, such as neural progenitors and
neuroblasts. Recent evidence also indicates that FABP7 is expressed prior
to the formation of the neural plate, as whole-mount in-situ hybridisation
showed a clear signal in the primitive streak of mouse embryo at E7.5 (Theiler
stage 11) [338, 339, 386].
In embryonic neurogenesis, FABP7 fulfils at least two important functions.
Firstly, it takes part in the control of radial glia growth and the projection of
their cellular processes, facilitating migration of associated neurones to form
the neocortex [7, 98]. Secondly, it takes part in the maintenance of and self-
renewal properties of NEP cells [8]. FABP7 has been suggested to have a
role in the regulation of Schwann cell-axon interaction [278] and to have a
role in re-myelination in multiple sclerosis (MS) lesions [200]. During the
course of MS, plaques of demyelination are enclosed by reactive astrocytes
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[200], which have undergone both morphological and biochemical changes
known as reactive gliosis. The mechanisms underpinning reactive gliosis are
largely unknown, but includes massive proliferation, cellular hypertrophy,
inflammation, leading to scar formation, and is a common hallmark of var-
ious brain pathologies [200, 350]. Work with a murine cortical stab injury
model indicated a direct involvement of FABP7 in astrocyte proliferation in
reactive gliosis, and it is believed that the functions of FABP7 in astrocytes
during gliosis might be partly different from its role in embryonic neuroge-
nesis [350]. Re-expression of FABP7 has been observed in ischemic monkey
brains [264], again indicating that FABP7 is functional in reactive gliosis after
ischemia.
Fig. 6.1: Temporal expression patterns of FABP7, FABP5 and FABP3 in rat brain based on data
from Owada et al. [306]
The involvement of FABPs in cancer is still largely elusive, however, as-
sociation between tumour malignancy and FABP expression has been estab-
lished. For instance, the progression of bladder, colon and liver cancer has
been shown to negatively correlate with the expression of FABP2, FABP4 and
FABP1, respectively [42, 68, 222], while for prostate cancer FABP5 expres-
sion has a positive correlation [2]. Elevated levels of FABP5 have also been
shown for breast cancer and to promote proliferation and metastasis in vitro
[229]. Another FABP member, FABP3 was initially identified as a inhibitor of
growth in lactating bovine mammary gland, hence named mammary-derived
growth inhibitor (MDGI), involved in mammary gland differentiation [29].
Reduced proliferation and promoted cellular differentiation upon transfec-
tion of FABP3 into breast cancer cell lines [456] as well as reduced tumour
formation in nude mice [170] suggests a role of FABP3 as a tumour suppres-
sor. LOH has been shown in the region encoding FABP3 in human breast
cancer in an attempt to identify possible inactivating mutations [315]. How-
ever, no mutations were found suggesting that mutation within FABP3 is
uncommon in breast tumourigenesis.
Although FABP7 is chiefly expressed in the brain, it has also been detected
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in mammary tissue [155, 357] and prostate [67]. Detection of FABP7 in other
tissues is mostly observed in the context of pathological conditions such as
cancer, where FABP7 expression is up-regulated. Beside several neurological
disorders such as bipolar disorder, schizophrenia, and Down syndrome [30,
90, 176, 278, 307, 309, 342, 405, 430], alterations of FABP7 expression have
been associated with aggressive types of cancer including GBM, breast cancer,
malignant cutaneous melanoma, and renal cell carcinoma [280, 367, 385, 465].
In respect to gliomagenesis, the brain specific FABP, FABP7, has been
shown to have increased expression in glioma tumour tissue and speculated
to be involved in migration and invasion of glioblastoma [118, 242, 280, 400].
For renal cell carcinoma, the expression of FABP7 also increased compared to
normal kidney [78], while for breast cancer and melanoma it has been shown
to have tumour suppressor-like functioning, being linked to better clinical
outcome and decrease progression when expressed [123, 465].
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1. Introduction
Due to copyrights the full version of this chapter has been omitted. In its
place, a summary has been provided highlighting the background and key
findings.
1 Introduction
The expression of FABP7 is considered as a marker of the radial glial cell
origin [280] and its function and regulation has been reviewed in the context
of normal brain development [249] as well as in GBM [72]. FABP7 is one
of the better-studied members of its family with respect to transcriptional
regulation and it has been shown that the transcriptional regulation of FABP7
is under tight spatiotemporal control. The expression of FABP7 has been
studied in human, mouse and rats, which all show a high degree of sequence
conservation [342].
By extensively reviewing the literature and data submitted to public elec-
tronic databases, this chapter aims at providing a comprehensive overview of
the regulatory elements governing FABP7 expression. The entire set of tran-
scription factors (TFs) is assumed to be finite and the expression of FABP7
both in normal development and under pathological conditions is a result of
their combination. An exhaustive list of FABP7 TFs, as well as a physical map
of their interactions was established (Figures 7.1 and 7.2). Establishing such
an overview will help us further understand the complexity of FABP7 tran-
scriptional regulation both in normal development and in disease pathologies
such as cancer.
2 Results
2.1 Mapping FABP7 Transcriptional Regulatory Elements and
Transcription Factors
Eleven nuclear TFs were identified (figure 7.3), all of which had not been
previously reported in the literature to bind upstream of the FABP7 promo-
tor. By accessing the ENCODE project [89], over 40 TFs were found, though
this was stratified to eleven TFs. This showed two initial observations (i)
an absence of RNA Pol II subunits, which indicated that FABP7 transcrip-
tional activity might globally be silenced in all cell lines investigated, and
(ii) the presence of three sites occupied by a triad of factors from the chro-
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Fig. 7.1: A map of FABP7 transcription factors from peer-reviewed literature. (a) Schematic
representation of FABP7 promoter. The region -1.6 kb upstream has been characterised by Feng
and Heintz [98]. The -0.8 kb region (RGE) regulates FABP7 in glial cells. Regulatory elements
identified in rodents (grey) and in man (white) are shown as boxes. Successive zoom levels are
shown: (i) -5 kbp upstream region, (ii) -1.6 kb, (iii) -0.8 kb, and (iv) -80 bp to -30 bp. TSS is
shown as an arrow at +1 bp. RGE = Radial glial element, DRGE = Dorsal root ganglion element,
DSCS = Dorsal spinal cord silencer. (b) TFs involved in regulation of FABP7 in GBM.
matid cohesion complex. With regard to non-nuclear modulators of FABP7
transcription, only three have been reported to date, NOTCH, ADAM10, and
EGFR.
Although several TFs are found to bind within or upstream of the FABP7
gene, only few regulatory elements have been investigated to date with re-
spect to FABP7 expression in GBM, e.g. NFI [27, 36], EGFR [184], and PAX6
[250]. Although EGFR is not a transcription factor, it has been established
that there is a correlation between FABP7 and EGFR expression [184]. How-
ever, it still remains to be understood by which signalling circuitry EGFR
interacts with FABP7 regulatory elements.
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Fig. 7.2: Position of ENCODE transcription factors at FABP7 locus and upstream inter-genic
region. Binding sites for TFs from the ENCODE project [391] are shown as stacks over an
arrowhead. In orange are TFs controlling chromatin dynamics and modelling. In blue are TFs
driving inflammatory or immune responses. Sites for PolII large subunit POL2R2A are shown as
small green arrowheads. The grey box adjacent to FABP7 represents the regulatory region from
-1.6 kb to -0.3 kb shown on Figure 7.1. Note the presence of 4 sites with the cohesin complex
CTCF/RAD21/SMC3.
2.2 FABP7 Regulation in Astrocytic Tumour and Associated Tran-
scription Factor Regulatory Network
A physical map of protein-protein interactions between the regulatory el-
ements of FABP7 and three core regulatory pathways controlling onset of
GBM [274] was generated. This revealed that none of the factors controlling
FABP7 expression reported here appeared within any of the three core reg-
ulatory modules, except for EGFR. However, the majority of the TFs were
associated with the regulatory modules, supporting previous findings about
FABP7 being a target gene in GBM.
Additionally, the FABP7 promoter shows several CTCF sites occupied by
members of the cohesin complex, which might control FABP7 silencing. Fi-
nally, it also appears that several factors are driving inflammatory and im-
mune responses, confirming a recently discovered role for FABP7 in these
processes.
3 Conclusion
The extensive literature review and database mining resulted in a more com-
prehensive picture of FABP7 transcriptional regulatory network, based on
already known (from published experimental evidence) or newly discovered
(from ENCODE) regulatory factors. Although most FABP7 TFs physically
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Fig. 7.3: Small interaction network of the eleven newly identified FABP7 TFs. Light blue is those
connected to one of the GBM modules, pink is those involved in inflammation and those with a
gradient are associated with both, the two in green are not associated with any of the two.
interact with one another and are closely connected to transcriptional reg-
ulators driving GBM through physical interaction, further experimental evi-
dence will be required to confirm those newly discovered TFs and their effect
on FABP7 transcriptional regulation. Furthermore, the presence of TFs clas-
sically associated to inflammation and immune response confirms the link
between FABP7 and these processes, and will deserve further investigations.
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1. Introduction
Due to copyrights this chapter has been summarised in the form of an
extended abstract and a full version has been placed in Appendix ??.
1 Introduction
FABP7 expression in radial glial cells has been proposed to be the malig-
nant glioma cell of origin [280] and has been identified as one of the most
distinct genes over expressed in glioblastoma multiform (GBM) cancer stem
cells [248]. It has been associated with regions of GBM tumour infiltration,
tumour relapse and reduced survival [72, 184, 242, 280, 281]. The invasive
nature could be a function of FABP7 overexpression, which emphasises the
importance of understanding the complex regulatory mechanisms underpin-
ning FABP7 expression in tumour growth dynamics.
We observed that the high level of FABP7 expression in tumour tissue was
not mirrored in vitro in primary cell cultures at the transcriptional or the pro-
tein level. This finding, supported by the re-expression of FABP7 when grown
as neurosphere culture and intracranial xenograft tumours, highlighted the
fact that the tumour microenvironment was supporting FABP7 expression.
2 Results
2.1 Differential expression of FABP7 and transcriptional regula-
tory factors
Combining, qPCR, microarray, and bioinformatic analysis, FABP7 expression
essentially grouped the tumours into low and high FABP7 expression. This
differential expression of FABP7 was further investigated with respect to tran-
scriptional regulatory factors. Several regulatory elements and their respec-
tive binding factors have been mapped in the promoter region of FABP7 (see
Chapter 7). These are partially responsible for the temporal spatial regula-
tion of FABP7. A number of TFs showed a significant correlation with the
expression of FABP7 in our tumour tissue cohort or databases, though only
few of these have been investigated to date with respect to FABP7 expression
in glioma and GBM (figure 8.1).
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2.2 Molecular subtypes and FABP7 expression
Since only few of the TFs showed a correlation with the expression of FABP7
it was further investigated whether the molecular subtype could influence
the inherent variation in FABP7 expression. FABP7 was found to be asso-
ciated with the classical subtype, though several of the samples exhibiting
high FABP7 expression were of mesenchymal subtype. This was consoli-
dated through public electronic databases (TCGA and Rembrandt). Several
of the TFs linked to FABP7 regulation were also found to be associated with
the classical subtype (figure 8.1).
Fig. 8.1: The distribution of molecular subtypes among the TFs regulating FABP7. The individual
TFs are highlighted whether their expression correlates with the expression of FABP7 (possitive
correlation: green; reverse correlation: red) with a shaded effect, dependent on whether they
correlated in one, two or tree set. The TFs are grouped and those associated with a GBM module
(see Chapter 7) are indicated with a bar above them. A dot below the TF signifies that the TF is
associated with Glioma/GBM
3 Conclusion
The elusive behaviour of FABP7 was investigated and the results suggested
that FABP7 expression could be dependent on the culturing environment
and the context of the tumour niche. Although the tumour samples exhibit a
large variation in FABP7 expression, only few TFs showed a correlation with
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respect to FABP7. Thus it was hypothesised that their molecular subtype
could influence this inherent variation. Here, FABP7 was associated with the
classical subtype along with ten of the TFs linked to FABP7 regulation. While
seven out of nine TFs linked to glioma correlated with FABP7, only three TFs
correlated with FABP7 in all three datasets. One of the TFs, ADAM10, is
furthermore linked to inflammation.
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This thesis has spanned the molecular landscape of GBM, looking at the gene
regulation, pre- and post-transcriptional (microRNA), and how this could
be linked in some way to the expression of stem cell like proteins that are
dysregulated. By looking at these in combination with clinicopathological
features, we have learnt more about the underlaying pathology of this disease
and its progression.
From the start, the objective was to look at the regulation of FABP7, a
protein that is highly dysregulated in GBM and to link this to the invasive
nature, survival and molecular subtypes. However, often the simplest task
can be more complex, the deeper you dig. The challenge was to investigate
the somewhat elusive behaviour of this protein in vitro and how this could
subsequently be reversed when changing the culturing milieu and microen-
vironment in vivo. The transcriptional regulatory network of this highly
interesting protein was gradually unfolded, and the complexity visualised
with the help of in vitro studies and extensive literature and bioinformatics
analysis. The role of miRNAs as modulators of key regulatory mechanisms
in GBM was reviewed, their potential as markers of risk and protection with
respect to disease progression was investigated and finally, this was linked to
clinicopathological features that aid us forward in our understanding of the
biology of GBM.
1 The Role of MicroRNA in Glioblastoma
Variation in miRNA profiles is a hallmark for almost all cancer types com-
pared to non-malignant tissue [254]. Because these aberrantly expressed miR-
NAs provide valuable information of the tumour state, e.g., with respect to
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proliferative or invasive capacity, they are able to serve as prognostic indica-
tors, and provide a basis for deciding on the treatment strategy [38, 384, 454].
Since our review in 2012 [282], there has been a steady increase in the number
of studies analysing different miRNAs and their functionality in GBM. In fact,
dysregylated miRNA expression profiles in GBM can differentiate between
different tumour grades and stages, and the specific function of individual
miRNAs has expanded our knowledge on disrupted signalling pathways,
hereby providing an additional regulatory level to take into account when
characterising the tumour. This has lead to a more in depth understanding
of GBM pathology [197].
Many miRNAs have been functionally characterised in numerous studies,
based on their specific targeting of mRNA transcripts involved in cancer-
associated signalling pathways. However, we know that the vast majority
of miRNAs known to be differentially expressed in GBM tumour tissue and
normal tissue have no functional characterisation, and thus may be of great
importance for disease progression and relevant for usage in prediction of
patient outcome, if their functionalities were to be characterised [282]. The
most extensively studied miRNA in GBM is miR-21. miR-21 is over expressed
in GBM in a grade-specific manner, and known to target many important
tumour suppressor mRNA transcripts [44, 48, 57, 60, 62, 79, 109, 114, 126, 168,
211, 212, 215, 221, 234, 239, 240, 268, 310, 328, 333, 334, 343, 346, 355, 361, 447,
462, 473, 475, 476]. In addition to regulating key apoptosis and proliferation
pathways, high expression of miR-21 is also linked to shorter progression-free
survival, and is therefore regarded as an oncogenic miRNA [46, 215, 325]. As
for miR-21, other microRNAs such as miR-17, miR-93, miR-221 and miR-222,
have the same oncogenic potential and all are known to be over expressed in
GBM and to inhibit the translation of important tumour suppressors [282].
With the use of microRNA target prediction software which has proven to
be a powerful tool, a number of predicted target sites in mammals have been
reliably validated in numerous experiments [205, 232].
2 MicroRNA Defined as Risk-associated vs Protec-
tive as Predictors of Clinical Outcome
Due to the appertaining dysfunction in key cancer-associated signalling path-
ways, the patterns of dysregulated miRNA expression in GBM are now be-
ing recognised as a tool to stratify GBM patients with respect to predictive
clinical outcome [16, 146, 197, 322, 374, 469]. Thus, many studies are provid-
ing miRNA signatures (with single or multiple miRNAs) that are associated
with longer or shorter survival times. In the review concerning this subject
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(Chapter 4), all literature was revised pertaining to the use of miRNA expres-
sion profiles as prognostic and/or diagnostic biomarkers [145]. The analy-
sis showed that numerous signatures had been proposed to aid in clinical
decision-making, but the same overall coherency of the signatures was poor,
even though a number of studies utilised data derived from the same pub-
licly available databases, like TCGA. Studies investigating individual tissue
cohorts to define miRNA signatures also lacked strong coherency, probably
because of differences in the number of miRNAs investigated, type of array
platform utilised, cohort size and especially the choice of control tissue. Sev-
eral studies chose to use control tissue from other diseased brains, such as
epilepsy brains, which must be expected to possess miRNA dysregulation
as well, therefore making true comparison between the individual studies
difficult.
Interestingly, several studies were found to identify specific miRNAs as
being associated with either risk or protection with respect to the clinical
outcome of GBM. For example, high expression of known oncogenic miR-
NAs, such as miR-221 and miR-222, were found to correlate with short-term
survival, whereas high expression of tumour suppressor miRNAs, such as
miR-181d and miR-328, were associated with long-term survival. However,
even though the association to survival correlated well with the known func-
tionality of these particular miRNAs, many miRNAs had validated functions
in vitro and in vivo (xenograft models) opposite to what would be expected
from their association with clinical outcome. This pointed to the fact that
assessment of individual miRNAs to define their function is not necessarily a
good indicator for the multifactorial pathogenesis and progression of GBM.
This may be due to the way miRNAs bind to and inhibit numerous target
mRNAs, encompassing both oncogenes and tumour suppressors [145]. Nev-
ertheless, some miRNAs associated with either risk or protection were iden-
tified in several miRNA signatures, suggesting that these specific miRNAs
could be relevant as biomarkers of disease, in prognosis, and as therapeutic
targets.
3 MicroRNA Expression, Prognosis and Linking this
to Clinical Findings
The association between microRNA expression profiles and survival was
highlighted by the analysis of tumours from a cohort of fourteen patients
diagnosed with primary GBM (Chapter 5) [146]. A microRNA signature was
determined with the potential of predicting either long-term or short-term
survival. When comparing the expressional profile of the miRNAs included
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in the signature in the GBM tumours to the available clinicopathological data,
a negative correlation between the expression of miR-125b and the stem cell
marker, NES, was found. This correlation could predict survival in the GBM
patient cohort, pointing towards the need of combining molecular profiling
with clinicopathological features in order to confidently determine patient
prognosis.
4 The Potential of MicroRNA Modulating the Tumour
Niche
Interestingly, the study in chapter 5 (table 5.4) showed that many of the dif-
ferentially expressed miRNAs possessed specific exosome-packaging motifs
(EXO-motifs) in their mature sequences, including some already known to
be abundant in glioma microvesicles [233]. This suggested that these mi-
croRNAs potentially participate in the intercellular communication within
the GBM tumour to modulate the behaviour of recipient cells [146, 188, 366].
Since exosomes have recently been shown to possess the potential of medi-
ating delivery of exogenous drugs (e.g., interfering RNAs), this could even-
tually be an interesting concept to pursue by combining the knowledge on
microRNA expression profiles associated with survival in GBM, and the pos-
sibility of interfering with these aberrant expression profiles by delivering
tumour suppressor microRNA via exosomes to GBM tumours.
5 FABP7: A Complex Regulatory Landscape
The loss of FABP7 expression in primary cultures pointed toward a selection
pressure with respect to cell type or niche adaptation where the culture en-
vironment no longer supported the expression of FABP7. Why this loss of
expression? This was a major question given the gene expression and corre-
sponding protein levels is tissue. Since the FABP7 promoter region has been
shown to be deprived of CpG islands, the role of hypermethylation was not
of compelling interest. But whether it was a change in the availability of tran-
scription factors or the involvement of miRNAs was more difficult to deduce.
The poor correlation between transcription factors and FABP7 expression,
however, suggested that the answer was broader than first expected. It was
no longer a question whether a certain transcription factor was present, but
apparently also a question whether the culture conditions were favourable
since the elusive behaviour of FABP7 was reversed when grown in vivo (Fig-
ure ??, Chapter ??).
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6 Piecing Together the Biological Dots: FABP7 Linked
to Molecular Subtype
To this end the molecular subtype of GBM was a compelling starting point,
since it is known that the subtypes behave differently when grown in culture,
especially when grown as a monolayer and the majority of the primary cul-
tures were initially grown with FCS, in monolayer format [253, 329, 349].
Clearly, the tissue levels of FABP7 were high (see Figure ?? in appendix
??) and FABP7 was observed in all tumour tissue but to a varying degree.
Through gene profiling, it was found that FABP7 belonged to the classical
subtype, based on the mRNA signature reported by Verhaak et al. [407].
However, molecular subtypes based on miRNA signatures have also been
reported [197]. This has revealed five classes of GBM; neural, oligoneu-
ral, multipotent, astrocytic, and neuromesenchymal. These five groups were
found to have gene markers corresponding to oligoneural, radial glial, neu-
ral, neuromesenchmal, and astrocytic. FABP7, a marker of the radial glial
group, was found to belong to the classical subtype [197]. This supported the
finding that FABP7 belonged to the classical subtype of GBM. Other genes
such as PAX6, NES, SOX2 and GFAP, all of which are related in one way
or another to FABP7 expression, was represented in this classical subtype
[8, 117, 118, 181, 243, 250, 285, 350]. Interestingly, EGFR was also associated
with the classical subtype, being amplified or expressed in the vIII mutated
form. Overexpression of EGFR has been associated with nuclear FABP7 lo-
calisation, migration and poor survival [184, 243] and FABP7 expression is
downstream of Ras-independent EGFR signalling in Schwann cells [278]. The
correlation between EGFR overexpression and FABP7 in GBM could there-
fore simply be a question of molecular subtype. FABP7 could still be reg-
ulated by EGFR in a yet undetermined fashion, and EGFR seems to have
an effect on the localisation and properties of FABP7, all of which further
strengthens the association of FABP7 to the classical subtype. The subtyping
of FABP7 as classical fits with its role in supporting tumour growth, how-
ever, the mesenchymal subtype has been associated with invasion [304] and
stem cell markers [316], both properties attributed to FABP7. In addition,
the mesenchymal class is furthermore associated with inflammation [9], and
tumour immunomodulation. Through database mining (chapter 6), FABP7
was found to be regulated in some way (yet to be identified) by transcription
factors linked to inflammation, all of which fall in the mesenchymal sub-
type (Chapter 7 and 8, respectively. Tables ?? and ??). The inflammatory
response mediates malignant gliomagenesis shaping the tumour microenvi-
ronment [61]. Reactive gliosis and scar formation, a result of inflammation,
are also observed in infiltrative forms of glioma [340]. It appears that FABP7
participate in the homeostasis of CD4+ T-cells [397] and it recently emerged
99
Chapter 9.
that FABP7 can function as an intracellular endocannabinoid transporter, an
important modulator of the immune system [21, 182, 311]. Based on this in-
formation, it could have been expected that FABP7 would belong to the more
mesenchymal grouping, however, tumours with high FABP7 expression were
of either classical or mesenchymal subtype in the tissue cohort, which lead
to the speculation of FABP7 having a dual role in GBM pathogenesis. Could
FABP7 belong to both classes, but have different functional roles or proper-
ties? This question can in part be answered by the fact that FABP7, though
predominantly expressed in the brain, is found in mammary tissue where it
has been shown to have properties of inhibiting tumour growth [155, 357].
7 Refining the Transcriptional Regulatory Landscape
to Include the Role of MicroRNA and FABP7 Ex-
pression
The elusiveness of FABP7 and the poor correlation between FABP7 expres-
sion and TFs analysed suggested that other “factors” are at play. Here, we
have considered the role of miRNA and there are no known miRNA that
are directly involved in FABP7 regulation. However, one miRNA has been
functionally characterised to target FABP7 in mouse, a microRNA that is
not predicted to target the human FABP7 counterpart. There are several mi-
croRNA candidates that could potentially target FABP7, which would need to
be confirmed experimentally. In a preliminary study, two microRNAs (miR-
181 and miR-382) identified through miRBase and known to be expressed
in GBM tissue were investigated for their impact on FABP7 expression in
vitro. Preliminary studies has shown that down regulation of FABP7 expres-
sion was observed in the model cells upon miRNA transfection . However,
further validation was needed to substantiate this finding with the aid of a
reporter gene system.
8 Tying Part One and Two Together
The functional role of many differentially regulated microRNAs are still to
be elucidated, however, it is apparent that microRNAs have a huge impact
on the biology of GBM. Of the microRNAs that were found differentially
regulated across the tumour samples, 36 were predicted to target FABP7.
However, three or more algorithms predicted only four microRNAs, namely
miR-181a, miR-181c, miR-382 and miR-383. That is not to say that these four
functionally target FABP7 or that any of the remaining 32 does not. How-
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ever, these four candidates could be interesting to further study with respect
to the FABP7 regulatory landscape. However, the involvement of microR-
NAs has a role in cell-to-cell communication and facilitating the progression
of tumour growth. The paracrine effect through miRNAs transported by
exosomes could very well target either FABP7 or any of its TFs. The inter-
connected web of regulatory elements is vast, and to this end, this thesis only
scratches the surface.
9 Future Perspectives
The complex web of regulation has only begun to be revealed. The findings
of this thesis has (i) gathered a basic understanding of the role of miRNAs in
GBM and given a comprehensive overview of all the available literature, (ii)
evaluated miRNA signatures as a function of prognosis and survival, (iii) in-
vestigated the possibility of combining miRNA expression with clinicopatho-
logical features, (iv) provided an up-to-date account of regulatory elements
of the FABP7 gene and (v) investigated the expression of FABP7 in GBM to
correlated it with the expression of known regulatory elements. However,
there are still several lines which are of great interest to pursue.
Based on the discovery that a large part of the differentially regulated
miRNAs in GBM contained EXO-motifs, an indication of cell-to-cell commu-
nication and paracrine signalling, it would be
[1] valuable to investigate the intercellular communication in GBM tumours.
This could provide further understanding on how miRNA signatures
are generated and regulated, and which underlying functions are re-
sponsible for the phenotype and patient outcome. Such work could
possibly identify GBM exosomes and their content as novel therapeutic
targets or biomarkers of disease.
Since miRNAs has a huge impact on the biology of GBMs and due to their
connection with the clinicopathological features, it would be highly relevant
to
[2] validate miRNAs found to target FABP7, since only one miRNA to date
(miR-21) has been found to regulate FABP7 in mouse.
This would expand the regulatory landscape of FABP7 which could further
explain the elusive behaviour of FABP7 in primary cell cultures and could be
combined with molecular subtypes og GBM which could shed light on the
diversity of GBM. With regard to the expression of FABP7 and the regulatory
map generated, the following would also be relevant to investigate further
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[3] Further experimental evidence will be required to confirm those newly
discovered TFs (from ENCODE) and their effect on FABP7 transcrip-
tional regulation.
[4] The intriguing presence at FABP7 locus of a cohesin complex and TFs
involved in chromatin dynamics opens new perspectives to study their
impact on FABP7 develpment expression and overexpression in aggres-
sive cancers.
[5] If it is assumed that FABP7 upregulation in non-neoplastic reactive
glioma is under control of TFs coordinating inflammatory or immune
responses, it would be interesting to determine whether these TFs also
control FABP7 re-expression in GBM.
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Table A.1: MicroRNAs upregulated in cluster 1 (long survival) and reported upregulated in
GBM compared to normal tissue.
hsa-let-7a hsa-miR-93* hsa-miR-194 hsa-miR-381 hsa-miR-519d
hsa-let-7b hsa-miR-99a hsa-miR-200b hsa-miR-383 hsa-miR-520d-3p
hsa-let-7f hsa-miR-125b-2* hsa-miR-200c hsa-miR-411 hsa-miR-532-3p
hsa-miR-16 hsa-miR-125b hsa-miR-204 hsa-miR-455-3p hsa-miR-532-5p
hsa-miR-20a hsa-miR-140-3p hsa-miR-222 hsa-miR-455-5p hsa-miR-589
hsa-miR-20b hsa-miR-140-5p hsa-miR-324-3p hsa-miR-484 hsa-miR-589
hsa-miR-23b hsa-miR-146a hsa-miR-345 hsa-miR-500 hsa-miR-625
hsa-miR-24 hsa-miR-150 hsa-miR-361-3p hsa-miR-501-5p hsa-miR-885-5p
hsa-miR-26a hsa-miR-152 hsa-miR-361-5p hsa-miR-517c
hsa-miR-30a-5p hsa-miR-191 hsa-miR-362-5p hsa-miR-518f
hsa-miR-30d hsa-miR-192* hsa-miR-374b hsa-miR-519a
Table A.2: MicroRNAs upregulated in cluster 1 (long survival) and reported downregulated
in GBM compared to normal tissue.
hsa-miR-29b hsa-miR-127-3p hsa-miR-139-5p hsa-miR-326 hsa-miR-422a
hsa-miR-29c hsa-miR-128 hsa-miR-146b-5p hsa-miR-328 hsa-miR-454
hsa-miR-34a hsa-miR-129-3p hsa-miR-149 hsa-miR-330-3p hsa-miR-487b
hsa-miR-95 hsa-miR-129-5p hsa-miR-181a hsa-miR-342-3p hsa-miR-491-5p
hsa-miR-98 hsa-miR-129* hsa-miR-181c hsa-miR-342-5p hsa-miR-495
hsa-miR-100 hsa-miR-132 hsa-miR-184 hsa-miR-369-5p hsa-miR-543
hsa-miR-103 hsa-miR-134 hsa-miR-197 hsa-miR-370 hsa-miR-574-3p
hsa-miR-124 hsa-miR-137 hsa-miR-203 hsa-miR-376a hsa-miR-598
hsa-miR-125a-5p hsa-miR-138 hsa-miR-218 hsa-miR-379 hsa-miR-628-3p
hsa-miR-126 hsa-miR-139-3p hsa-miR-323-3p hsa-miR-410
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Table A.3: MicroRNAs upregulated in cluster 1 (long survival) and with disputed reports
about their regulation in GBM compared to normal tissue.
hsa-let-7d hsa-miR-27b hsa-miR-143 hsa-miR-195 hsa-miR-338-5p hsa-miR-26b
hsa-miR-30c hsa-miR-145
Table A.4: MicroRNAs upregulated in cluster 1 (long-term survival) with no reported dysreg-
ulation in GBM.
hsa-let-7e hsa-miR-99a* hsa-miR-365 hsa-miR-512-3p hsa-miR-874
hsa-let-7g hsa-miR-99b* hsa-miR-376c hsa-miR-539 hsa-miR-935
hsa-miR-31 hsa-miR-126* hsa-miR-377* hsa-miR-551b* hsa-miR-1179
hsa-miR-628-5p hsa-miR-151-3p hsa-miR-382 hsa-miR-592 hsa-miR-1180
hsa-miR-26b* hsa-miR-151-5p hsa-miR-409-3p hsa-miR-642 hsa-miR-1244
hsa-miR-27b* hsa-miR-181c* hsa-miR-433 hsa-miR-655 hsa-miR-1253
hsa-miR-29a hsa-miR-186 hsa-miR-485-3p hsa-miR-664 hsa-miR-1260
hsa-miR-29b-1* hsa-miR-213 hsa-miR-488 hsa-miR-758 hsa-miR-1271
hsa-miR-29b-2* hsa-miR-331-5p hsa-miR-488 hsa-miR-769-5p
hsa-miR-30b hsa-miR-339-3p hsa-miR-502-3p hsa-miR-770-5p
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[313] Peinado, H. , Alečković, M. , Lavotshkin, S. , Matei, I. , Costa-Silva, B.
, Moreno-Bueno, G. , Hergueta-Redondo, M. , Williams, C. , García-
Santos, G. , Ghajar, C. , Nitadori-Hoshino, A. , Hoffman, C. , Badal, K.
, Garcia, B. A. , Callahan, M. K. , Yuan, J. , Martins, V. R. , Skog, J. ,
Kaplan, R. N. , Brady, M. S. , Wolchok, J. D. , Chapman, P. B. , Kang,
Y. , Bromberg, J. , and Lyden, D. . Melanoma exosomes educate bone
marrow progenitor cells toward a pro-metastatic phenotype through
MET. Nature Medicine, 18(6):883–891, June 2012.
[314] Peters, P. J. , Geuze, H. J. , Van der Donk, H. A. , Slot, J. W. , Griffith,
J. M. , Stam, N. J. , Clevers, H. C. , and Borst, J. . Molecules relevant for
144
References
T cell-target cell interaction are present in cytolytic granules of human
T lymphocytes. European journal of immunology, 19(8):1469–1475, July
1989.
[315] Phelan, C. M. , Larsson, C. , Baird, S. , Futreal, P. A. , Ruttledge, M. H. ,
Morgan, K. , Tonin, P. , Hung, H. , Korneluk, R. G. , Pollak, M. N. , and
Narod, S. A. . The human mammary-derived growth inhibitor (MDGI)
gene: genomic structure and mutation analysis in human breast tu-
mors. Genomics, 34(1):63–68, May 1996.
[316] Phillips, H. S. , Kharbanda, S. , Chen, R. , Forrest, W. F. , Soriano, R. H.
, Wu, T. D. , Misra, A. , Nigro, J. M. , Colman, H. , Soroceanu, L. ,
Williams, P. M. , Modrusan, Z. , Feuerstein, B. G. , and Aldape, K. .
Molecular subclasses of high-grade glioma predict prognosis, delineate
a pattern of disease progression, and resemble stages in neurogenesis.
Cancer Cell, 9(3):157–173, 2006.
[317] Plas, D. and Thompson, C. . Akt-Dependent Transformation: There is
More to Growth Than Just Surviving. Oncogene, 24:7435–7442, 2005.
[318] Pollard, J. W. . Tumour-educated macrophages promote tumour pro-
gression and metastasis. Nature Reviews Cancer, 4(1):71–78, Dec. 2003.
[319] Potolicchio, I. , Carven, G. J. , Xu, X. , Stipp, C. , Riese, R. J. , Stern,
L. J. , and Santambrogio, L. . Proteomic analysis of microglia-derived
exosomes: metabolic role of the aminopeptidase CD13 in neuropeptide
catabolism. Journal of Immunology, 175(4):2237–2243, Aug. 2005.
[320] Qian, Q. , Kuo, L. , Yu, Y. T. , and Rottman, J. N. . A concise
promoter region of the heart fatty acid-binding protein gene dictates
tissue-appropriate expression. Circulation research, 84(3):276–289, Feb.
1999.
[321] Qiu, S. , Huang, D. , Yin, D. , Li, F. , Li, X. , Kung, H.-F. , and Peng, Y.
. Suppression of tumorigenicity by microRNA-138 through inhibition
of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.
Biochimica et biophysica acta, 1832(10):1697–1707, Oct. 2013.
[322] Qiu, S. , Lin, S. , Hu, D. , Feng, Y. , Tan, Y. , and Peng, Y. . Interactions of
miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prog-
nostic indicators for clinical outcome of glioblastoma patients. Journal
of translational medicine, 11:10, 2013.
[323] Quant, E. C. and Wen, P. Y. . Response Assessment in Neuro-Oncology.
Current Oncology Reports, 13(1):50–56, Nov. 2010.
145
References
[324] Quintavalle, C. , Garofalo, M. , Zanca, C. , Romano, G. , Iaboni, M. ,
Caro, M. d. B. D. , Martinez-Montero, J. C. , Incoronato, M. , Nuovo,
G. , Croce, C. M. , and Condorelli, G. . miR-221/222 overexpession
in human glioblastoma increases invasiveness by targeting the protein
phosphate PTPµ. Oncogene, 31(7):858–868, July 2011.
[325] Quintavalle, C. , Donnarumma, E. , Iaboni, M. , Roscigno, G. , Garo-
falo, M. , Romano, G. , Fiore, D. , De Marinis, P. , Croce, C. M. , and
Condorelli, G. . Effect of miR-21 and miR-30b/c on TRAIL-induced
apoptosis in glioma cells. Oncogene, 32(34):4001–4008, Aug. 2013.
[326] Quintavalle, C. , Mangani, D. , Roscigno, G. , Romano, G. , Diaz-
Lagares, A. , Iaboni, M. , Donnarumma, E. , Fiore, D. , De Marinis,
P. , Soini, Y. , Esteller, M. , and Condorelli, G. . MiR-221/222 target the
DNA methyltransferase MGMT in glioma cells. PLoS ONE, 8(9):e74466,
2013.
[327] Rak, J. and Guha, A. . Extracellular vesicles–vehicles that spread cancer
genes. BioEssays : News and Reviews in Molecular, Cellular and Develop-
mental Biology, 34(6):489–497, June 2012.
[328] Rao, S. A. M. , Santosh, V. , and Somasundaram, K. . Genome-wide
expression profiling identifies deregulated miRNAs in malignant as-
trocytoma. Modern pathology : an official journal of the United States and
Canadian Academy of Pathology, Inc, 23(10):1404–1417, Oct. 2010.
[329] Rape, A. , Ananthanarayanan, B. , and Kumar, S. . Engineering strate-
gies to mimic the glioblastoma microenvironment. Advanced Drug De-
livery Reviews, 79-80:172–183, 2014.
[330] Raposo, G. , Nijman, H. W. , Stoorvogel, W. , Liejendekker, R. , Harding,
C. V. , Melief, C. J. , and Geuze, H. J. . B lymphocytes secrete antigen-
presenting vesicles. The Journal of experimental medicine, 183(3):1161–
1172, Mar. 1996.
[331] Reardon, D. A. , Galanis, E. , DeGroot, J. F. , Cloughesy, T. F. , Wefel,
J. S. , Lamborn, K. R. , Lassman, A. B. , Gilbert, M. R. , Sampson, J. H.
, Wick, W. , Chamberlain, M. C. , Macdonald, D. R. , Mehta, M. P. ,
Vogelbaum, M. A. , Chang, S. M. , Van den Bent, M. J. , and Wen, P. Y. .
Clinical trial end points for high-grade glioma: the evolving landscape.
Neuro-oncology, 13(3):353–361, Feb. 2011.
[332] Record, M. , Subra, C. , Silvente-Poirot, S. , and Poirot, M. . Exosomes as
intercellular signalosomes and pharmacological effectors. Biochemical
pharmacology, 81(10):1171–1182, May 2011.
146
References
[333] Ren, Y. , Kang, C.-S. , Yuan, X.-B. , Zhou, X. , Xu, P. , Han, L. , Wang, G.-
X. , Jia, Z. , Zhong, Y. , Yu, S. , Sheng, J. , and Pu, P.-Y. . Co-delivery of as-
miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human
glioma cell growth in vitro. Journal of biomaterials science. Polymer edition,
21(3):303–314, 2010.
[334] Ren, Y. , Zhou, X. , Mei, M. , Yuan, X.-B. , Han, L. , Wang, G.-X. ,
Jia, Z.-F. , Xu, P. , Pu, P.-Y. , and Kang, C.-S. . MicroRNA-21 inhibitor
sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229
(PTEN-wild type) to taxol. BMC cancer, 10:27, 2010.
[335] Ribatti, D. , Nico, B. , Crivellato, E. , Roccaro, A. M. , and Vacca, A.
. The history of the angiogenic switch concept. Leukemia, 21(1):44–52,
Jan. 2007.
[336] Ricci-Vitiani, L. , Pallini, R. , Biffoni, M. , Todaro, M. , Invernici, G. ,
Cenci, T. , Maira, G. , Parati, E. A. , Stassi, G. , Larocca, L. M. , and
De Maria, R. . Tumour vascularization via endothelial differentiation
of glioblastoma stem-like cells. Nature, 468(7325):824–828, Dec. 2010.
[337] Rich, J. N. , Guo, C. , McLendon, R. E. , Bigner, D. D. , Wang, X. F. ,
and Counter, C. M. . A genetically tractable model of human glioma
formation. Cancer Research, 61(9):3556–3560, Apr. 2001.
[338] Richardson, L. , Venkataraman, S. , Stevenson, P. , Yang, Y. , Moss, J. ,
Graham, L. , Burton, N. , Hill, B. , Rao, J. , Baldock, R. A. , and Armit,
C. . EMAGE mouse embryo spatial gene expression database: 2014
update. Nucleic Acids Research, 42(D1):D835–D844, Dec. 2013.
[339] Ringwald, M. , Baldock, R. , Bard, J. , Kaufman, M. , Eppig, J. T. ,
Richardson, J. E. , Nadeau, J. H. , and Davidson, D. . A Database for
Mouse Development. Science, 265:1–3, 1994.
[340] Rivera-Zengotita, M. and Yachnis, A. T. . Gliosis versus glioma?: don’t
grade until you know. Advances in anatomic pathology, 19(4):239–249,
July 2012.
[341] Saeed, A. I. , Sharov, V. , White, J. M. , Liang, W. , Bhagabati, N. ,
Braisted, J. , Klapa, M. , Currier, T. , Thiagarajan, M. , Sturn, A. , Snuffin,
M. , Rezantsev, A. , Kostikovich, E. , Borisovsky, I. , Lui, Z. , Vinsavich,
A. , Trush, V. , and Quackenbush, J. . TM4: A free, open-source system
for microarray data management and analysis. Biotechniques, 34(2):374–
378, Feb. 2003.
[342] Sanchez-Font, M. F. , Bosch-Comas, A. , Gonzalez-Duarte, R. , and
Marfany, G. . Overexpression of FABP7 in Down syndrome fetal brains
147
References
is associated with PKNOX1 gene-dosage imbalance. Nucleic Acids Re-
search, 31(11):2769–2777, Mar. 2003.
[343] Sasayama, T. , Nishihara, M. , Kondoh, T. , Hosoda, K. , and Kohmura,
E. . MicroRNA-10b is overexpressed in malignant glioma and associ-
ated with tumor invasive factors, uPAR and RhoC. International Journal
of Cancer, 125(6):1407–1413, Sept. 2009.
[344] Schmidt, E. E. , Ichimura, K. , Reifenberger, G. , and Collins, V. P. .
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in
the majority of glioblastomas. Cancer Research, 54(24):6321–6324, Dec.
1994.
[345] Schraivogel, D. , Weinmann, L. , Beier, D. , Tabatabai, G. , Eichner, A. ,
Zhu, J. Y. , Anton, M. , Sixt, M. , Weller, M. , Beier, C. P. , and Meister,
G. . CAMTA1 is a novel tumour suppressor regulated by miR-9/9&ast;
in glioblastoma stem cells. The EMBO Journal, 30(20):4309–4322, Aug.
2011.
[346] Schramedei, K. , Mörbt, N. , Pfeifer, G. , Läuter, J. , Rosolowski, M.
, Tomm, J. M. , von Bergen, M. , Horn, F. , and Brocke-Heidrich,
K. . MicroRNA-21 targets tumor suppressor genes ANP32A and
SMARCA4. Oncogene, 30(26):2975–2985, June 2011.
[347] Schwarz, D. S. , Hutvágner, G. , Du, T. , Xu, Z. , Aronin, N. , and
Zamore, P. D. . Asymmetry in the assembly of the RNAi enzyme com-
plex. Cell, 115(2):199–208, Oct. 2003.
[348] Segurado, A. A. , Malaque, C. M. , Sumita, L. M. , Pannuti, C. S. , and
Lal, R. B. . Laboratory characterization of human T cell lymphotropic
virus types 1 (HTLV-1) and 2 (HTLV-2) infections in blood donors from
Sao Paulo, Brazil. American Journal of Tropical Medicine and Hygiene, 57
(2):142–148, July 1997.
[349] Shankavaram, U. T. , Bredel, M. , Burgan, W. E. , Carter, D. , Tofilon,
P. , and Camphausen, K. . Molecular profiling indicates orthotopic
xenograft of glioma cell lines simulate a subclass of human glioblas-
toma. Journal of Cellular and Molecular Medicine, 16(3):545–554, May
2012.
[350] Sharifi, K. , Morihiro, Y. , Maekawa, M. , Yasumoto, Y. , Hoshi, H.
, Adachi, Y. , Sawada, T. , Tokuda, N. , Kondo, H. , Yoshikawa, T. ,
Suzuki, M. , and Owada, Y. . FABP7 expression in normal and stab-
injured brain cortex and its role in astrocyte proliferation. Histochem-
istry and Cell Biology, 136(5):501–513, Sept. 2011.
148
References
[351] Sharma, S. , Das, K. , Woo, J. , and Gimzewski, J. K. . Nanofilaments on
glioblastoma exosomes revealed by peak force microscopy. Journal of
the Royal Society, Interface / the Royal Society, 11(92):20131150–20131150,
Mar. 2014.
[352] Sharma, S. V. and Settleman, J. . Oncogene addiction: setting the stage
for molecularly targeted cancer therapy. Genes & Development, 21(24):
3214–3231, Dec. 2007.
[353] Shaughnessy, S. , Smith, E. R. , Kodukula, S. , Storch, J. , and Fried,
S. K. . Adipocyte metabolism in adipocyte fatty acid binding protein
knockout mice (aP2-/-) after short-term high-fat feeding: functional
compensation by the keratinocyte [correction of keritinocyte] fatty acid
binding protein. Diabetes, 49(6):904–911, June 2000.
[354] Sherr, C. J. and McCormick, F. . The RB and p53 pathways in cancer.
Cancer Cell, 2(2):103–112, Aug. 2002.
[355] Shi, L. , Chen, J. , Yang, J. , Pan, T. , Zhang, S. , and Wang, Z. . MiR-
21 protected human glioblastoma U87MG cells from chemotherapeutic
drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio
and caspase-3 activity. Brain research, 1352:255–264, Sept. 2010.
[356] Shi, L. , Wan, Y. , Sun, G. , Zhang, S. , Wang, Z. , and Zeng, Y. . miR-125b
inhibitor may enhance the invasion-prevention activity of temozolo-
mide in glioblastoma stem cells by targeting PIAS3. BioDrugs : clinical
immunotherapeutics, biopharmaceuticals and gene therapy, 28(1):41–54, Feb.
2014.
[357] Shi, Y. E. , Ni, J. , Xiao, G. , Liu, Y. E. , Fuchs, A. , Yu, G. , Su, J. ,
Cosgrove, J. M. , Xing, L. , Zhang, M. , Li, J. , Aggarwal, B. B. , Meager,
A. , and Gentz, R. . Antitumor Activity of the Novel Human Breast
Cancer GrowthInhibitor, Mammary-derived Growth Inhibitor-related
Gene, MRG. Cancer Research, 57:3084–3091, 1997.
[358] Shi, Z.-M. , Wang, J. , Yan, Z. , You, Y.-P. , Li, C.-y. , Qian, X. , Yin, Y.
, Zhao, P. , Wang, Y.-y. , Wang, X.-F. , Li, M.-n. , Liu, L.-Z. , Liu, N. ,
and Jiang, B.-H. . MiR-128 inhibits tumor growth and angiogenesis by
targeting p70S6K1. PLoS ONE, 7(3):e32709, 2012.
[359] Shi, Z.-M. , Wang, X.-F. , Qian, X. , Tao, T. , Wang, L. , Chen, Q.-D.
, Wang, X.-R. , Cao, L. , Wang, Y.-Y. , Zhang, J.-X. , Jiang, T. , Kang,
C.-S. , Jiang, B.-H. , Liu, N. , and You, Y.-P. . MiRNA-181b suppresses
IGF-1R and functions as a tumor suppressor gene in gliomas. RNA, 19
(4):552–560, Apr. 2013.
149
References
[360] Sidhu, S. S. , Mengistab, A. T. , Tauscher, A. N. , LaVail, J. , and
Basbaum, C. . The microvesicle as a vehicle for EMMPRIN in tumor-
stromal interactions. Oncogene, 23(4):956–963, Jan. 2004.
[361] Silber, J. , Lim, D. A. , Petritsch, C. , Persson, A. I. , Maunakea, A. K. ,
Yu, M. , Vandenberg, S. R. , Ginzinger, D. G. , James, C. D. , Costello,
J. F. , Bergers, G. , Weiss, W. A. , Alvarez-Buylla, A. , and Hodgson,
J. G. . miR-124 and miR-137 inhibit proliferation of glioblastoma multi-
forme cells and induce differentiation of brain tumor stem cells. BMC
medicine, 6:14, 2008.
[362] Silber, J. , Jacobsen, A. , Ozawa, T. , Harinath, G. , Pedraza, A. , Sander,
C. , Holland, E. C. , and Huse, J. T. . miR-34a Repression in Proneural
Malignant Gliomas Upregulates Expression of Its Target PDGFRA and
Promotes Tumorigenesis. PLoS ONE, 7(3):e33844, 2012.
[363] Singh, S. K. , Clarke, I. D. , Terasaki, M. , Bonn, V. E. , Hawkins, C.
, Squire, J. , and Dirks, P. B. . Identification of a cancer stem cell in
human brain tumors. Cancer Research, 63(18):5821–5828, Sept. 2003.
[364] Singh, S. K. , Hawkins, C. , Clarke, I. D. , Squire, J. A. , Bayani, J.
, Hide, T. , Henkelman, R. M. , Cusimano, M. D. , and Dirks, P. B.
. Identification of human brain tumour initiating cells. Nature, 432
(7015):396–401, Nov. 2004.
[365] Skalsky, R. L. and Cullen, B. R. . Reduced expression of brain-enriched
microRNAs in glioblastomas permits targeted regulation of a cell death
gene. PLoS ONE, 6(9):e24248, 2011.
[366] Skog, J. , Wurdinger, T. , van Rijn, S. , Meijer, D. H. , Gainche, L. ,
Sena-Esteves, M. , Curry, W. T. , Carter, B. S. , Krichevsky, A. M. , and
Breakefield, X. O. . Glioblastoma microvesicles transport RNA and pro-
teins that promote tumour growth and provide diagnostic biomarkers.
Nature Cell Biology, 10(12):1470–1476, Dec. 2008.
[367] Slipicevic, A. , Jørgensen, K. , Skrede, M. , and Rosnes, A. . The fatty
acid binding protein 7 (FABP7) is involved in proliferation and invasion
of melanoma cells. BMC Cancer, 2008.
[368] Smits, M. , Wurdinger, T. , van het Hof, B. , Drexhage, J. A. R. , Geerts,
D. , Wesseling, P. , Noske, D. P. , Vandertop, W. P. , de Vries, H. E.
, and Reijerkerk, A. . Myc-associated zinc finger protein (MAZ) is
regulated by miR-125b and mediates VEGF-induced angiogenesis in
glioblastoma. FASEB journal : official publication of the Federation of Amer-
ican Societies for Experimental Biology, 26(6):2639–2647, June 2012.
150
References
[369] Sofroniew, M. V. . Reactive astrocytes in neural repair and protection.
The Neuroscientist : a review journal bringing neurobiology, neurology and
psychiatry, 11(5):400–407, Oct. 2005.
[370] Sofroniew, M. V. and Vinters, H. V. . Astrocytes: biology and pathology.
Acta neuropathologica, 119(1):7–35, Jan. 2010.
[371] Son, M. J. , Woolard, K. , Nam, D.-H. , Lee, J. , and Fine, H. A. .
SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human
Glioblastoma. Cell stem cell, 4(5):440–452, Dec. 2008.
[372] Sonoda, Y. , Ozawa, T. , Hirose, Y. , Aldape, K. D. , McMahon, M. ,
Berger, M. S. , and Pieper, R. O. . Formation of intracranial tumors by
genetically modified human astrocytes defines four pathways critical
in the development of human anaplastic astrocytoma. Cancer Research,
61(13):4956–4960, June 2001.
[373] Speranza, M. C. , Frattini, V. , Pisati, F. , Kapetis, D. , Porrati, P. , Eoli,
M. , Pellegatta, S. , and Finocchiaro, G. . NEDD9, a novel target of
miR-145, increases the invasiveness of glioblastoma. Oncotarget, 3(7):
723–734, July 2012.
[374] Srinivasan, S. , Patric, I. R. P. , and Somasundaram, K. . A ten-
microRNA expression signature predicts survival in glioblastoma.
PLoS ONE, 6(3):e17438, 2011.
[375] Stieber, D. , Golebiewska, A. , Evers, L. , Lenkiewicz, E. , Brons, N. H. C.
, Nicot, N. , Oudin, A. , Bougnaud, S. , Hertel, F. , Bjerkvig, R. , Vallar,
L. , Barrett, M. T. , and Niclou, S. P. . Glioblastomas are composed of
genetically divergent clones with distinct tumourigenic potential and
variable stem cell-associated phenotypes. Acta neuropathologica, 127(2):
203–219, Oct. 2013.
[376] Stoorvogel, W. . Functional transfer of microRNA by exosomes. Blood,
119(3):646–648, Jan. 2012.
[377] Storch, J. and Córsico, B. . The emerging functions and mechanisms of
mammalian fatty acid-binding proteins. Annual review of nutrition, 28
(1):73–95, 2008.
[378] Storch, J. and McDermott, L. . Structural and functional analysis of fatty
acid-binding proteins. Journal of lipid research, 50 Suppl(Supplement):
S126–31, Apr. 2009.
[379] Stratton, M. R. , Campbell, P. J. , and Futreal, P. A. . The cancer genome.
Nature, 458(7239):719–724, Apr. 2009.
151
References
[380] Streit, W. J. , Conde, J. R. , Fendrick, S. E. , Flanary, B. E. , and Mari-
ani, C. L. . Role of microglia in the central nervous system’s immune
response. Neurological research, 27(7):685–691, Oct. 2005.
[381] Sun, B. , Pu, B. , Chu, D. , Chu, X. , Li, W. , and Wei, D. . MicroRNA-650
expression in glioma is associated with prognosis of patients. Journal of
Neuro-Oncology, 115(3):375–380, Dec. 2013.
[382] Sun, Y. , Kong, W. , Falk, A. , Hu, J. , Zhou, L. , Pollard, S. , and Smith,
A. . CD133 (Prominin) negative human neural stem cells are clonogenic
and tripotent. PLoS ONE, 4(5):e5498–e5498, Dec. 2008.
[383] Suzuki, H. I. , Mihira, H. , Watabe, T. , Sugimoto, K. , and Miyazono,
K. . Widespread inference of weighted microRNA-mediated gene reg-
ulation in cancer transcriptome analysis. Nucleic Acids Research, 41(5):
e62–e62, Mar. 2013.
[384] Takamizawa, J. . Reduced Expression of the let-7 MicroRNAs in Human
Lung Cancers in Association with Shortened Postoperative Survival.
Cancer Research, 64(11):3753–3756, June 2004.
[385] Takaoka, N. , Takayama, T. , Teratani, T. , Sugiyama, T. , Mugiya, S. , and
Ozono, S. . Analysis of the regulation of fatty acid binding protein 7
expression in human renal carcinoma cell lines. BMC molecular biology,
12(1):31, 2011.
[386] Tamplin, O. J. , Kinzel, D. , Cox, B. J. , Bell, C. E. , Rossant, J. , and Lick-
ert, H. . Microarray analysis of Foxa2 mutant mouse embryos reveals
novel gene expression and inductive roles for the gastrula organizer
and its derivatives. BMC Genomics, 9(1):511, 2008.
[387] Tano, K. , Shiota, S. , Collier, J. , Foote, R. S. , and Mitra, S. . Isolation
and structural characterization of a cDNA clone encoding the human
DNA repair protein for O6-alkylguanine. PNAS, 87(2):686–690, Dec.
1989.
[388] Tao, T. , Wang, Y. , Luo, H. , Yao, L. , Wang, L. , Wang, J. , Yan, W. ,
Zhang, J. , Wang, H. , Shi, Y. , Yin, Y. , Jiang, T. , Kang, C. , Liu, N. , and
You, Y. . Involvement of FOS-mediated miR-181b/miR-21 signalling in
the progression of malignant gliomas. European journal of cancer (Oxford,
England : 1990), 49(14):3055–3063, Sept. 2013.
[389] Taylor, C. M. , Sauvageot, C. M. , Wen, P. Y. C. , and Stiles, C. D. .
Cellular Origins of Malignant Glioma: The Cancer Stem Cell Polemic.
In Primary Central Nervous System Tumors, pages 45–53. Humana Press,
Totowa, NJ, Nov. 2010.
152
References
[390] Taylor, D. D. and Gercel-Taylor, C. . MicroRNA signatures of tumor-
derived exosomes as diagnostic biomarkers of ovarian cancer. Gyneco-
logic Oncology, 110(1):13–21, June 2008.
[391] The ENCODE Project Consortium. A User’s Guide to the Encyclopedia
of DNA Elements (ENCODE). PLoS Biology, 9(4):e1001046, Apr. 2011.
[392] The UniProt Consortium. The Universal Protein Resource (UniProt).
Nucleic Acids Research, 36(Database):D190–D195, Dec. 2007.
[393] Thiery, J. P. . Epithelial-mesenchymal transitions in tumour progres-
sion. Nature Reviews Cancer, 2(6):442–454, May 2002.
[394] Thomson, D. W. , Bracken, C. P. , and Goodall, G. J. . Experimental
strategies for microRNA target identification. Nucleic Acids Research, 39
(16):6845–6853, Aug. 2011.
[395] Tian, R. Q. , Wang, X. H. , Hou, L. J. , Jia, W. H. , Yang, Q. , Li, Y. X. ,
Liu, M. , Li, X. , and Tang, H. . MicroRNA-372 Is Down-regulated and
Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human
Cervical Cancer, Which May Contribute to Tumorigenesis. The Journal
of biological chemistry, 286(29):25556–25563, July 2011.
[396] Tivnan, A. and McDonald, K. L. . Current Progress for the Use of
miRNAs in Glioblastoma Treatment. Molecular Neurobiology, Apr. 2013.
[397] Tokuda, N. N. , Adachi, T. T. , Adachi, Y. Y. , Higashi, M. M. , Sharifi,
K. K. , Tuerxun, T. T. , Sawada, T. T. , Kondo, H. H. , and Owada, Y. Y.
. Identification of FABP7 in fibroblastic reticular cells of mouse lymph
nodes. Histochemistry and Cell Biology, 134(5):445–452, Oct. 2010.
[398] Toledo, F. and Wahl, G. M. . Regulating the p53 pathway: in vitro
hypotheses, in vivo veritas. Nature Reviews Cancer, 6(12):909–923, Dec.
2006.
[399] Tomita, T. , Akimoto, J. , Haraoka, J. , and Kudo, M. . Clinicopatholog-
ical significance of expression of nestin, a neural stem/progenitor cell
marker, in human glioma tissue. Brain tumor pathology, 31(3):162–171,
July 2014.
[400] Tso, C.-L. , Shintaku, P. , Chen, J. , Liu, Q. , Liu, J. , Chen, Z. , Yoshimoto,
K. , Mischel, P. S. , Cloughesy, T. F. , Liau, L. M. , and Nelson, S. F.
. Primary glioblastomas express mesenchymal stem-like properties.
Molecular cancer research : MCR, 4(9):607–619, Sept. 2006.
[401] Tunca, B. , Tezcan, G. , Cecener, G. , Egeli, U. , Ak, S. , Malyer, H. ,
Tumen, G. , and Bilir, A. . Olea europaea leaf extract alters microRNA
153
References
expression in human glioblastoma cells. Journal of cancer research and
clinical oncology, 138(11):1831–1844, Nov. 2012.
[402] Ueki, K. , Ono, Y. , Henson, J. W. , Efird, J. T. , von Deimling, A. ,
and Louis, D. N. . CDKN2/p16 or RB alterations occur in the majority
of glioblastomas and are inversely correlated. Cancer Research, 56(1):
150–153, Dec. 1995.
[403] Uhrbom, L. , Dai, C. , Celestino, J. C. , Rosenblum, M. K. , Fuller, G. N.
, and Holland, E. C. . Ink4a-Arf loss cooperates with KRas activation
in astrocytes and neural progenitors to generate glioblastomas of vari-
ous morphologies depending on activated Akt. Cancer Research, 62(19):
5551–5558, Sept. 2002.
[404] Uhrbom, L. , Kastemar, M. , Johansson, F. K. , Westermark, B. , and
Holland, E. C. . Cell type-specific tumor suppression by Ink4a and
Arf in Kras-induced mouse gliomagenesis. Cancer Research, 65(6):2065–
2069, Mar. 2005.
[405] Urigüen, L. , Arteta, D. , Díez-Alarcia, R. , Ferrer-Alcón, M. , Díaz, A. ,
Pazos, A. , and Meana, J. J. . Gene expression patterns in brain cortex of
three different animal models of depression. Genes, Brain and Behavior,
7(6):649–658, July 2008.
[406] Valadi, H. , Ekström, K. , Bossios, A. , Sjöstrand, M. , Lee, J. J. , and
Lötvall, J. O. . Exosome-mediated transfer of mRNAs and microRNAs
is a novel mechanism of genetic exchange between cells. Nature Cell
Biology, 9(6):654–659, June 2007.
[407] Verhaak, R. G. W. , Hoadley, K. A. , Purdom, E. , Wang, V. , Qi, Y. ,
Wilkerson, M. D. , Miller, C. R. , Ding, L. , Golub, T. , Mesirov, J. P. ,
Alexe, G. , Lawrence, M. , O’Kelly, M. , Tamayo, P. , Weir, B. A. , Gabriel,
S. , Winckler, W. , Gupta, S. , Jakkula, L. , Feiler, H. S. , Hodgson, J. G. ,
James, C. D. , Sarkaria, J. N. , Brennan, C. , Kahn, A. , Spellman, P. T. ,
Wilson, R. K. , Speed, T. P. , Gray, J. W. , Meyerson, M. , Getz, G. , Perou,
C. M. , Hayes, D. N. , and Cancer Genome Atlas Research Network.
Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR,
and NF1. Cancer Cell, 17(1):98–110, Jan. 2010.
[408] Verweij, F. J. , van Eijndhoven, M. A. J. , Hopmans, E. S. , Vendrig, T.
, Wurdinger, T. , Cahir-McFarland, E. , Kieff, E. , Geerts, D. , van der
Kant, R. , Neefjes, J. , Middeldorp, J. M. , and Pegtel, D. M. . LMP1
association with CD63 in endosomes and secretion via exosomes lim-
its constitutive NF-κB activation. The EMBO Journal, 30(11):2115–2129,
June 2011.
154
References
[409] Vescovi, A. L. , Galli, R. , and Reynolds, B. A. . Brain tumour stem cells.
Nature Reviews Cancer, 6(6):425–436, June 2006.
[410] Vickers, K. C. , Rye, K.-A. , and Tabet, F. . microRNAs in the onset and
development of cardiovascular disease. Clinical science (London, England
: 1979), 126(3):183–194, Feb. 2014.
[411] Villarroya-Beltri, C. , zquez, C. G. e. r.-V. a. , nchez Cabo, F. a. t. S. a.
, ndez, D. P. e. r.-H. a. , zquez, J. u. s. V. a. , Martin-Cofreces, N. ,
Martinez-Herrera, D. J. , Pascual-Montano, A. , Mittelbrunn, M. i. a.
, and nchez Madrid, F. S. a. . Sumoylated hnRNPA2B1 controls the
sorting of miRNAs into exosomes through binding to specific motifs.
Nature Communications, 4:1–10, Dec. 2013.
[412] Vivanco, I. and Sawyers, C. . The Phosphatidylinositol 3-Kinase AKT
Pathway in Human Cancer. Nature Reviews Cancer, 2:489–501, 2002.
[413] Vlassov, A. V. , Magdaleno, S. , Setterquist, R. , and Conrad, R. . Ex-
osomes: current knowledge of their composition, biological functions,
and diagnostic and therapeutic potentials. Biochimica et Biophysica Acta,
1820(7):940–948, June 2012.
[414] Vo, D. T. , Qiao, M. , Smith, A. D. , Burns, S. C. , Brenner, A. J. , and
Penalva, L. O. F. . The oncogenic RNA-binding protein Musashi1 is
regulated by tumor suppressor miRNAs. RNA Biology, 8(5):817–828,
Sept. 2011.
[415] Volinia, S. , Calin, G. A. , Liu, C. G. , Ambs, S. , Cimmino, A. , Petrocca,
F. , Visone, R. , Iorio, M. , Roldo, C. , Ferracin, M. , Prueitt, R. L. ,
Yanaihara, N. , Lanza, G. , Scarpa, A. , Vecchione, A. , Negrini, M. ,
Harris, C. C. , and Croce, C. M. . A microRNA expression signature
of human solid tumors defines cancer gene targets. Proceedings of the
National Academy of Sciences of the United States of America, 103(7):2257–
2261, Feb. 2006.
[416] Vousden, K. H. and Lu, X. . Live or let die: the cell’s response to p53.
Nature Reviews Cancer, 2002.
[417] Wagner, S. , Czub, S. , Greif, M. , Vince, G. H. , Süss, N. , Kerkau, S.
, Rieckmann, P. , Roggendorf, W. , Roosen, K. , and Tonn, J. C. . Mi-
croglial/macrophage expression of interleukin 10 in human glioblas-
tomas. International Journal of Cancer, 82(1):12–16, July 1999.
[418] Wan, Y. , Fei, X.-F. , Wang, Z.-M. , Jiang, D.-Y. , Chen, H.-C. , Yang, J.
, Shi, L. , and Huang, Q. . Expression of miR-125b in the new, highly
invasive glioma stem cell and progenitor cell line SU3. Chinese journal
of cancer, 31(4):207–214, Apr. 2012.
155
References
[419] Wan, Y. , Sun, G. , Zhang, S. , Wang, Z. , and Shi, L. . MicroRNA-125b
inhibitor sensitizes human primary glioblastoma cells to chemothera-
peutic drug temozolomide on invasion. In vitro cellular & developmental
biology. Animal, 49(8):599–607, Sept. 2013.
[420] Wan, Y. , Sun, G. , Wang, Z. , Guo, J. , and Shi, L. . miR-125b promotes
cell proliferation by directly targeting Lin28 in glioblastoma stem cells
with low expression levels of miR-125b. Neuroreport, 25(5):289–296, Mar.
2014.
[421] Wang, J. , Sakariassen, P. Ø. , Tsinkalovsky, O. , Immervoll, H. , Bøe,
S. O. , Svendsen, A. , Prestegarden, L. , Røsland, G. , Thorsen, F. , Stuhr,
L. , Molven, A. , Bjerkvig, R. , and Enger, P. Ø. . CD133 negative glioma
cells form tumors in nude rats and give rise to CD133 positive cells.
International Journal of Cancer, 122(4):761–768, Feb. 2008.
[422] Wang, J. , Sai, K. , Chen, F.-r. , and Chen, Z.-p. . miR-181b modulates
glioma cell sensitivity to temozolomide by targeting MEK1. Cancer
chemotherapy and pharmacology, 72(1):147–158, July 2013.
[423] Wang, Q. , Li, P. , Li, A. , Jiang, W. , Wang, H. , Wang, J. , and Xie, K.
. Plasma specific miRNAs as predictive biomarkers for diagnosis and
prognosis of glioma. Journal of experimental & clinical cancer research :
CR, 31:97, 2012.
[424] Wang, S. , Lu, S. , Geng, S. , Ma, S. , Liang, Z. , and Jiao, B. . Expression
and clinical significance of microRNA-326 in human glioma miR-326
expression in glioma. Medical oncology (Northwood, London, England), 30
(1):373, Mar. 2013.
[425] Wang, W. , Dai, L. X. , Zhang, S. , Yang, Y. , Yan, N. , Fan, P. , Dai,
L. , Tian, H. W. , Cheng, L. , Zhang, X. M. , Li, C. , Zhang, J. F. , Xu,
F. , Shi, G. , Chen, X. L. , Du, T. , Li, Y. M. , Wei, Y. Q. , and Deng,
H. X. . Regulation of epidermal growth factor receptor signaling by
plasmid-based microRNA-7 inhibits human malignant gliomas growth
and metastasis in vivo. Neoplasma, 60(3):274–283, 2013.
[426] Wang, X. , Han, L. , Zhang, A. , Wang, G. , Jia, Z. , Yang, Y. , Yue,
X. , Pu, P. , Shen, C. , and Kang, C. . Adenovirus-mediated shRNAs
for co-repression of miR-221 and miR-222 expression and function in
glioblastoma cells. Oncology reports, 25(1):97–105, Jan. 2011.
[427] Wang, X.-F. , Shi, Z.-M. , Wang, X.-R. , Cao, L. , Wang, Y.-Y. , Zhang,
J.-X. , Yin, Y. , Luo, H. , Kang, C.-S. , Liu, N. , Jiang, T. , and You, Y.-P. .
MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and
Bcl-2. Journal of Cancer Research and Clinical Oncology, 138(4):573–584,
Apr. 2012.
156
References
[428] Wang, X.-R. , Luo, H. , Li, H.-L. , Cao, L. , Wang, X.-F. , Yan, W. ,
Wang, Y.-Y. , Zhang, J.-X. , Jiang, T. , Kang, C.-S. , Liu, N. , You, Y.-
P. , and (CGCG), C. G. C. G. . Overexpressed let-7a inhibits glioma
cell malignancy by directly targeting K-ras, independently of PTEN.
Neuro-oncology, 15(11):1491–1501, Nov. 2013.
[429] Wang, Z. , Bao, Z. , Yan, W. , You, G. , Wang, Y. , Li, X. , and Zhang,
W. . Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA
signature predicts favorable prognosis in glioblastoma patients with
IDH1 wild type. Journal of experimental & clinical cancer research : CR, 32
(1):59, Aug. 2013.
[430] Watanabe, A. , Toyota, T. , Owada, Y. , Hayashi, T. , Iwayama, Y. ,
and Matsumata, M. . Fabp7 Maps to a Quantitative Trait Locus for
a Schizophrenia Endophenotype. PLoS Biology, 5(11):e297–e297, Mar.
2007.
[431] Watanabe, K. , Tachibana, O. , and Sato, K. . Overexpression of the EGF
receptor and p53 mutations are mutually exclusive in the evolution of
primary and secondary glioblastomas. Brain Pathology, 1996.
[432] Watters, J. J. , Schartner, J. M. , and Badie, B. . Microglia function in
brain tumors. Journal of Neuroscience Research, 81(3):447–455, Aug. 2005.
[433] Watts, G. S. G. , Pieper, R. O. R. , Costello, J. F. J. , Peng, Y. M. Y. , Dalton,
W. S. W. , and Futscher, B. W. B. . Methylation of discrete regions of
the O6-methylguanine DNA methyltransferase (MGMT) CpG island
is associated with heterochromatinization of the MGMT transcription
start site and silencing of the gene. Molecular and Cellular Biology, 17(9):
5612–5619, Aug. 1997.
[434] Wen, P. Y. and Kesari, S. . Malignant gliomas in adults. New England
Journal of Medicine, 2008.
[435] Wiese, C. , Rolletschek, A. , Kania, G. , Blyszczuk, P. , Tarasov, K. V. ,
Tarasova, Y. , Wersto, R. P. , Boheler, K. R. , and Wobus, A. M. . Nestin
expression - a property of multi-lineage progenitor cells? Cellular and
molecular life sciences : CMLS, 61(19-20):2510–2522, Oct. 2004.
[436] Wikstrand, C. J. , Hale, L. P. , Batra, S. K. , and Hill, M. L. . Monoclonal
antibodies against EGFRvIII are tumor specific and react with breast
and lung carcinomas and malignant gliomas. Cancer Research, 1995.
[437] Winter, J. and Diederichs, S. . MicroRNA biogenesis and cancer. Meth-
ods in Molecular Biology, 676:3–22, Dec. 2010.
157
References
[438] Winter, J. , Jung, S. , Keller, S. , Gregory, R. I. , and Diederichs, S.
. Many roads to maturity: microRNA biogenesis pathways and their
regulation. Nature Cell Biology, 11(3):228–234, Mar. 2009.
[439] Witwer, K. W. , Buzás, E. I. , Bemis, L. T. , Bora, A. , Lässer, C. , Lötvall,
J. , Nolte-’t Hoen, E. N. , Piper, M. G. , Sivaraman, S. , Skog, J. , Théry,
C. , Wauben, M. H. , and Hochberg, F. . Standardization of sample col-
lection, isolation and analysis methods in extracellular vesicle research.
Journal of extracellular vesicles, 2(0):18389, 2013.
[440] Wong, A. J. , Ruppert, J. M. , Bigner, S. H. , Grzeschik, C. H. ,
Humphrey, P. A. , Bigner, D. S. , and Vogelstein, B. . Structural alter-
ations of the epidermal growth factor receptor gene in human gliomas.
PNAS, 89(7):2965–2969, Mar. 1992.
[441] Wu, N. , Zhao, X. , Liu, M. , Liu, H. , Yao, W. , Zhang, Y. , Cao, S.
, and Lin, X. . Role of microRNA-26b in glioma development and its
mediated regulation on EphA2. PLoS ONE, 6(1):e16264, Jan. 2011.
[442] Wu, N. , Xiao, L. , Zhao, X. , Zhao, J. , Wang, J. , Wang, F. , Cao, S. ,
and Lin, X. . miR-125b regulates the proliferation of glioblastoma stem
cells by targeting E2F2. FEBS letters, 586(21):3831–3839, Nov. 2012.
[443] Wu, N. , Lin, X. , Zhao, X. , Zheng, L. , Xiao, L. , Liu, J. , Ge, L. , and Cao,
S. . MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell
apoptosis through p53 and p38MAPK-independent pathways. British
Journal of Cancer, 109(11):2853–2863, Nov. 2013.
[444] Wu, S. , Yan, G. , and Zhu, W. . Evolvement of MicroRNAs as Thera-
peutic Targets for Malignant Gliomas, 2013.
[445] Wu, Z. , Sun, L. , Wang, H. , Yao, J. , Jiang, C. , Xu, W. , and Yang,
Z. . MiR-328 Expression Is Decreased in High-Grade Gliomas and Is
Associated with Worse Survival in Primary Glioblastoma. PLoS ONE,
7(10):e47270, Jan. 2012.
[446] Wu, Z. , Wang, L. , Li, G. , Liu, H. , Fan, F. , Li, Z. , Li, Y. , and Gao, G. .
Increased expression of microRNA-9 predicts an unfavorable prognosis
in human glioma. Molecular and cellular biochemistry, 384(1-2):263–268,
Dec. 2013.
[447] Wuchty, S. , Arjona, D. , Li, A. , Kotliarov, Y. , Walling, J. , Ahn, S. ,
Zhang, A. , Maric, D. , Anolik, R. , Zenklusen, J. C. , and Fine, H. A.
. Prediction of Associations between microRNAs and Gene Expression
in Glioma Biology. PLoS ONE, 6(2):e14681, 2011.
158
References
[448] Wurdinger, T. and Tannous, B. A. . Glioma angiogenesis: Towards novel
RNA therapeutics. Cell adhesion & migration, 3(2):230–235, Apr. 2009.
[449] Xia, H. , Qi, Y. , Ng, S. S. , Chen, X. , Li, D. , Chen, S. , Ge, R. ,
Jiang, S. , Li, G. , Chen, Y. , He, M.-L. , Kung, H.-f. , Lai, L. , and Lin,
M. C. . microRNA-146b inhibits glioma cell migration and invasion by
targeting MMPs. Brain research, 1269:158–165, May 2009.
[450] Xia, H.-F. , He, T.-Z. , Liu, C.-M. , Cui, Y. , Song, P.-P. , Jin, X.-H. , and
Ma, X. . MiR-125b expression affects the proliferation and apoptosis of
human glioma cells by targeting Bmf. Cellular physiology and biochem-
istry : international journal of experimental cellular physiology, biochemistry,
and pharmacology, 23(4-6):347–358, 2009.
[451] Xiao, A. , Wu, H. , Pandolfi, P. P. , Louis, D. N. , and Van Dyke, T. .
Astrocyte inactivation of the pRb pathway predisposes mice to malig-
nant astrocytoma development that is accelerated by PTEN mutation.
Cancer Cell, 1(2):157–168, Dec. 2001.
[452] Xiao, Y. , Ping, Y. , Fan, H. , Xu, C. , Guan, J. , Zhao, H. , Li, Y. , Lv,
Y. , Jin, Y. , Wang, L. , and Li, X. . Identifying dysfunctional miRNA-
mRNA regulatory modules by inverse activation, cofunction, and high
interconnection of target genes: A case study of glioblastoma. Neuro-
oncology, 15(7):818–828, June 2013.
[453] Yan, H. , Parsons, D. W. , Jin, G. , McLendon, R. , Rasheed, B. A. , Yuan,
W. , Kos, I. , Batinic-Haberle, I. , Jones, S. , Riggins, G. J. , Friedman, H.
, Friedman, A. , Reardon, D. , Herndon, J. , Kinzler, K. W. , Velculescu,
V. E. , Vogelstein, B. , and Bigner, D. D. . IDH1 and IDH2 mutations in
gliomas. New England Journal of Medicine, 360(8):765–773, Feb. 2009.
[454] Yanaihara, N. , Caplen, N. , Bowman, E. , Seike, M. , Kumamoto, K.
, Yi, M. , Stephens, R. M. , Okamoto, A. , Yokota, J. , and Tanaka, T.
. Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer cell, 9(3):189–198, Mar. 2006.
[455] Yang, G. , Zhang, R. , Chen, X. , Mu, Y. , Ai, J. , Shi, C. , Liu, Y. , Shi,
C. , Sun, L. , Rainov, N. G. , Li, H. , Yang, B. , and Zhao, S. . MiR-
106a inhibits glioma cell growth by targeting E2F1 independent of p53
status. Journal of Molecular Medicine, 89(10):1037–1050, Oct. 2011.
[456] Yang, Y. , Spitzer, E. , Kenney, N. , Zschiesche, W. , Li, M. , Kromminga,
A. , Muller, T. , Spener, F. , Lezius, A. , and Veerkamp, J. H. . Members
of the fatty acid binding protein family are differentiation factors for
the mammary gland. The Journal of Cell Biology, 127(4):1097–1109, Nov.
1994.
159
References
[457] Yang, Y. , Wu, J. , Guan, H. , Cai, J. , Fang, L. , Li, J. , and Li, M. . MiR-
136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2.
FEBS letters, 586(20):3608–3612, Oct. 2012.
[458] Yi, R. , Qin, Y. , Macara, I. G. , and Cullen, B. R. . Exportin-5 mediates
the nuclear export of pre-microRNAs and short hairpin RNAs. 17(24):
3011–3016, Dec. 2003.
[459] Yin, D. , Ogawa, S. , Kawamata, N. , Leiter, A. , Ham, M. , Li, D. ,
Doan, N. B. , Said, J. W. , Black, K. L. , and Phillip Koeffler, H. . miR-
34a functions as a tumor suppressor modulating EGFR in glioblastoma
multiforme. Oncogene, 32(9):1155–1163, May 2012.
[460] Yusuf, D. , Butland, S. L. , Swanson, M. I. , Bolotin, E. , Ticoll, A. ,
Cheung, W. A. , Zhang, X. Y. C. , Dickman, C. T. , Fulton, D. L. , Lim,
J. S. , Schnabl, J. M. , Ramos, O. H. , Vasseur-Cognet, M. , de Leeuw,
C. N. , Simpson, E. M. , Ryffel, G. U. , Lam, E. W.-F. , Kist, R. , Wilson,
M. S. , Marco-Ferreres, R. , Brosens, J. J. , Beccari, L. L. , Bovolenta, P.
, Benayoun, B. A. , Monteiro, L. J. , Schwenen, H. D. , Grontved, L. ,
Wederell, E. , Mandrup, S. , Veitia, R. A. , Chakravarthy, H. , Hoodless,
P. A. , Mancarelli, M. M. , Torbett, B. E. , Banham, A. H. , Reddy, S. P.
, Cullum, R. L. , Liedtke, M. , Tschan, M. P. , Vaz, M. , Rizzino, A. ,
Zannini, M. , Frietze, S. , Farnham, P. J. , Eijkelenboom, A. , Brown,
P. J. , Laperrière, D. , Leprince, D. , de Cristofaro, T. , Prince, K. L. ,
Putker, M. , del Peso, L. , Camenisch, G. , Wenger, R. H. , Mikula, M. ,
Rozendaal, M. , Mader, S. , Ostrowski, J. , Rhodes, S. J. , Van Rechem,
C. , Boulay, G. , Olechnowicz, S. W. , Breslin, M. B. , Lan, M. S. , Nanan,
K. K. , Wegner, M. , Hou, J. , Mullen, R. D. , Colvin, S. C. , Noy, P. J. ,
Webb, C. F. , Witek, M. E. , Ferrell, S. , Daniel, J. M. , Park, J. , Waldman,
S. A. , Peet, D. J. , Taggart, M. , Jayaraman, P.-S. , Karrich, J. J. , Blom,
B. , Vesuna, F. , O’Geen, H. , Sun, Y. , Gronostajski, R. M. , Woodcroft,
M. W. , Hough, M. R. , Chen, E. , Europe-Finner, G. N. , Karolczak-
Bayatti, M. , Bailey, J. , Hankinson, O. , Raman, V. , LeBrun, D. P. ,
Biswal, S. , Harvey, C. J. , DeBruyne, J. P. , Hogenesch, J. B. , Hevner,
R. F. , Héligon, C. , Luo, X. M. , Blank, M. C. , Millen, K. J. , Sharlin,
D. S. , Forrest, D. , Dahlman-Wright, K. , Zhao, C. , Mishima, Y. , Sinha,
S. , Chakrabarti, R. , Portales-Casamar, E. , Sladek, F. M. , Bradley,
P. H. , and Wasserman, W. W. . The Transcription Factor Encyclopedia.
Genome biology, 13(3):R24, Mar. 2012.
[461] Zawlik, I. , Kita, D. , Vaccarella, S. , Mittelbronn, M. , Franceschi, S. , and
Ohgaki, H. . Common polymorphisms in the MDM2 and TP53 genes
and the relationship between TP53 mutations and patient outcomes in
glioblastomas. Brain Pathology, 19(2):188–194, Apr. 2009.
160
References
[462] Zhang, C. , Han, L. , Zhang, A. , Yang, W. , Zhou, X. , Pu, P. , Du, Y. ,
Zeng, H. , and Kang, C. . Global changes of mRNA expression reveals
an increased activity of the interferon-induced signal transducer and
activator of transcription (STAT) pathway by repression of miR-221/222
in glioblastoma U251 cells. International journal of oncology, 36(6):1503–
1512, 2010.
[463] Zhang, C. , Zhang, J. , Hao, J. , Shi, Z. , Wang, Y. , Han, L. , Yu, S. ,
You, Y. , Jiang, T. , Wang, J. , Liu, M. , Pu, P. , and Kang, C. . High level
of miR-221/222 confers increased cell invasion and poor prognosis in
glioma. Journal of translational medicine, 10(1):119, 2012.
[464] Zhang, C.-Z. , Zhang, J.-X. , Zhang, A.-L. , Shi, Z.-D. , Han, L. , Jia, Z.-F.
, Yang, W.-D. , Wang, G.-X. , Jiang, T. , You, Y.-P. , Pu, P.-Y. , Cheng,
J.-Q. , and Kang, C.-S. . MiR-221 and miR-222 target PUMA to induce
cell survival in glioblastoma. Molecular cancer, 9:229, 2010.
[465] Zhang, H. , Rakha, E. A. , Ball, G. R. , Spiteri, I. , Aleskandarany, M.
, Paish, E. C. , Powe, D. G. , Macmillan, R. D. , Caldas, C. , Ellis, I. O.
, and Green, A. R. . The proteins FABP7 and OATP2 are associated
with the basal phenotype and patient outcome in human breast cancer.
Breast cancer research and treatment, 121(1):41–51, May 2010.
[466] Zhang, J. , Han, L. , Ge, Y. , Zhou, X. , Zhang, A. , Zhang, C. , Zhong, Y.
, You, Y. , Pu, P. , and Kang, C. . miR-221/222 promote malignant pro-
gression of glioma through activation of the Akt pathway. International
journal of oncology, 36(4):913–920, Apr. 2010.
[467] Zhang, Q.-Q. , Xu, H. , Huang, M.-B. , Ma, L.-M. , Huang, Q.-J. , Yao, Q.
, Zhou, H. , and Qu, L.-H. . MicroRNA-195 plays a tumor-suppressor
role in human glioblastoma cells by targeting signaling pathways in-
volved in cellular proliferation and invasion. Neuro-oncology, 14(3):278–
287, Mar. 2012.
[468] Zhang, W. , Zhang, J. , Hoadley, K. , Kushwaha, D. , Ramakrishnan,
V. , Li, S. , Kang, C. , You, Y. , Jiang, C. , Song, S. W. , Jiang, T. ,
and Chen, C. C. . miR-181d: a predictive glioblastoma biomarker that
downregulates MGMT expression. Neuro-oncology, 14(6):712–719, June
2012.
[469] Zhang, W. , Zhang, J. , Yan, W. , You, G. , Bao, Z. , Li, S. , Kang,
C. , Jiang, C. , You, Y. , Zhang, Y. , Chen, C. C. , Song, S. W. , and
Jiang, T. . Whole-genome microRNA expression profiling identifies a
5-microRNA signature as a prognostic biomarker in Chinese patients
with primary glioblastoma multiforme. Cancer, 119(4):814–824, Feb.
2013.
161
References
[470] Zhang, Y. , Chao, T. , Li, R. , Liu, W. , Chen, Y. , Yan, X. , Gong, Y. , Yin,
B. , Liu, W. , Qiang, B. , Zhao, J. , Yuan, J. , and Peng, X. . MicroRNA-
128 inhibits glioma cells proliferation by targeting transcription factor
E2F3a. Journal of molecular medicine (Berlin, Germany), 87(1):43–51, Sept.
2008.
[471] Zhang, Y. , Dutta, A. , and Abounader, R. . The role of microRNAs in
glioma initiation and progression. Frontiers in bioscience : a journal and
virtual library, 17:700–712, Jan. 2012.
[472] Zheng, H. , Ying, H. , Yan, H. , Kimmelman, A. C. , Hiller, D. J. , Chen,
A.-J. , Perry, S. R. , Tonon, G. , Chu, G. C. , Ding, Z. , Stommel, J. M.
, Dunn, K. L. , Wiedemeyer, R. , You, M. J. , Brennan, C. , Wang, Y. A.
, Ligon, K. L. , Wong, W. H. , Chin, L. , and Depinho, R. A. . p53
and Pten control neural and glioma stem/progenitor cell renewal and
differentiation. Nature, 455(7216):1129–1133, Oct. 2008.
[473] Zhi, F. , Chen, X. , Wang, S. , Xia, X. , Shi, Y. , Guan, W. , Shao, N. , Qu,
H. , Yang, C. , Zhang, Y. , Wang, Q. , Wang, R. , Zen, K. , Zhang, C.-Y.
, Zhang, J. , and Yang, Y. . The use of hsa-miR-21, hsa-miR-181b and
hsa-miR-106a as prognostic indicators of astrocytoma. European journal
of cancer (Oxford, England : 1990), 46(9):1640–1649, June 2010.
[474] Zhong, J. , Paul, A. , Kellie, S. J. , and O’Neill, G. M. . Mesenchymal
migration as a therapeutic target in glioblastoma. Journal of oncology,
2010:430142, 2010.
[475] Zhou, X. , Ren, Y. , Moore, L. , Mei, M. , You, Y. , Xu, P. , Wang, B. ,
Wang, G. , Jia, Z. , Pu, P. , Zhang, W. , and Kang, C. . Downregulation
of miR-21 inhibits EGFR pathway and suppresses the growth of human
glioblastoma cells independent of PTEN status. Laboratory investigation;
a journal of technical methods and pathology, 90(2):144–155, Feb. 2010.
[476] Zhou, X. , Zhang, J. , Jia, Q. , Ren, Y. , Wang, Y. , Shi, L. , Liu, N. ,
Wang, G. , Pu, P. , You, Y. , and Kang, C. . Reduction of miR-21 induces
glioma cell apoptosis via activating caspase 9 and 3. Oncology reports,
24(1):195–201, July 2010.
[477] Zhu, S. , Pan, W. , and Qian, Y. . MicroRNA in immunity and autoim-
munity. Journal of Molecular Medicine, 91(9):1039–1050, May 2013.
[478] Zhu, T. S. , Costello, M. A. , Talsma, C. E. , Flack, C. G. , Crowley, J. G.
, Hamm, L. L. , He, X. , Hervey-Jumper, S. L. , Heth, J. A. , Muraszko,
K. M. , DiMeco, F. , Vescovi, A. L. , and Fan, X. . Endothelial Cells Create
a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That
Nurture Self-Renewal of Cancer Stem-Like Cells. Cancer Research, 71
(18):6061–6072, Sept. 2011.
162
References
[479] Zhu, Y. , Guignard, F. , Zhao, D. , Liu, L. , Burns, D. K. , and Mason,
R. P. . Early inactivation of p53 tumor suppressor gene cooperating
with NF1 loss induces malignant astrocytoma. Cancer Cell, 2005.
[480] Zinn, P. O. , Sathyan, P. , Mahajan, B. , Bruyere, J. , Hegi, M. , Majumder,
S. , and Colen, R. R. . A novel volume-age-KPS (VAK) glioblastoma
classification identifies a prognostic cognate microRNA-gene signature.
PLoS ONE, 7(8):e41522, 2012.
[481] Zitvogel, L. , Regnault, A. , Lozier, A. , Wolfers, J. , Flament, C. , Tenza,
D. , Ricciardi-Castagnoli, P. , Raposo, G. , and Amigorena, S. . Erad-
ication of established murine tumors using a novel cell-free vaccine:
dendritic cell-derived exosomes. Nature Medicine, 4(5):594–600, Apr.
1998.
163
M
IC
H
A
EL TØ
R
N
G
R
EN
 H
EN
R
IK
SEN
M
IC
R
O
R
N
A SIG
N
ATU
R
ES A
N
D
 TR
A
N
SC
R
IPTIO
N
A
L
R
EG
U
LATO
RY N
ETW
O
R
K
S IN
 G
LIO
B
LA
STO
M
A
ISSN (online): 2246-1302
ISBN (online): 978-87-7112-890-1
